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14Der Bericht »Krebs in Deutschland« wird alle zwei Jahre als gemeinsame 
Publikation der Gesellschaft der epidemiologischen Krebsregister in Deutsch-
land e. V. (GEKID) und des Zentrums für Krebsregisterdaten (ZfKD) im 
Robert Koch-Institut herausgegeben. Die Ergebnisse der vorliegenden 11. Aus-
gabe beruhen auf Daten der epidemiologischen Krebsregistrierung bis zum 
Jahr 2014. Die Zahl der Krebsneuerkrankungen in Deutschland wurde für die-
ses Jahr vom ZfKD auf 476.000 geschätzt. Frauen sind nach wie vor am häufigs-
ten von Brustkrebs (ca. 69.200) betroffen, Männer am häufigsten von Prostata-
krebs (ca. 57.400). Von 2004 bis 2014 hat die Zahl der Krebsneuerkrankungen 
zugenommen, vor allem bedingt durch die Zunahme älterer Menschen. Alters-
standardisiert ist bei Männern ein Rückgang um 10 %, bei Frauen ein Anstieg 
von 3 % zu erkennen. Neben den in dieser Ausgabe dargestellten Ergebnissen 
sind zusätzliche Auswertungen unter www.krebsdaten.de zu finden.
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Over the coming years, the ZfKD – responsible 
for cancer surveillance at the federal level – will also 
take on many new tasks. On the one hand, it will 
contribute towards the further development and har-
monisation of cancer registration in Germany; on the 
other, it will conduct research using new data sources 
and explore methods of defi ning cancer that provide 
more precise and timely description of the diff erent 
public health related aspects of cancer. This will in-
volve the important role of drawing attention to the 
rising rates of certain types of cancer and, thereby, 
signalling the need for further epidemiological re-
search. This work will have to be done together with 
the registers. However, at the same time, it is essen-
tial that the ZfKD clearly demonstrates the potential 
for cancer prevention and describes the impact of 
measures and programmes that have already been 
put in place in primary and secondary prevention at 
the population level. In addition to studies on the 
early detection of cancer, this especially includes 
highlighting the importance of the HPV vaccine, 
which has been recommended by the Standing Com-
mission on Vaccination (STIKO) at the RKI since 
2007.
Cancer in Germany, which is now in its 11th edi-
tion, is particularly intended as a means for providing 
information to the public; it is supplemented by fur-
ther reports, information on the internet and scien-
tifi c publications with the aim of meeting the needs 
of a diverse group of addressees and interested par-
ties.
The complex challenges facing health policy and 
public health today can only be met through close 
cooperation with other institutions. Therefore, in or-
der to fulfi l the RKI’s mission to generate evidence, 
share knowledge and protect and improve health, the 
ZfKD will also focus on broadening its networking at 
the national and international level. The existing 
close cooperation with the cancer registries of the 
federal-states, which is also refl ected in this joint re-
port, will provide a crucial foundation for this work 
in the future.
Professor Lothar H Wieler
President of the Robert Koch Institute
The main task of the Robert Koch Institute (RKI) is 
to collect and analyse data on health risks that occur 
within people’s living environments (monitoring, 
surveillance). The aim of this work is to gather 
together reliable data which help to develope re-
commendations on the implementation of targeted 
measures. Although the RKI has been conducting 
research into infectious diseases ever since it was 
founded in 1891, as a public health institute, it is no 
longer limited to this issue.
Even during Robert Koch’s time, when neither 
the public nor the health service viewed the disease 
with the same level of importance as they do today, 
the need for epidemiological data was patently clear. 
In 1900, during the German Empire, this situation 
led to the establishment of the fi rst collective research 
by the Committee for Cancer Research. Robert Koch 
and Rudolf Virchow were honorary members, and its 
fi rst director, Ernst von Leyden, had already initiated 
similar surveys of the spread of infl uenza and tuber-
culosis.
Unfortunately, more than 100 years were to 
elapse between the committee’s fi rst cross-sectional 
survey and the gradual establishment of a compre-
hensive cancer surveillance system using data from 
population-based cancer registries from all German 
federal states, which was fi nalized in 2009. This pro-
cess also resulted in the foundation of the German 
Centre for Cancer Registry Data (ZfKD). Neverthe-
less, nationwide population-based studies of cancer 
have been carried out at the RKI since 1994, when the 
Central Cancer Documentation Unit as part of the 
former Institute for Social Medicine and Epidemiol-
ogy was transferred to the RKI.
Since then, it has become clear that cancer reg-
istration off ers more opportunities than the periodi-
cal presentations of cancer incidence data. Therefore, 
a signifi cant change is currently taking place in the 
fi eld of cancer registration in Germany: in the future, 
cancer registration will be primarily used to assess 
the quality of the care provided to cancer patients. 
The resulting data on the individual’s course of the 
disease including all cancer directed treatments be 
collected as part of nationwide system of clinical can-
cer registration that will have been established by the 
end of 2018. These changes will result in tremendous 
opportunities for research. Nevertheless, the regis-
ters will face a number of considerable challenges 




Cancer in Germany 7
German registry data has been used for international 
comparisons of survival rates.
Because of demographic developments in Germany, 
the number of new cancer cases is expected to in-
crease by more than 20 % between 2010 and 2030.
Predicting the future number of new cancer cases is 
an important aspect of health services requirement 
planning. Population-based cancer registries provide 
the baseline data needed for this.
The data from population-based cancer regis-
tries is also used for scientific research into the 
causes of cancer or for health services research. Such 
studies investigate a variety of topics:
▶ What are the causes of childhood leukaemia?
▶ Do women who take hormone-replacement ther-
apy for menopausal problems have a higher risk 
of developing breast cancer?
▶ Does lung cancer develop more frequently in
people in certain occupational groups?
▶ Are diagnosis, therapy and aftercare being car-
ried out according to the latest standards?
Population-based cancer registries make it possible 
for research projects to include all cases of the disease 
that have occurred in a defined population. If the pa-
tient participation rate in the project is high, the find-
ings of such studies should be generalizable to the 
broader population. Population-based case-control 
studies and cohort studies consequently use data 
from population-based cancer registries for research 
into the causes and risks of cancer.
Further or specific issues may also be analysed 
using registry data. Examples include:
▶ Detailed analyses regarding survival of cancer
patients
▶ Examination of oncological care and long-term
quality of life of cancer patients
▶ Occurrence of second cancers after a different
primary cancer
▶ Evaluation of screening measures such as mam-
mography screening or colonoscopy screening
for bowel cancer
▶ Studies of the connection between social status
and cancer incidence and mortality
▶ Cooperation with cancer centres, e. g. in the as-
sessment of the long-term patient survival
A detailed list can be found at 
www.gekid.de/home
A population-based (epidemiological) cancer registry 
is an institution for the collection, storage, process-
ing, analysis and interpretation of data on the inci-
dence and prevalence of cancers within a defined 
registration area (e. g. a German federal state). Cancer 
registry data also forms an indispensable basis for 
further studies into the causes of cancer, the assess-
ment of early detection measures and popula-
tion-based care of cancer patients.
Findings from population-based cancer regis-
tries include:
In Germany, 480,000 people are diagnosed with can-
cer each year.
Cancer incidence (i. e. how many cancers occur an-
nually in a certain population group) can be described 
using the data from population-based cancer regis-
tries. The incidence is calculated according to cancer 
type, patient age and gender, as well as other charac-
teristics. Reliable information regarding incidence is 
indispensable for characterizing the burden that can-
cer places on a population.
For some years lung cancer has been diagnosed 
among women under the age of forty just as often as 
among men of the same age.
Only by using data from population-based cancer reg-
istries can developments in incidence over time 
(trends) be observed. The registries serve a key func-
tion for the surveillance of these trends in the context 
of health reporting.
Regional differences in the incidence of malignant 
melanoma of the skin can be observed in Europe and 
within Germany.
Population-based cancer registries can analyse the re-
gional distribution of various types of cancer. It is also 
within their remit to investigate any cancer clusters ob-
served. Further clarification of possible causes of these 
clusters usually involves targeted analytical studies.
In recent years, diff erences in the prognosis of cancer 
patients between western and eastern federal states 
have largely disappeared.
Population-based cancer registries conduct surviv-
al-time analyses of all cancer patients in their regis-
tration region. Population-based survival rates are an 
important parameter for assessing the effectiveness 
of diagnosis, therapy and aftercare. In recent years, 
1 Epidemiological cancer registration in Germany
1.1 Aims and tasks of population-based cancer registries
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In order to pool information about an individual 
cancer case from diff erent sources, data is collected 
by the registries such that all reports concerning the 
same person are identifiable. Furthermore, for cer-
tain research purposes it must be possible to re-estab-
lish the link between the data and the individual. 
However, in order to safeguard patientsʼ privacy and 
ensure their rights according to data protection legis-
lation, all population-based registries have adopted 
extensive precautions to protect and secure personal 
data.
Undistorted evaluation of registry data is only 
possible if at least 90 % of all new cancer cases are 
registered. The cooperation of all physicians and den-
tists involved in diagnosis, treatment and aftercare is 
therefore crucial to obtaining data of high informa-
tional value. Patients are also requested to take an 
active part in cancer registration. Ask your doctor to 
report your case to the appropriate cancer registry! 
This way you too can contribute to cancer surveil-
lance, cancer research and also help to improve can-
cer detection, treatment and aftercare.
1.2  Current development of 
cancer registration in Germany
Since 2009, regional legislation stipulates that all 
new cases of cancer in Germany shall be systemati-
cally recorded in a register. Epidemiological cancer 
registration in Germany, therefore, is currently going 
through a highly encouraging phase. In 2014, 12 Ger-
man federal states are estimated to have registered at 
least 90 % of all cases of cancer diagnosed among 
residents of their respective jurisdictions. As such, 
reliable data on new cases of cancer are now available 
for a population of nearly 65 million people. In 2014, 
the registries recorded around 93 % of the estimated 
new cases of cancer in Germany – ten years earlier, 
this fi gure was close to 65 %. Very few other countries 
with a comparable population size have achieved 
such a high completeness rate.
Numerous initiatives aimed at improving cancer 
registration throughout Germany have contributed to 
this welcome result. The implementation of the 
2009 German Federal Cancer Registry Data Act and 
the establishment of the ZfKD at the Robert Koch 
Institute (RKI) continued the support of epidemio-
logical cancer registration at the national level. Since 
the end of 2011, all regional cancer registries have 
annually provided the ZfKD with anonymised data in 
a standardised format. These data provide the basis 
for the analyses undertaken by the ZfKD presented 
here in this 11th edition of Cancer in Germany.
In the coming years, the evaluation of organised 
screening programs introduced in Germany will 
present a particular challenge for the popula-
tion-based cancer registries. Using the data provided 
by the registries, it will be possible to assess whether 
screening has had the desired effect of reducing the 
number of advanced cancers within the population. 
By linking the registry data with the respective 
screening program it should also be possible to eval-
uate reductions in mortality among participants in 
such measures.
Germany’s National Cancer Plan emphasises 
the central role of cancer registration in assessing the 
effects of organised cancer early detection programs. 
A number of implementation recommendations 
have been adopted in the plan to improve coordina-
tion between the early detection programs and the 
information collected in the cancer registries. These 
recommendations have been integrated into the fed-
eral Cancer Screening and Cancer Registration Act.
One initial focus in this regard has been the as-
sessment of mammography screening, which had 
been introduced nationwide by 2009. The popula-
tion-based cancer registries have already provided 
detailed baseline data for the first evaluation re-
ports on mammography screening (www.mammo- 
programm.de), and this is being used for quality as-
surance and an initial assessment of the program. A 
new task scheduled here is the identification of inter-
val carcinomas (incidence of breast cancer following 
a negative screening examination). First results from 
other countries have been published already and 
show that the objectives from European screening 
guidelines haven’t been achieved.
The early detection of colon and cervical cancers 
is currently being adapted according to the Cancer 
Screening and Cancer Registration Act. The cancer 
registries will play an important role in the evaluation 
of the population-level eff ects of these programs as 
well.
A longer-term task of the population-based can-
cer registries is also to examine the effectiveness of 
the vaccination program for girls between 9 and 
14 years of age against human papillomaviruses 
(HPV), which aims to significantly reduce the num-
ber of new cases of cervical cancer.
In order to fulfil the stated objectives and tasks 
of cancer registration, population-based, nationwide 
cancer registries are needed. By 2009, legal frame-
works for comprehensive cancer registration were 
established in all federal states. The Federal Cancer 
Registry Data Act, which came into force that same 
year, further improved the collection and evaluation 
of anonymised cancer registry data at the national 
level through creation of the German Centre for Can-
cer Registry Data at the Robert Koch Institute.
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registry data. The GEKID’s updated Interactive Can-
cer Atlas is one important result of this work. The 
atlas now depicts current cancer incidence and mor-
tality throughout the federal states. Furthermore, it 
also includes survival rates from cancer at the feder-
al-state level. The atlas is available on the GEKID’s 
website (www.gekid.de/home) as an inter-active 
map that allows regional comparisons to be made 
for 23 types of cancer.
In addition to presenting cancer registry data, 
the epidemiological cancer registries and the GEKID 
have participated in planning and conducting epide-
miological cancer research projects. A focus here was 
the German Cancer Aid’s funding priority »Cancer 
Epidemiology«. This led to a wide-ranging study of 
cancer survival that was undertaken together with the 
German Cancer Research Centre in Heidelberg; the 
fi ndings were published in international scientifi c 
journals.
In addition, several publications with signifi cant 
international reach have emerged from other re-
search projects, some of which have addressed link-
age of research datasets with cancer registry data. 
Information on further research projects and current 
publications is available on the GEKID’s website and 
in the annex of this report.
These examples demonstrate that the focus of 
epidemiological cancer registration in Germany is 
currently shifting from merely collecting data 
towards using data for scientifi c research. This devel-
opment is essential, because without in-depth scien-
tifi c analysis, the knowledge gained from this – pain-
stakingly collected – data would clearly be limited. 
Additionally, the anonymised data from all the regis-
tries may now be accessed and analysed by external 
researchers on application to the ZfKD; use of this 
option has increased over the past two years. The di-
verse work of the cancer registries and the ZfKD also 
constitute important elements of federal health 
reporting. With the publication of the fi rst Federal 
 Report on Cancer in Germany, the ZfKD set the course 
towards integrating a wide range of data sources into 
cancer reporting.
The systematic data collection by clinical cancer 
registries heralds a brand new era. In the future, data 
from the clinical cancer registries will be available for 
comprehensive quality assurance and particularly for 
health services research. This means that cancer reg-
istries will become increasingly important for onco-
logical research and healthcare and, therefore, for 
cancer patients. The current developments in cancer 
registration and the use of data on cancer in Germany 
are certainly to be welcomed, and they promise con-
siderable prospects for the future. Moreover, Germa-
ny’s nationwide clinical cancer registration has placed 
the country among the forerunners in this fi eld.
The 2013 adoption of the Cancer Screening and 
Registration Act (KFRG) constitutes a further mile-
stone in the development of cancer registration in 
Germany. This law focuses on the implementation of 
the National Cancer Plan’s most important recom-
mendations. The KFRG requires that the federal 
states establish a system of clinical cancer registra-
tion in addition to the previously established epide-
miological registration. The expanded clinical data 
includes detailed information on therapies and 
disease progression. The past two years have been 
marked by the reorganisation and expansion of 
cancer registries in Germany. Most regions that 
previously had no clinical cancer registration have 
expanded their epidemiological cancer registries into 
clinical-epidemiological registries. In areas where 
clinical registries had already been established, these 
have been adapted to meet the requirements of the 
KFRG. This has resulted in the passing of new cancer 
registry laws in almost all German federal states and 
the beginning of formal clinical cancer registration.
In order to further standardise cancer registra-
tion in Germany and to coordinate regional regula-
tions, a working group has been set up with represen-
tatives from all federal states. Experts from the 
registries, organised as the platform »Paragraph 65c 
Clinical Cancer Registries«, provide support to the 
working group. Together, the working group and the 
platform attend to the practical implementation of 
the KFRG across federal-state borders, ensure that a 
joint approach to outstanding issues is developed 
wherever possible, defi ne national standards and cre-
ate synergies during IT implementation. The Asso-
ciation of Population-based Cancer Registries in 
Germany (GEKID) and the Association of German 
Tumour Centres (ADT) also actively support the 
working group and the platform.
In order to promote further harmonisation and 
standardisation, the GEKID and the ADT will soon 
publish a manual on cancer registration as a guide-
line for collecting and analysing epidemiological and 
clinical cancer registry data.
The data from the German cancer registries are 
also used internationally. These data are available to-
gether with those from other European countries on 
the websites of the European Network of Cancer Reg-
istries (ENCR – see www.encr.eu) and of the Europe-
an Commission’s Joint Research Centre (JRC). Addi-
tionally, the ECIS – the European Cancer Information 
System – can be used to compare data from Germany 
with those from other European registries.
During the last two years, the GEKID, whose 
members also include researchers working in the 
fi eld of cancer epidemiology as well as representa-
tives of the epidemiological cancer registries, has 
continued to focus on improving the use of cancer 
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tutes in Berlin to support interdisciplinary research 
in the fi eld of disease processes associated with 
aging.
The ZfKD is particularly focused on supporting 
the next generation of researchers, including super-
vising master’s and PhD theses of internal as well as 
external candidates. Furthermore, during the last two 
years, the ZfKD has received around 200 inquiries 
from the public, students, the press, researchers and 
politicians.
In the coming years, the ZfKD will prioritise ac-
tivities focused on the impact of primary and second-
ary prevention measures, such as HPV vaccination, 
mammography screening or the development of cer-
vical and colorectal cancer screening into organised 
early detection programmes. This will mainly involve 
describing the eff ects that these measures have on 
the incidence and mortality associated with the dis-
eases. On these topics, the ZfKD will seek an inten-
sive exchange of ideas with other researchers.
Finally, the ZfKD is committed to further stand-
ardisation and harmonisation of cancer registration 
in Germany. Representatives of the ZfKD are in-
volved in preparing the new manual on clinical-epi-
demiological cancer registration. Participation in an 
IARC working group in connection with the 11th edi-
tion of the International Classifi cation of Diseases 
(ICD-11), which is scheduled for 2018, is also planned. 
The new edition will lead to considerable changes for 
some types of tumours, such as brain tumours 
or neoplasms of the lymphatic and hematopoietic 
system, with signifi cant consequences for cancer 
registration.
Other focal points include the further develop-
ment of analysis methods and expanding the infor-
mation provided to the public. Fact sheets are cur-
rently being developed on the epidemiology of 
common forms of cancer together with the Cancer 
Information Service of the German Cancer Research 
Centre.
The ZfKD website (www.krebsdaten.de/english) 
provides information about the ZfKD’s current 
 projects and activities.
1.3  Current priorities of the German 
Centre for Cancer Registry Data 
(ZfKD)
After publishing the last issue of Cancer in Germany, 
the ZfKD initially focused on producing the fi rst ever 
Federal Report on Cancer in Germany, which was pub-
lished at the end of November 2016 and was well re-
ceived. The report provided not only in-depth assess-
ments of cancer registry data but also information 
(including fi gures) on other aspects of cancer (from 
prevention to disease sequelae); this was the fi rst 
time this had been done in Germany. Since then, the 
ZfKD has published various short articles on topics 
from the report on its website under »Topic of the 
Month« (available only in German). This was often 
done using updated data and in a journalistic format. 
The report also provided the ZfKD with the impetus 
to conduct further networking with other data hold-
ers, the German Cancer Research Center (DKFZ) and 
the German Cancer Society. For the Cancer Society’s 
specialist journal Der Onkologe, the ZfKD, together 
with representatives from the registries, helped es-
tablish a regular section on epidemiology, including 
short reports on the main topic of each issue.
In 2016 and 2017, the ZfKD received 20 applica-
tions for external use of the cancer registry dataset, 
almost all of which were approved; however, in some 
cases minor restrictions were imposed due to data 
economy requirements. As such, the number of ap-
plications has increased signifi cantly: the ZfKD only 
received an average of about three applications per 
year between 2010 and 2015. Furthermore, external 
researchers are showing greater interest in working 
with the ZfKD, and this has already led to several 
joint publications on the epidemiology of some rare 
tumours such as pleural mesothelioma and gynaeco-
logical sarcoma. Together with the Department of 
Obstetrics and Gynaecology at Charité University 
Hospital in Berlin, a project was developed on the 
topic of long-term survival of patients with ovarian 
cancer. This project was funded by the Focus Area 
DynAge, a joint collaborative eff ort by research insti-
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(M/I Index) can largely be assumed to be regionally 
constant for the respective cancer diagnosis, provided 
there are no fundamental differences in diagnosis 
and therapy and, therefore, in the survival prospects 
of cancer patients in Germany. By combining the M/I 
Index in a reference region where registration is as-
sumed to be complete with regional mortality data, 
the regional incidence can be estimated and com-
pared with the number of cases actually recorded. 
The completeness of the registries in the reference 
region is also estimated in this way. Cases identified 
through death certificate only (DCO cases) are not 
taken into account here.
The following inclusion criteria were established 
for the reference region in 2010.
2 Methodological Aspects
2.1  Estimating the degree of capture in 
the epidemiological cancer regis-
tries (Estimation of Completeness)
The usefulness of population-based data with regard 
to cancer largely depends on the level of complete-
ness with which new cancer cases are registered. 
Therefore the German Centre for Cancer Registry Data 
(ZfKD) annually checks the completeness of the data 
from the population-based cancer registries in Ger-
many; since 2010 this has been done for all federal 
states. The estimation is made with the help of an 
internationally accepted indicator of completeness, 
namely the ratio of mortality to incidence. This ratio 
Figure 2.1.1
Development of the estimated completeness of the population-based cancer registries in Germany 2000 to 2002 and 2014, 
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1 1953 East-Berlin, 1995 Berlin (re-united)
2 1986 Münster administrative district, 2005 all North Rhine-Westphalia
3 2003 Darmstadt administrative district, 2007 all Hesse
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registration. Due to the current restructuring of can-
cer registration in some regions, temporary reduc-
tions in registration activity – particularly for diagno-
sis years 2015 through 2017 – cannot be ruled out. 
After completion of this restructuring, epidemiolog-
ical cancer registration should also profi t from the 
expansion of clinical registration, which is expected 
to help fi ll current holes in data collection.
2.2  Estimating national incidence 
for Germany
The estimation of cancer incidence rates for Ger-
many is based on the completeness estimates as ex-
plained in section 2.1. The estimated nationwide 
number of new cases for individual diagnoses and 
years are derived on one hand from the cases report-
ed by registries with estimated completeness above a 
certain threshold and the expected cases from those 
regions that are not (yet) deemed to be complete for 
the respective year.
For all diagnoses except thyroid cancer and ma-
lignant melanoma, registries with completeness of at 
least 90 % are considered as complete. Due to strong 
fluctuations in the ratio of mortality to incidence, the 
threshold levels for thyroid cancer and for malignant 
melanoma were set to 70 % and 80 %, respectively.
Death Certificate Only (DCO) cases from com-
plete registries were included beginning from the 
sixth year of statewide registration. For incomplete 
registries and for the first five years of statewide reg-
istration, the DCO proportions from the reference 
registries (according to site, age and gender) were 
used to calculate DCO cases. Because of diff ering 
stages of registry development, North Rhine-West-
phalia was divided into three regions (the administra-
tive districts of Münster, Düsseldorf/Cologne and 
Arnsberg/Detmold).
Because the entire dataset is analyzed anew 
each year to estimate incidence, the results may 
change (usually slightly) from estimate to estimate. 
This can partly be caused by delayed notification of 
incident cases and partly by the estimation method-
ology itself. Thus, the current incidence estimate for 
the year 2012 is approximately 2.5 % higher than the 
estimate from the last report. This is nearly equal to 
the number of delayed registration for this year. For 
the individual diagnoses that appear in this report, 
the deviations ranged from –1 % (vulva) to +10 % (leu-
kemias).
This report presents estimated trends over time 
since 1999. Since population-based cancer registries 
in some populous federal states only commenced 
registration between 2002 and 2009, the estimates 
▶ Comprehensive cancer registration for a period 
of at least ten years
▶ Completeness of more than 90 % for cancer 
overall over the past ten years (using the pre-
vious RKI estimation method) and more than 
80 % for all individual years
▶ Proportion of DCO-cases of less than 15 % for 
cancer overall over the past ten years or at least 
from the sixth year since the beginning of regis-
tration
These criteria are currently met by the registries in 
Saarland, Hamburg, Bremen, Schleswig-Holstein, 
Lower Saxony, Bavaria, Brandenburg, Mecklen-
burg-Western Pomerania, Saxony, Thuringia and the 
administrative district of Münster (North Rhine-West-
phalia). Due to a delay in providing their data, cases 
from Bremen and Saarland could not be used in the 
current reference region.
According to the principle described above, the 
expected incidence is calculated for six age groups 
and for 16 (for men) or 17 (for women) diagnosis 
groups. In order to compensate for random fluc-
tuations the observed and expected values were 
smoothed using log-linear models.
If mortality in the region being studied is too low 
(less than five cases of death per year on average) the 
modelled (smoothed) incidence in the reference re-
gion is used instead of the quotients derived from 
incidence and mortality for the appropriate age group 
in order to calculate the expected number of new cas-
es. The estimated degree of completeness for each 
diagnosis group is the result of the ratio of observed 
and expected case figures accumulated across all age 
groups. The completeness for cancer overall is again 
estimated by summing the observed and expected 
values for all diagnosis groups.
The described procedure has limitations, espe-
cially if the mortality for one type of cancer is low in 
absolute terms or relative to incidence (testicular can-
cer, malignant melanoma, thyroid cancer), or if the 
real ratio of mortality to incidence differs between the 
regions. This may, for example, be the case if early 
detection measures are utilised to varying degrees in 
the federal states or if they are introduced at different 
points in time, as was the case with mammogra-
phy-screening. Regional differences can also be 
caused by diff erent distributions of tumor stage or 
subtypes (as with thyroid cancer, for example).
According to current estimates, 12 federal states 
achieved an estimated completeness of at least 90 % 
for 2014, as compared with the aforementioned ref-
erence region; seven states achieved over 95 % com-
pleteness. Over the past few years, completeness in 
most registries has stabilized. Positive developments 
have particularly been seen for Baden-Württemberg, 
the last federal state to implement statewide cancer 
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nual number of new cases per 100,000 inhabitants 
for the respective age group and year.
Age-standardised rates
As the age-specific incidence for men and women in 
this report shows, the cancer incidence rate usually 
increases considerably with age. Thus, before com-
paring incidence or mortality in different countries 
or regions, or within the same population at different 
times, differences in the age structure of the com-
pared populations must first be removed with the 
help of age-standardisation. This is achieved through 
weighting and subsequent summing of the observed 
age-specific rates. An age-standardised rate indicates 
the incidence of an illness or cause of death per 
100,000 people in a pre-defined age structure (stand-
ard population). In this report the old European 
Standard Population has been used.
Cancer incidence and mortality risks
Age-specific incidence rates and mortality rates may 
be interpreted as age- and sex-specific risks of devel-
oping or dying from a specific cancer within a year. 
In order to make this form of risk communication 
clearer, age- and sex-specific risks of developing or 
dying from a specific form of cancer within the next 
ten years or at any point in the future were calculated. 
The results are presented both as a percentage and as 
one in N individuals of the same age and sex. So-
called »competing risks« – for example, the probabil-
ity that a 75-year-old man will die from a cause other 
than cancer within the next ten years – were also taken 
into consideration. Similarly, the »lifetime risk« was 
calculated, i.e. the risk of developing a certain cancer 
at any point during an entire lifespan. However, only 
the respective current rates (incidence and mortality 
rates and general life expectancy) are used in the cal-
culations. No prediction is therefore made regarding 
future changes in these values. Furthermore, these 
results are to be viewed as average values for the en-
tire German population, and individual risks may 
differ considerably due to the presence or absence of 
specific risk factors. The DevCan programme devel-
oped by the US National Cancer Institute was used to 
perform the calculations.
International comparison
To place the estimated cancer incidence and cancer 
mortality in Germany in an international context, we 
compared current age-standardised incidence and 
mortality rates with those in the countries bordering 
on Germany as well as the United Kingdom, Finland, 
Sweden, and the USA (see Annex for data sources). 
These statistics were not checked for plausibility or 
completeness, and so an underestimation – particu-
larly of the incidence – cannot be ruled out. For 
France, only mortality fi gure are given, since current 
for recent years are based on substantially more data 
than those for the period before 2002. Although the 
same methodology was used for both periods, esti-
mates for recent years can generally be viewed as 
more reliable. Estimates were also conducted for rarer 
types of cancer according to the same principle, but 
under the assumption that completeness within the 
diagnosis groups does not differ substantially. The 
results are shown in Chapter 3.29 and in even more 
detail on the website www.krebsdaten.de/database.
An estimate of the incidence of non-melanoma 
skin cancers (C44) is not possible using the method 
described above, due amongst other things to its low 
mortality. Experience shows that the acquisition of 
data on these diseases in population-based cancer 
registries is difficult, since treatment often occurs on 
a purely out-patient basis. Consequently, there is very 
little reliable data, even in an international context. 
However, in recent years some registries in Germany 
have made successful efforts to integrate registered 
dermatologists into the registration process. The es-
timate of nationwide incidence is thus based on the 
data of those registries where the age-standardised 
incidence rate over the past two years deviated by less 
than 25 % from the federal state with the highest re-
corded incidence (Schleswig-Holstein, Lower Saxony, 
North Rhine-Westphalia, Saarland, Hesse, Mecklen-
burg-Western Pomerania and Rhineland-Palatinate). 
The calculation was performed by projecting the 
pooled, age-specific incidence rates in these states 
onto the entire German population. However, a great 
degree of uncertainty still surrounds the incidence 
estimates for non-melanoma skin cancers, and these 
do not yet allow any reliable statements to be made 
regarding trends over time, which is why they are not 
presented in their own chapter. Non-melanoma skin 
cancers are not included in total cancer incidence 
(chapter 3.1), an internationally common practice.
2.3  Indicators and graphical 
presentations
The following section explains the statistical meas-
ures and graphical presentations found in the results 
chapters.
Age-specific rates
The age-specific rate is determined by dividing the 
number of cases of cancer or deaths in a certain 
age group by the corresponding number of men or 
women in this age group within the population. The 
graphical presentation of these rates shows the rela-
tionship between age and incidence by gender. The 
age-specifi c incidence rates are expressed as the an-
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Regional comparison
The mean age-standardised incidence rates (old Eu-
ropean Standard) for 2013 and 2014 from the federal 
states are depicted in bar plots alongside the corre-
sponding nationwide estimates for Germany. Federal 
states with an estimated completeness for the year 
2014 of less than 90 % (80 % for melanoma and 70 % 
for thyroid) are indicated by lighter colors of the 
 respective incidence bars. Mean age-standardised 
 mortality for the same years is shown by diagnosis, 
sex and federal state in comparison to nationwide 
mortality in Germany, using data from the German 
Federal Statistical Office (www.gbe-bund.de).
Crude rates
A crude incidence or mortality rate for a specific can-
cer site and population is calculated by dividing the 
total number of new cases of cancer reported (inci-
dence) or the number of deaths due to cancer (mor-
tality) in a pre-determined time period by the total 
number of all women and/or men in the correspond-
ing population (in this case the residential population 
of Germany). The result is expressed as the number 
of new diagnoses or deaths per 100,000 residents per 
year. In contrast to the age-standardised rates, crude 
rates are highly dependent on the age structure of a 
population.
Survival rates
The survival analyses in this report describe the aver-
age survival prospects of patients 15 years of age or 
older at diagnosis of a specific cancer type. Absolute 
and relative survival rates from one to ten years have 
been calculated for this purpose. Absolute survival 
rates represent the proportion of patients who are 
still alive at a certain time after their diagnosis. For 
example, an absolute 5-year survival rate of 80 % 
means that 80 people out of 100 with a specific type 
of cancer have survived the first five years after their 
diagnosis.
Relative survival rates approximate the cancer-re-
lated mortality in terms of the ratio of the absolute 
survival of cancer patients to the expected survival in 
the general population of the same age and sex. For 
example, a relative 5-year survival rate of 100 % means 
that within 5 years of diagnosis, just as many persons 
with cancer have died as would have been expected 
even without the diagnosis. The relative survival rate 
is always higher than the corresponding absolute 
rate. Expected survival has been calculated using the 
so-called »Ederer II method« using lifetables from 
the German Federal Statistical Office.
Based on previously determined data quality 
 criteria, data from Hamburg, Lower Saxony, Bran-
denburg, Mecklenburg-Western Pomerania, Saxony 
and the administrative district of Münster (North 
Rhine-Westphalia) were used for current survival es-
data on nationwide incidence were unavailable by the 
editorial deadline. For some types of cancer (e.g. blad-
der cancer, renal cancer) the grouping of diagnoses 
according to ICD-10 in some countries differs some-
what from that used in Germany. Therefore, com-
parability in these cases is somewhat limited (see 
appropriate footnote).
Median age at diagnosis and death
The median age at diagnosis by cancer site and sex 
was calculated using data from complete registries 
and included cases diagnosed in 2013 and 2014. The 
inclusion of DCO cases, for which the age at death is 
used place of the unknown age at diagnosis, inevita-
bly leads to a slight overestimation of this value. The 
median age at death was calculated with an approxi-
mation equation using offi  cial cause-of-death statis-
tics from the Federal Statistical Offi  ce, which are only 
available in 5-year age groups.
Mortality
Cancer mortality is based on annual numbers of 
deaths due to cancer according to the official cause-
of-death statistics. The deaths are attributed to the 
underlying cause of death and grouped by age and 
sex. The mortality rate is expressed as the ratio of the 
annual number of deaths to the size of the underlying 
population. The rates are relative to 100,000 people. 
In this report, the absolute number of deaths, as well 
as crude and the age-standardised (old European 
Standard) mortality rates from 1999 to 2015 are pre-
sented.
Prediction of incidence for 2018
To predict the number of cancer cases for the year 
2018, current sex- and age group-specifi c trends were 
determined for all diagnoses covered in this report. 
For this, the Joinpoint method was used, which uses 
regression models to identify time points at which 
there is a statistically signifi cant change in time 
trend. The average annual percent change since the 
most recent joinpoint was carried forward to the year 
2018 to calculate the prognoses. The resulting age- 
and sex-specifi c rates for the year 2018 were trans-
formed into absolute case numbers using the 13th 
coordinated population prognosis (variation 4) from 
the Federal Statistical Offi  ce. For malignant mela-
noma and prostate cancer as well as breast cancer 
among women in the age group 50-74 years, the cur-
rent trends are heavily infl uenced by recently intro-
duced screening programs or by changes in the utili-
zation of opportunistic screening, such that the 
projection of current trends to the year 2018 would 
seem unrealistic. Therefore, the age-specifi c inci-
dence rates in 2014 were held constant for these di-
agnoses, thereby intentionally indicating only demo-
graphic eff ects on the projected number of new cases.
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Tumour stage distribution
The extent of solid malignant tumours at the time of 
diagnosis in the years 2013 to 2014 was evaluated 
using the TNM-classification (7th edition). Given the 
missing data on lymph node status and distant me-
tastases, only the distribution of T stages (tumour 
size or spread) are presented here. Those registries 
with proportions of missing values (including DCO 
cases) less than 50 % for the respective cancer site 
were included in the stage analyses. The stages of 
sites for which fewer than four federal states were 
able to fulfil this criterion, are not presented.
5-year prevalence
The 5-year prevalence refers to the number of people 
living at a given time (here 31 December 2014) who 
had been newly diagnosed with cancer within the 
previous five years, i. e. between 2010 and 2014. The 
prevalence is calculated using the Pisani method 
from the estimated incidence rates for Germany and 
the absolute survival rates calculated using the Ka-
plan-Meier method (according to age, sex, cancer site, 
and calendar year) for the regions listed under ›sur-
vival rates‹ (see above).
Additional analyses
For some cancer sites, additional analyses – for exam-
ple by histology or sub-site – can be found in this 
 report or on the ZfKD website (www.krebsdaten.de/
english). When not otherwise indicated, these analy-
ses are based on the data from complete registries 
(estimated completeness > 90 % for the respective 
diagnosis).
timates. Three registries that were included in sur-
vival estimates in the last edition of »Cancer in Ger-
many« had not completed mortality linkage for 2014 
prior to the current data transmission. Therefore, 
data from these registries was not included in analy-
ses presented here. This limits the comparability of 
survival estimates with those from earlier editions.
In order to make the most up-to-date estimates 
of survival prospects possible, the so-called »period 
method« was used. This takes into account the sur-
vival of people with cancer who have been alive 
during a specific period (in this case 2013–2014).
The ranges quoted for five- and ten- year survival 
represent the lowest and highest values in the indi-
vidual regions included, though for these purposes 
only regions with a standard error for the estimated 
survival of less than 7 % were taken into account. If 
this criterion was not met by at least four regions, no 
range details are presented. The ranges reflect diff er-
ences in the quality of care most likely only to a very 
small degree. Diff erences in data quality or in the 
proportion of DCO cases may play a role, as well as 
random fluctuations, especially for smaller federal 
states. Diff erences in registration practices between 
registries may also influence results, in particular 
trace-back for DCO cases, which is not performed in 
all federal states. Survival calculations 10 years after 
diagnosis are based on far fewer cases than for sur-
vival after fi ve years. For this reason, the registry-spe-
cifi c 10-year survival demonstrates a larger statistical 
uncertainty than 5-year survival. Therefore, it may 
occur that some values for the range of 10-year sur-
vival lie slightly higher than the corresponding values 
for 5-year survival.
Overall, it can be assumed that the estimated 
survival rates for Germany are slightly over-estimat-
ed, at least for cancers with poor prognosis. However, 
this is probably also the case for most internationally 
published results.
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3 Results
3.0 Overview of incident cancer cases and cancer deaths
Table 3.0.1
Estimated numbers of incident cancer cases in Germany 2014
No. of incident cases Incidence rate1
Cancer site ICD-10 Men Women Men Women
Oral cavity and pharynx C00 – C14 9,130 3,700 16.9 5.9
Oesophagus C15 5,370 1,560 9.3 2.2
Stomach C16 9,340 6,090 15.3 7.7
Colon and rectum C18 – C21 33,120 27,890 54.0 35.7
Liver C22 6,370 2,710 10.4 3.6
Gallbladder and biliary tract C23, C24 2,380 2,990 3.7 3.4
Pancreas C25 8,550 8,580 13.9 10.4
Larynx C32 2,980 520 5.3 0.9
Lung C33, C34 34,560 19,280 57.3 29.0
Malignant melanoma of the skin C43 10,910 10,310 19.5 18.6
Mesothelioma C45 1,290 310 1.9 0.4
Soft tissue not incl. Mesothelioma C46 – C49 2,040 1,870 3.9 3.2
Breast C50 650 69,220 1.1 114.6
Vulva C51 3,130 4.4
Cervix C53 4,540 9.2
Uterus C54, C55 10,680 15.9
Ovaries C56 7,250 11.0
Prostate C61 57,370 92.7
Testis C62 4,070 10.3
Kidney C64 9,480 5,480 16.5 7.8
Bladder C67 11,680 4,170 18.2 4.9
Central nervous system C70 – C72 3,880 3,160 7.6 5.4
Thyroid gland C73 1,840 4,280 3.8 9.2
Hodgkin's lymphoma C81 1,340 1,030 3.1 2.4
Non-Hodgkin lymphomas C82 – C88 9,160 7,880 15.9 11.2
Multiple myeloma C90 3,550 2,960 5.7 3.8
Leukaemias C91 – C95 7,640 6,060 13.6 8.9
Other cancer sites 12,460 11,340 21.1 15.0
Total cancer2 C00 – C97 w/o C44 249,160 226,960 420.9 344.3
Figure 3.0.1
Most frequent tumour sites as a percentage of all new cancer cases in Germany 2014 
(not including non-melanoma skin cancer)
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Table 3.0.2
Number of deaths from cancer in Germany 2014
Source: Offi  cial cause of death statistics, Federal Statistical Offi  ce, Wiesbaden
No. of deaths Mortality rate1
Cancer site ICD-10 Men Women Men Women
Oral cavity and pharynx C00 – C14 4,095 1,353 7.3 1.9
Oesophagus C15 4,107 1,236 6.9 1.6
Stomach C16 5,545 4,065 8.8 4.6
Colon and rectum C18 – C21 13,580 11,932 21.0 12.8
Liver C22 5,246 2,440 8.2 2.9
Gallbladder and biliary tract C23, C24 1,544 2,199 2.4 2.3
Pancreas C25 8,231 8,384 13.0 9.5
Larynx C32 1,301 224 2.2 0.3
Lung C33, C34 29,560 15,524 47.6 21.7
Malignant melanoma of the skin C43 1,804 1,270 2.9 1.7
Mesothelioma C45 1,151 277 1.7 0.3
Soft tissue not incl. Mesothelioma C46 – C49 724 901 1.2 1.2
Breast C50 134 17,670 0.2 23.0
Vulva C51 849 0.9
Cervix C53 1,506 2.4
Uterus C54, C55 2,472 2.9
Ovaries C56 5,354 6.9
Prostate C61 13,704 19.7
Testis C62 153 0.3
Kidney C64 3,243 2,035 5.1 2.2
Bladder C67 3,897 1,795 5.8 1.8
Central nervous system C70 – C72 3,340 2,765 6.1 4.1
Thyroid gland C73 342 390 0.6 0.4
Hodgkin's lymphoma C81 183 150 0.3 0.2
Non-Hodgkin lymphomas C82 – C88 3,560 2,949 5.5 3.1
Multiple myeloma C90 2,071 1,910 3.1 2.1
Leukaemias C91 – C95 4,168 3,575 6.4 4.0
Other cancer sites 9,648 8,416 15.3 9.3
Total cancer2 C00 – C97 w/o C44 121,331 101,641 191.5 124.1
Figure 3.0.2
Most frequent tumour sites when cancer was the cause of death in Germany 2014 
1 age-standardised (old European Standard)  2 not including non-melanoma skin cancer (C44)
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certain or unknown behaviour have been defi ned 
diff erently in the past –for example, this has been the 
case with tumours of the bladder. Finally, non-mela-
notic forms of skin cancer (»white skin cancer«) are 
not included in »all cancer sites«, which is common 
practice in cancer registration internationally. Esti-
mates of the frequency of this widespread, yet seldom 
life-threatening disease can be found in chapter 3.29.
Malignant neoplasms can occur in all kinds of 
organs in the body and develop from many diff erent 
types of cell. Nevertheless, most cancers are found on 
internal or external body surfaces (epithelia). Approx-
imately 70 % of cancers are adenocarcinomas that 
originate in glandular tissue. A further 15 % are squa-
mous-cell carcinomas, malignant tumours of the 
transitional epithelium (urothelium carcinoma) and 
small-cell carcinoma, which occur, for example, in 
the lung. Leukaemias and lymphomas develop from 
blood-forming bone marrow and lymphoid tissues, 
lymph nodes or the spleen. However, malignant tu-
mours may also develop out of the supporting cells of 
the nervous system (glial cells) or from pigment-form-
ing cells (melanomas). Cancers of connective tissues 
(such as the bone, cartilage and blood vessels), in-
cluding mesotheliomas and sarcomas, are among the 
rarer types of cancer.
3.1 All cancer sites
Epidemiology
The term »all cancer sites« refers to all forms of 
 malignant neoplasms including lymphomas and leu-
kaemias. When used in this report, »malignant tu-
mours« (in other words, tumours that invade the 
surrounding tissue or spread via the blood and lym-
phatic systems) is used in line with the defi nition 
drawn up by the International Statistical Classifi ca-
tion of Diseases and Related Health Problems (ICD 
10, Chapter C). Tumours can be described as either 
benign or malignant neoplasms depending on their 
characteristic forms of growth. However, the catego-
ries that this leads to have been subject to change and 
do not always refl ect the clinical course of a disease. 
Some tumours, such as non-invasive papillary carci-
nomas of the urinary bladder and certain neoplasms 
of the blood-forming organs (such as myelodysplastic 
syndromes), are associated with greater risks and 
heavier burdens for the patients than certain thyroid 
tumours, for example, which, although malignant, 
have a particularly favourable prognosis. Further-
more, for tumours of the central nervous system, the 
risks of serious complications are less dependent on 
the patterns of growth they display than on their lo-
calisation. The categories that result from dividing 
neoplasms as benign, malignant or tumours of un-
Table 3.1.1
Overview of key epidemiological parameters for Germany, ICD-10 C00 – C97 without C44
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 255,830 231,280 249,160 226,960 259,300 234,300
Crude incidence rate1 648.2 561.7 627.7 549.7 647.1 567.4
Standardised incidence rate1,2 439.9 354.1 420.9 344.3 415.1 347.8
Median age at diagnosis 70 69 70 69
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 121,313 101,775 121,331 101,641 122,452 103,071
Crude mortality rate1 307.4 247.2 305.7 246.2 304.8 248.3
Standardised mortality rate1,2 196.5 126.7 191.5 124.1 189.1 124.2
Median age at death 73 76 74 76 74 76
1 per 100,000 persons  2 age-standardised (old European Standard)
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 774,100 771,500 1,304,200 1,322,400
Absolute survival rate (2013 – 2014)3 50 (48 – 51) 58 (55 – 59) 38 (36 – 39) 47 (44 – 48)
Relative survival rate (2013 – 2014)3 59 (57 – 61) 65 (63 – 66) 55 (53 – 56) 60 (58 – 63)
3 in percentages (lowest and highest value of the included German federal states)
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Risk factors and early detection
The aetiology of many cancers is often unknown, and 
even in cases where it is known, there may be no way 
of infl uencing the risk factors associated with the dis-
ease. As such, prevention strategies can only have an 
impact on the incidence of certain types of tumours. 
Nevertheless, this includes cancer that aff ects large 
numbers of people. In fact, the World Health Organi-
zation estimates that more than 30 % of all cancer 
cases could be avoided with preventive measures.
Tobacco consumption is the most important 
avoidable risk factor associated with cancer. Accord-
ing to estimates by the German Centre for Cancer 
Registry Data, a total of around 16 % of all cancer cases 
in Germany are attributable to smoking. For a long 
time, observational epidemiological investigations 
have shown that overweight and a lack of exercise are 
also linked to cancer. Moreover, recent research into 
metabolic syndrome is revealing the possible biologi-
cal mechanisms behind this link. Metabolic syndrome 
is a chronic »metabolic imbalance« linked to hyper-
tension, high blood cholesterol levels and hypergly-
caemia. Inflammatory processes in adipose tissue are 
also suspected of being associated with cancer.
Among the factors linked to diet, alcohol plays 
an important role. Low quantities of fruit, vegetables, 
and dietary fi bre, often combined with a high intake 
of red meat, have also been identified as risk factors 
associated with a number of frequently occurring 
types of cancer. In observational studies, however, the 
infl uence of certain foodstuff s and the substances 
that they contain cannot always be separated from a 
person’s energy balance or other factors.
Ultraviolet light (UV radiation) from sunlight is 
a further avoidable risk factor linked to cancer. Many 
people overestimate the influence of hazardous sub-
stances and impurities in foodstuff s, as well as envi-
ronmental factors or exposure to toxins in the work-
place in Germany. However, these factors can also 
play a substantial role in the development of cancer, 
even in this country. Examples include radon, a nat-
urally occurring noble gas, which is estimated to be 
responsible for about 5 % of lung cancer deaths in 
Germany, or occupational exposure to asbestos in the 
past, which, due to its long latency period, still leads 
to mesotheliomas of the pleural cavity and peritone-
um. Even medical procedures may have an impact on 
an individual’s risk of cancer. Potential risks include 
diagnostic procedures and therapies involving expo-
sure to radiation, cytostatic agents used in chemo-
therapy and hormone replacement therapy for meno-
pausal women, which has been identified as a risk 
factor for breast cancer. Chronic infections are now 
known as risk factors associated with some wide-
spread forms of cancer. Vaccinations or causal thera-
In 2014, the ZfKD estimates that around 
476,000 cases of cancer were initially diagnosed in 
Germany (men: approximately 249,200; women: 
227,000). Breast cancer accounted for over half of all 
cases (69,900), followed by cancer of the bowel 
(61,000), the prostate (57,400) and the lung (53,800) 
(see Table 3.0.1).
Between 2004 and 2014, the absolute number of 
new cancer cases increased among men by around 
6 % and among women by 9 %. These fi gures, partic-
ularly in the case of men, can be explained by the 
diff erences that have occurred to the age structure of 
the population (the increase in the number of elderly 
people). Once these fi gures have been adjusted for 
age, it becomes clear that a 10 % drop occurred in the 
rate of new cases of cancer among men whereas the 
rate rose by 3 % among women. These contrasting 
tendencies mainly refl ect the diff erent trends among 
men and women in terms of lung cancer and other 
smoking-related cancers (see Chapter 3.10).
Between 2005 and 2015, age-standardised mor-
tality rates decreased by 12 % among men and 7 % 
among women. However, due to demographic 
changes, the absolute number of deaths from cancer 
have actually increased by 10 % among men and 4 % 
among women. On the other hand, the proportion of 
deaths attributed to cancer as an underlying cause 
has remained constant since the end of the 1990s 
(women: 22 %; men 28 %). This indicates that 
achievements in in cancer treatment and prevention 
have contributed to an increased life expectancy of 
about two or three years over this period.
Every second man and woman in Germany can 
expect to develop cancer during the course of life. 
Although cancer is generally less common among 
women, it tends to aff ect women earlier. Women 
 under the age of 55 have higher incidences of cancer 
than men of the same age, but this trend is reversed 
among higher age groups with the incidence for men 
aged over 65 almost twice as high as that among 
women.
Relative 5-year survival rates compare the higher 
mortality of cancer patients to that of the general pop-
ulation of the same age and gender. They range from 
favourable rates of above 90 % for malignant mela-
noma of the skin, testicular cancer, and prostate can-
cer, to survival rates of less than 20 % for lung, liver 
and pancreatic cancer and mesothelioma (see Figure 
3.1.0). During the last thirty years, the overall progno-
sis for cancer patients in Germany has improved con-
siderably. The most signifi cant improvements among 
adult cancer patients have been achieved for malig-
nant tumours of the breast, bowel and prostate, while 
for children, particularly the prognosis for leukaemia 
patients has been improved substantially.
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pies, in contrast, can help lower the risk of cancer. 
These include vaccinations against hepatitis viruses 
(a risk factor linked to liver cancer), and it is hoped 
that vaccination against human papilloma viruses will 
have a similar eff ect in reducing the incidence of cer-
vical carcinoma. In addition to avoidable risk factors, 
however, genetic causes may also increase the risk of 
developing cancer. Until now, only very few of these 
genetic mutations have been clearly identified. The 
risk factors linked to specific types of cancer are pre-
sented in more detail in the individual sections.
Finally, the statutory health insurers in Germany 
provide cancer screening for malignant tumours of 
the skin and bowel as well as for breast and cervical 
cancer in women and prostate cancer in men. These 
investigative measures are described in more detail in 
the relevant sections.
Figure 3.1.0
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Figure 3.1.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C00 – C97 without C44, 
Germany 1999 – 2014/2015
Figure 3.1.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C00 – C97 without C44, 
Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.1.2
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Table 3.1.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C00 – C97 without C44, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 1.2 % (1 in 84) 50.5 % (1 in 2) 0.2 % (1 in 410) 25.9 % (1 in 4)
45 years 3.5 % (1 in 28) 50.4 % (1 in 2) 1.2 % (1 in 87) 26.0 % (1 in 4)
55 years 10.2 % (1 in 10) 50.0 % (1 in 2) 3.7 % (1 in 27) 25.8 % (1 in 4)
65 years 20.3 % (1 in 5) 47.3 % (1 in 2) 7.9 % (1 in 13) 24.4 % (1 in 4)
75 years 27.2 % (1 in 4) 39.9 % (1 in 3) 12.7 % (1 in 8) 21.0 % (1 in 5)
Lifetime risk 50.4 % (1 in 2) 25.7 % (1 in 4)
Women aged in the next ten years ever in the next ten years ever
35 years 2.2 % (1 in 45) 43.1 % (1 in 2) 0.3 % (1 in 320) 20.1 % (1 in 5)
45 years 4.9 % (1 in 20) 41.9 % (1 in 2) 1.1 % (1 in 95) 19.9 % (1 in 5)
55 years 8.6 % (1 in 12) 39.4 % (1 in 3) 2.6 % (1 in 38) 19.3 % (1 in 5)
65 years 13.2 % (1 in 8) 34.6 % (1 in 3) 4.9 % (1 in 20) 17.6 % (1 in 6)
75 years 16.7 % (1 in 6) 26.7 % (1 in 4) 7.9 % (1 in 13) 14.4 % (1 in 7)
Lifetime risk 43.5 % (1 in 2) 20.1 % (1 in 5)
Figure 3.1.4a
Absolute survival rates up to 10 years after fi rst diagnosis, 
by sex, ICD-10 C00 – C97 without C44, 
Germany 2013 – 2014
Figure 3.1.4b
Relative survival rates up to 10 years after fi rst diagnosis, 
by sex, ICD-10 C00 – C97 without C44, 
Germany 2013 – 2014
Figure 3.1.3
Distribution of T-stages at fi rst diagnosis by sex

















23ICD-10 C00 – C97 without C44 Cancer in Germany
Figure 3.1.5
Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C00 – C97 without C44, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.1.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C00 – C97 without C44, 2013 – 2014 or latest available year (details and sources, see appendix)











































































1 data incl. D09.0–1, D30.1–9, D35.2–4, D41.1–9, D32–D33, D42–D43, D44.3–5, D46–D47 but excl. C46.0
2 no data for incidence
0 100 200 300 400 500 600
24 Cancer in Germany Oral cavity and pharynx
Epidemiology
Cancer of the oral cavity and the pharynx are part of 
a heterogeneous group of malignant neoplasms. In 
terms of their histology, more than 90 % of cases 
occur as squamous cell carcinomas, with slightly 
more than 5 % of cases developing as adenocarcino-
mas, most of which are of the salivary glands.
Men are more likely to develop these forms of can-
cer than women are, and, on average, they do so three 
years earlier than women do (men: 63; women: 66).
Age-standardised mortality rates have increased 
slightly over the previous 15 years among women, but 
there has been a recent decline among men. Death 
and disease rates increased more in men and women 
aged 60 years and older, but decreased among the 
younger age groups.
Overall, women have a higher relative 5-year sur-
vival rate (59 %) than men (48 %). Due to diff erences 
in alcohol and tobacco use, a lower proportion of 
women develop cancers of the mouth, tongue or 
throat. The lower survival rates associated with these 
cancers compared to malignant tumours of the lip 
and salivary glands contribute towards the diff erences 
in survival rates. According to the data available on 
tumour stages (which are available for between 75 % 
and 80 % of cases), more than one in three tumours 
are diagnosed at an early stage among women (T1), 
but this can be said of only every fourth case in men.
Risk factors
The most important risk factors linked to cancer of 
the mouth and throat are tobacco use and alcohol con-
sumption. Importantly, these two risk factors re-
inforce each another in combination.
Another main risk factor is chronic infection 
with high-risk human papilloma viruses (HPV). In 
particular, some cancers of the parts of the pharynx 
that adjoin the oral cavity (oropharynx) may be partly 
caused by these viruses.
Further possible risk factors include a one-sided 
diet that is low in vitamins, and excessive meat con-
sumption. A lack of proper oral hygiene and mechan-
ical irritations, such as those caused by poorly fitting 
dentures, are also possible risk factors. Exposure to 
sunlight can contribute to carcinoma of the lips. Peo-
ple with type 2 diabetes, a marked immunodeficiency, 
as well as rare pre-existing illnesses, may also have an 
increased risk of tumours of the oral cavity and the 
lips.
Epstein-Barr virus is regarded as a further viral 
risk factor, in particular for nasopharyngeal carcino-
ma. Finally, there is clear evidence that a genetic pre-
disposition also plays a role in the development of 
carcinomas in the head and neck area.
3.2 Oral cavity and pharynx
Table 3.2.1
Overview of key epidemiological parameters for Germany, ICD-10 C00 – C14
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 9,630 3,740 9,130 3,700 9,400 4,300
Crude incidence rate1 24.4 9.1 23.0 9.0 23.4 10.4
Standardised incidence rate1,2 18.2 6.1 16.9 5.9 16.4 6.5
Median age at diagnosis 62 66 63 66
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 4,084 1,389 4,095 1,353 4,086 1,378
Crude mortality rate1 10.4 3.4 10.3 3.3 10.2 3.3
Standardised mortality rate1,2 7.5 2.0 7.3 1.9 7.2 1.9
Median age at death 64 71 65 71 65 71
1 per 100,000 persons  2 age-standardised (old European Standard) 
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 28,200 12,600 44,700 20,600
Absolute survival rate (2013 – 2014)3 43 (40 – 45) 53 (52 – 58) 29 (29 – 30) 40 (37 – 49)
Relative survival rate (2013 – 2014)3 48 (43 – 51) 59 (57 – 65) 36 (34 – 38) 50 (47 – 60)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.2.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C00 – C14, Germany 1999 – 2014/2015
Figure 3.2.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C00 – C14, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.2.2
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Table 3.2.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C00 – C14, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 2,000) 1.7 % (1 in 60) < 0.1 % (1 in 8,000) 0.8 % (1 in 130)
45 years 0.2 % (1 in 410) 1.6 % (1 in 61) 0.1 % (1 in 1,100) 0.8 % (1 in 130)
55 years 0.6 % (1 in 180) 1.4 % (1 in 69) 0.2 % (1 in 430) 0.7 % (1 in 140)
65 years 0.6 % (1 in 180) 1.0 % (1 in 100) 0.3 % (1 in 380) 0.5 % (1 in 190)
75 years 0.4 % (1 in 270) 0.5 % (1 in 190) 0.2 % (1 in 470) 0.3 % (1 in 300)
Lifetime risk 1.7 % (1 in 61) 0.8 % (1 in 130)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 4,600) 0.7 % (1 in 150) < 0.1 % (1 in 24,700) 0.3 % (1 in 380)
45 years 0.1 % (1 in 1,200) 0.7 % (1 in 150) < 0.1 % (1 in 5,000) 0.3 % (1 in 380)
55 years 0.2 % (1 in 560) 0.6 % (1 in 170) 0.1 % (1 in 1,900) 0.2 % (1 in 400)
65 years 0.2 % (1 in 510) 0.4 % (1 in 230) 0.1 % (1 in 1,400) 0.2 % (1 in 490)
75 years 0.2 % (1 in 610) 0.3 % (1 in 360) 0.1 % (1 in 1,400) 0.1 % (1 in 670)
Lifetime risk 0.7 % (1 in 140) 0.3 % (1 in 380)
Figure 3.2.4a
Absolute survival rates up to 10 years after fi rst diagnosis, 
by sex, ICD-10 C00 – C14, Germany 2013 – 2014
Figure 3.2.4b
Relative survival rates up to 10 years after fi rst diagnosis, 
by sex, ICD-10 C00 – C14, Germany 2013 – 2014
Figure 3.2.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C00 – C14, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
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26% 28% 21% 25%
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Figure 3.2.5
Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C00 – C14, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.2.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C00 – C14, 2013 – 2014 or latest available year (details and sources, see appendix)
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Epidemiology
Cancer of the oesophagus causes about 3 % of all can-
cer deaths in men and 1 % in women. In Germany, 
men are diagnosed with cancer of the oesophagus 
around four to five times more frequently than wom-
en and, at an average age of 67, typically four years 
earlier. Whereas the incidence rates among men aged 
65 or above remain almost constant, death rates for 
both genders rise with increasing age.
Since 1999, age-standardised incidence and mor-
tality rates have continued to increase among women 
but have remained virtually unchanged in men. In 
addition, this type of cancer is occurring less among 
people aged under 60 years, but increasing among 
older age groups.
Squamous-cell carcinomas account for between 
50 % and 60 % of all cases of cancer of the oesopha-
gus. The proportion of adenocarcinomas, which are 
almost exclusively found in the transitionary area be-
tween the oesophagus and the stomach, has risen by 
more than one third over recent years.
Men and women who develop oesophageal carci-
noma have unfavourable survival prospects, with a 
relative 5-year survival rate of just 21 %. Only one in 
seven tumours is diagnosed at an early stage (T1).
Risk factors
Alcohol and tobacco consumption are among the 
most important risk factors associated with the most 
common forms of squamous cell carcinomas of the 
oesophagus. These factors reinforce each other in 
combination. Studies have also shown that people 
aff ected by this form of cancer often eat very low levels 
of fruit and vegetables.
The somewhat rarer adenocarcinomas are often 
associated with gastroesophageal refl ux diseases (per-
sistent refl ux of gastric juice into the oesophagus/
chronic heartburn). This can also lead to mucosal 
changes in the lower section of the oesophagus, and 
the development of »Barrett’s oesophagus«, which 
is regarded as a precancerous condition. A lower-than- 
average consumption of fruit and vegetables also 
increases the risk of developing adenocarcinomas. 
Further risk factors include smoking and overweight; 
family clusters of cases have been recorded. Finally, 
research into the possible links between this type of 
cancer and human papilloma viruses has produced 
contradictory fi ndings.
Table 3.3.1
Overview of key epidemiological parameters for Germany, ICD-10 C15
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 5,150 1,490 5,370 1,560 5,700 1,700
Crude incidence rate1 13.0 3.6 13.5 3.8 14.2 4.1
Standardised incidence rate1,2 9.1 2.1 9.3 2.2 9.3 2.3
Median age at diagnosis 67 73 67 71
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 4,244 1,192 4,107 1,236 4,269 1,238
Crude mortality rate1 10.8 2.9 10.3 3.0 10.6 3.0
Standardised mortality rate1,2 7.4 1.5 6.9 1.6 7.1 1.5
Median age at death 69 74 70 74 69 75
1 per 100,000 persons  2 age-standardised (old European Standard) 
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 9,100 2,500 12,400 3,500
Absolute survival rate (2013 – 2014)3 18 (13 – 22) 18 (13 – 23) 12 (8 – 15) 13 (10 – 18)
Relative survival rate (2013 – 2014)3 21 (15 – 24) 21 (14 – 27) 16 (11 – 20) 17 (13 – 23)
3 in percentages (lowest and highest value of the included German federal states)
3.3 Oesophagus
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Figure 3.3.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C15, Germany 1999 – 2014/2015
Figure 3.3.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C15, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.3.2
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Table 3.3.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C15, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 6,800) 1.0 % (1 in 100) < 0.1 % (1 in 9,500) 0.8 % (1 in 120)
45 years 0.1 % (1 in 960) 1.0 % (1 in 100) 0.1 % (1 in 1,400) 0.8 % (1 in 120)
55 years 0.3 % (1 in 380) 0.9 % (1 in 110) 0.2 % (1 in 500) 0.8 % (1 in 130)
65 years 0.4 % (1 in 270) 0.7 % (1 in 140) 0.3 % (1 in 330) 0.7 % (1 in 150)
75 years 0.3 % (1 in 320) 0.4 % (1 in 230) 0.3 % (1 in 330) 0.4 % (1 in 230)
Lifetime risk 1.0 % (1 in 100) 0.8 % (1 in 120)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 23,400) 0.3 % (1 in 350) < 0.1 % (1 in 48,700) 0.2 % (1 in 430)
45 years < 0.1 % (1 in 4,800) 0.3 % (1 in 350) < 0.1 % (1 in 8,400) 0.2 % (1 in 430)
55 years 0.1 % (1 in 1,900) 0.3 % (1 in 370) < 0.1 % (1 in 2,800) 0.2 % (1 in 440)
65 years 0.1 % (1 in 1,200) 0.2 % (1 in 440) 0.1 % (1 in 1,500) 0.2 % (1 in 490)
75 years 0.1 % (1 in 980) 0.2 % (1 in 610) 0.1 % (1 in 1,200) 0.2 % (1 in 650)
Lifetime risk 0.3 % (1 in 350) 0.2 % (1 in 430)
Figure 3.3.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C15, Germany 2013 – 2014
Figure 3.3.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C15, Germany 2013 – 2014
Figure 3.3.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C15, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
16% 14% 55% 16%
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Figure 3.3.5
Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C15, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.3.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C15, 2013 – 2014 or latest available year (details and sources, see appendix)
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Epidemiology
A steady decline in the incidence and mortality asso-
ciated with gastric cancer has been observed in Ger-
many over many decades, as in other industrial na-
tions. This trend applies to all age groups, and both 
women and men. The decline in gastric cancer is 
particularly due to fewer cases of tumours occurring 
in the gastric outlets (the antrum and pylorus). The 
risk of developing this form of cancer, however, in-
creases steadily with age. On average, men are diag-
nosed with gastric cancer at 72; women are most like-
ly to be diagnosed with the disease at 75. About 1 % of 
all deaths in Germany are due to stomach cancer. The 
5-year relative survival rate is currently estimated to be 
33 % for women and 30 % for men. Although pros-
pects for survival have improved recently, they are still 
unfavourable compared to other cancers. The stage of 
the tumour is noted on just over half of all diagnoses. 
In about two-thirds of these cases, cancer was discov-
ered at an advanced stage (T3 or T4). In terms of his-
tology, the stomach is predominately aff ected by spe-
cial forms of adenocarcinoma. Mucosa-associated 
MALT lymphomas that originate in the mucosa of the 
stomach and which are counted among low-grade 
non-Hodgkin lymphomas, are particularly notewor-
thy in this respect.
Risk factors
The most important risk factor linked to gastric can-
cer is a bacterial infection of the stomach with Heli-
cobacter pylori. Smoking and excessive alcohol con-
sumption also increase the risk of stomach cancer. 
Nutritional factors play a complex role: diets that are 
low in vegetables, or rich in animal products, are as-
sociated with a higher risk. In addition, there are in-
dications that chronic heartburn or gastro-oesopha-
geal reflux disease increase the risk of certain forms 
of tumour at the transition from the stomach to the 
oesophagus. Obesity can also promote the develop-
ment of these carcinomas. Low socio-economic status 
and stomach surgery in the past continue to be asso-
ciated with a higher frequency of stomach cancer.
First-degree relatives of patients are at a two to 
three times higher risk than the general population. 
It is not always clear whether this is due to a shared 
lifestyle, the transmission of H. pylori within the fam-
ily, or hereditary genetic conditions. Some hereditary 
syndromes certainly increase the risk of gastric carci-
nomas.
Pernicious anaemia and certain other pre-exist-
ing diseases increase the risk of this cancer but are 
relevant only for comparatively few people.
3.4 Stomach
Table 3.4.1
Overview of key epidemiological parameters for Germany, ICD-10 C16
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 9,490 6,380 9,340 6,090 9,100 5,600
Crude incidence rate1 24.0 15.5 23.5 14.8 22.5 13.4
Standardised incidence rate1,2 15.8 8.1 15.3 7.7 14.0 6.9
Median age at diagnosis 72 75 72 75
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 5,591 4,031 5,545 4,065 5,429 3,829
Crude mortality rate1 14.2 9.8 14.0 9.9 13.5 9.2
Standardised mortality rate1,2 9.1 4.6 8.8 4.6 8.4 4.3
Median age at death 74 78 74 79 74 79
1 per 100,000 persons  2 age-standardised (old European Standard)  
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 19,300 13,300 29,600 20,700
Absolute survival rate (2013 – 2014)3 25 (24 – 29) 27 (22 – 30) 18 (17 – 21) 19 (16 – 22)
Relative survival rate (2013 – 2014)3 30 (29 – 36) 33 (27 – 36) 28 (26 – 32) 29 (25 – 32)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.4.1b
Absolute numbers of incident cases and deaths, by sex,
ICD-10 C16, Germany 1999 – 2014/2015
Figure 3.4.1a
Age-standardised incidence and mortality rates, by sex, 
ICD-10 C16, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.4.2
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Table 3.4.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C16, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 2,800) 2.0 % (1 in 51) < 0.1 % (1 in 6,300) 1.2 % (1 in 82)
45 years 0.1 % (1 in 760) 1.9 % (1 in 51) 0.1 % (1 in 1,500) 1.2 % (1 in 82)
55 years 0.3 % (1 in 310) 1.9 % (1 in 53) 0.2 % (1 in 620) 1.2 % (1 in 84)
65 years 0.6 % (1 in 170) 1.7 % (1 in 58) 0.3 % (1 in 310) 1.1 % (1 in 87)
75 years 0.9 % (1 in 110) 1.4 % (1 in 70) 0.6 % (1 in 170) 1.0 % (1 in 96)
Lifetime risk 1.9 % (1 in 52) 1.2 % (1 in 83)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 3,500) 1.2 % (1 in 80) < 0.1 % (1 in 6,400) 0.8 % (1 in 120)
45 years 0.1 % (1 in 1,400) 1.2 % (1 in 82) < 0.1 % (1 in 3,000) 0.8 % (1 in 120)
55 years 0.2 % (1 in 620) 1.2 % (1 in 85) 0.1 % (1 in 1,300) 0.8 % (1 in 130)
65 years 0.3 % (1 in 340) 1.1 % (1 in 93) 0.2 % (1 in 620) 0.7 % (1 in 130)
75 years 0.5 % (1 in 200) 0.9 % (1 in 110) 0.3 % (1 in 290) 0.7 % (1 in 150)
Lifetime risk 1.2 % (1 in 80) 0.8 % (1 in 120)
Figure 3.4.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C16, Germany 2013 – 2014
Figure 3.4.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C16, Germany 2013 – 2014
Figure 3.4.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C16, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
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19% 13% 45% 23%
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Figure 3.4.5
Registered age-standardised incidence and mortality rates in German federal states, by sex, 
ICD-10 C16, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.4.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C16, 2013 – 2014 or latest available year (details and sources, see appendix)
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36 Cancer in Germany Colon and rectum
Epidemiology
About every eighth person with cancer in Germany 
has cancer of the colon and rectum. In 2014, around 
33,100 men and 27,900 women were diagnosed with 
the disease. Over the course of life, one in 15 men and 
one in 18 women develop cancer of the colon and rec-
tum. Almost two-thirds of cases are detected in the 
colon.
Rectal cancers account for 26 % of colorectal can-
cer cases among women and 33 % of cases among 
men. Fewer cases are being reported as originating 
from the transition zone between the colon and rec-
tum (rectosigmoid tumours). Only a small number of 
cancers (1 % – 2 %) occur in the anal canal, but their 
incidence is increasing.
The risk of colorectal cancer rises with age. This 
leads to a comparatively high mean age of onset 
(women: 75 years; men: 72 years). More than half of 
patients aff ected are diagnosed after they have reached 
the age of 70, only about 10 % of cases being diag-
nosed below the age of 55 years.
The decline in age-standardised incidence rates, 
which began around 2003, has gathered pace recent-
ly. In addition, the decline in age-standardised mortal-
ity rates has been particularly pronounced during the 
last 10 years – with this period accounting for more 
than 20 % of the reduction. The 5-year relative surviv-
al rates for colorectal cancer are approximately 62 % 
for women and men.
Risk factors and early detection
The most important risk factors for colorectal cancer 
are tobacco use and obesity, followed by a lack of exer-
cise and a diet low in fi bre. People who regularly con-
sume alcohol or eat a lot of red or processed red meat 
are also more prone to developing colorectal cancer. 
First-degree relatives of colorectal cancer patients also 
have an above-average risk of developing this cancer 
themselves, and people with rare hereditary condi-
tions have a very high risk of contracting this form of 
cancer at a young age. Chronic infl ammatory bowel 
diseases also slightly increase the risk of developing 
colorectal cancer. Chronic infection with human 
 papillomavirus increases the risk of anal cancer.
People aged between 50 and 54 years in Germany 
are eligible to have their stool tested annually for traces 
of blood as part of the cancer screening programme. 
From the age of 55, one can undergo a colonoscopy. 
This enables colorectal adenomas to be removed, as 
these could develop into cancer later on. If the proce-
dure fi nds nothing untoward, the person is entitled to 
a further colonoscopy in ten years. Alternatively, peo-
ple aged 55 years or above can have a stool test con-
ducted every two years instead of a colonoscopy. If the 
test returns a positive result, a colonoscopy is usually 
recommended. However, diff erent recommendations 
apply to people at increased risk of colorectal cancer.
3.5 Colon and rectum
Table 3.5.1
Overview of key epidemiological parameters for Germany, ICD-10 C18 – C21
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 34,100 28,410 33,120 27,890 32,900 26,000
Crude incidence rate1 86.4 69.0 83.4 67.6 81.6 62.6
Standardised incidence rate1,2 56.7 36.5 54.0 35.7 50.6 32.8
Median age at diagnosis 72 75 72 75
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 13,608 12,085 13,580 11,932 13,649 11,769
Crude mortality rate1 34.5 29.4 34.2 28.9 34.0 28.4
Standardised mortality rate1,2 21.6 13.0 21.0 12.8 20.6 12.4
Median age at death 75 80 75 79 75 80
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 112,500 95,000 188,500 161,600
Absolute survival rate (2013 – 2014)3 51 (50 – 53) 52 (50 – 53) 36 (36 – 37) 39 (36 – 43)
Relative survival rate (2013 – 2014)3 62 (62 – 64) 63 (60 – 65) 56 (54 – 59) 59 (57 – 67)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.5.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C18 – C21, Germany 1999 – 2014/2015
Figure 3.5.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C18 – C21, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.5.2









































38 Cancer in Germany Colon and rectum
Table 3.5.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C18 – C21, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 850) 6.9 % (1 in 14) < 0.1 % (1 in 4,800) 3.0 % (1 in 33)
45 years 0.4 % (1 in 240) 6.9 % (1 in 14) 0.1 % (1 in 960) 3.0 % (1 in 33)
55 years 1.2 % (1 in 83) 6.8 % (1 in 15) 0.4 % (1 in 280) 3.0 % (1 in 33)
65 years 2.4 % (1 in 42) 6.2 % (1 in 16) 0.9 % (1 in 120) 3.0 % (1 in 34)
75 years 3.3 % (1 in 31) 5.0 % (1 in 20) 1.5 % (1 in 65) 2.7 % (1 in 38)
Lifetime risk 6.9 % (1 in 15) 3.0 % (1 in 34)
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 890) 5.5 % (1 in 18) < 0.1 % (1 in 4,800) 2.5 % (1 in 40)
45 years 0.3 % (1 in 300) 5.5 % (1 in 18) 0.1 % (1 in 1,300) 2.5 % (1 in 40)
55 years 0.8 % (1 in 130) 5.2 % (1 in 19) 0.2 % (1 in 490) 2.5 % (1 in 40)
65 years 1.4 % (1 in 70) 4.8 % (1 in 21) 0.5 % (1 in 210) 2.4 % (1 in 42)
75 years 2.2 % (1 in 45) 3.8 % (1 in 26) 1.0 % (1 in 96) 2.2 % (1 in 46)
Lifetime risk 5.5 % (1 in 18) 2.5 % (1 in 40)
Figure 3.5.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C18 – C21, Germany 2013 – 2014
Figure 3.5.4b
Relative survival rates up to 10 years after fi rst diagnosis, 
by sex, ICD-10 C18 – C21, Germany 2013 – 2014
Figure 3.5.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C18 – C21, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
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15% 15% 54% 17%
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Figure 3.5.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C18 – C21, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.5.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C18 – C21, 2013 – 2014 or latest available year (details and sources, see appendix)
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40 Cancer in Germany Liver
Epidemiology
Although liver cancer is relatively rare, its poor prog-
nosis means that it is one of the forms of cancer that 
is most likely to result in death. There are currently 
around 9,100 new cases per year in Germany and 
nearly 8,000 deaths. One in 84 men and one in 190 
women in Germany will develop a malignant liver 
tumour during the course of their life. The 5-year 
 relative survival rates are currently 14 % for men and 
11 % for women.
Around 64 % of malignant tumours develop 
from liver cells (hepatocellular carcinomas), and 25 % 
from cells in the intrahepatic bile ducts (cholangiocar-
cinoma). The diff erences between these fi gures is 
wider among men than women.
Between 1999 and 2006, the age-standardised 
incidence and mortality rates rose slightly for both 
sexes. Among men this increase has been somewhat 
stronger and can be seen as early as the early 1980s. 
Since about 2006, however, the rates seem to have 
stabilised.
Currently, incidence and mortality rates in north-
west Germany are somewhat lower than in other parts 
of the country. Finally, an international comparison 
shows high mortality rates in France, particularly 
among men: the rate in France is about three times 
higher than in the Netherlands.
Risk factors and early detection
Cirrhosis is the most important risk factor associated 
with liver cancer. In Germany, cirrhosis is usually 
caused by high levels of alcohol consumption and 
chronic hepatitis C infections. Non-alcoholic fatty 
 liver disease also increases the risk of liver cancer. 
This condition may, for example, occur as a conse-
quence of diabetes mellitus or metabolic syndrome. 
Metabolic syndrome is often triggered by obesity.
A chronic hepatitis B infection, even without liver 
cirrhosis, also constitutes a risk factor for liver can -
cer, as does smoking. The consumption of mouldy 
foods containing afl atoxin B1 (a toxin produced by 
mould) is particularly relevant in less developed coun-
tries. Finally, hereditary metabolic diseases such as 
hemochromatosis can also increase the risk of liver 
cancer.
No statutory liver of cancer screening programme 
has been implementedfor the general population. 
Regular ultrasound check-ups are recommended for 
all patients with liver cirrhosis, chronic hepatitis B or 
C infections, or fatty liver disease. Blood tests (for 




Overview of key epidemiological parameters for Germany, ICD-10 C22
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 6,240 2,700 6,370 2,710 7,200 3,100
Crude incidence rate1 15.8 6.6 16.1 6.6 17.9 7.5
Standardised incidence rate1,2 10.5 3.6 10.4 3.6 11.0 3.9
Median age at diagnosis 71 74 71 75
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 5,000 2,467 5,246 2,440 5,231 2,611
Crude mortality rate1 12.7 6.0 13.2 5.9 13.0 6.3
Standardised mortality rate1,2 8.1 3.0 8.2 2.9 8.1 3.1
Median age at death 72 76 73 76 73 76
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 8,300 3,200 10,500 4,400
Absolute survival rate (2013 – 2014)3 12 (7 – 17) 10 (8 – 16) 7 (4 – 10) 7 (5 – 13)
Relative survival rate (2013 – 2014)3 14 (9 – 19) 11 (9 – 18) 10 (6 – 13) 9 (7 – 18)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.6.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C22, Germany 1999 – 2014/2015
Figure 3.6.1a
Age-standardised incidence and mortality rates, 
by sex,  ICD-10 C22, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.6.2









































42 Cancer in Germany Liver
Table 3.6.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C22, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 8,800) 1.2 % (1 in 81) < 0.1 % (1 in 17,400) 1.0 % (1 in 98)
45 years 0.1 % (1 in 1,600) 1.2 % (1 in 81) < 0.1 % (1 in 2,300) 1.0 % (1 in 98)
55 years 0.3 % (1 in 390) 1.2 % (1 in 82) 0.2 % (1 in 560) 1.0 % (1 in 98)
65 years 0.5 % (1 in 220) 1.1 % (1 in 94) 0.4 % (1 in 270) 0.9 % (1 in 110)
75 years 0.5 % (1 in 180) 0.8 % (1 in 130) 0.5 % (1 in 210) 0.7 % (1 in 140)
Lifetime risk 1.2 % (1 in 82) 1.0 % (1 in 100)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 13,000) 0.5 % (1 in 190) < 0.1 % (1 in 13,200) 0.5 % (1 in 210)
45 years < 0.1 % (1 in 3,600) 0.5 % (1 in 190) < 0.1 % (1 in 5,400) 0.5 % (1 in 210)
55 years 0.1 % (1 in 1,200) 0.5 % (1 in 200) 0.1 % (1 in 1,700) 0.5 % (1 in 210)
65 years 0.1 % (1 in 700) 0.4 % (1 in 230) 0.1 % (1 in 810) 0.4 % (1 in 230)
75 years 0.2 % (1 in 460) 0.3 % (1 in 300) 0.2 % (1 in 470) 0.4 % (1 in 280)
Lifetime risk 0.5 % (1 in 190) 0.5 % (1 in 210)
Figure 3.6.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C22, Germany 2013 – 2014
Figure 3.6.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C22, Germany 2013 – 2014
Figure 3.6.3
Distribution of T-stages at fi rst diagnosis by sex
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Figure 3.6.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C22, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.6.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C22, 2013 – 2014 or latest available year (details and sources, see appendix)
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44 Cancer in Germany Gall bladder and biliary tract
Epidemiology
In Germany, about 5,370 new malignant gallbladder 
tumours and extrahepatic tumours of the biliary tracts 
were diagnosed in 2014 (gall bladder: 35 %; biliary 
tract: 65 %). Among women, roughly equal propor-
tions of these two types of cancer were recorded: 46 % 
gallbladder cancer versus 54 % cancer of the biliary 
tract. Among men, however,, tumours of the extrahe-
patic biliary tracts are much more common (79 %). In 
terms of histology, the majority of gall bladder and 
biliary tract cancers are adenocarcinomas; about 12 % 
of biliary tract cancers were »Klatskin tumours«.
As with liver cancer, the risk of developing this 
type of cancer increases steadily with age. One in 
 every 170 women and one in every 200 men will de-
velop gall bladder or biliary tract cancer during the 
course of their life.
Since 1999, age-standardised incidence rates in 
Germany have declined among women (particularly 
with regard to gall bladder cancer), but have remained 
largely unchanged among men. Age-standardised 
mortality rates dropped until around 2009, after 
which they began to rise slightly among men. Both 
sexes have seen reductions in gall bladder cancer in-
cidence and death rates.
The 5-year relative survival rates for malignant 
tumours of the gall bladder and biliary tract are quite 
low at 18 % for women and 21 % for men.
Risk factors
Factors that cause bile duct and gallbladder carcino-
mas have not yet been clearly established, although 
severe obesity is considered to be a risk factor asso-
ciated with both tumours. Gallbladder polyps, infl am-
mation of the gallbladder, and gallbladder stones can 
increase the risk of gallbladder carcinomas.
Possible risk factors associated with bile duct car-
cinomas include chronic infl ammatory diseases of 
the bile ducts, such as primary sclerosing cholangitis 
(PSC), congenital anomalies of the biliary tract (Caro-
li syndrome), bile duct stones in the liver, choledochal 
cysts, diabetes mellitus (diabetes mellitus), hepatitis 
B and C virus infections, liver diseases due to high 
levels of alcohol consumption, chronic infl ammatory 
bowel disease and smoking. In Asia, in particular, 
parasitic liver fl ukes are also linked to carcinomas of 
the bile ducts and gallbladder.
3.7 Gall bladder and biliary tract
Table 3.7.1
Overview of key epidemiological parameters for Germany, ICD-10 C23 – C24
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 2,460 3,030 2,380 2,990 2,600 2,600
Crude incidence rate1 6.2 7.4 6.0 7.2 6.3 6.3
Standardised incidence rate1,2 3.9 3.6 3.7 3.4 3.7 2.9
Median age at diagnosis 73 76 74 77
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 1,489 2,086 1,544 2,199 1,611 2,090
Crude mortality rate1 3.8 5.1 3.9 5.3 4.0 5.0
Standardised mortality rate1,2 2.3 2.3 2.4 2.3 2.4 2.2
Median age at death 74 78 75 78 75 78
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 4,000 4,000 5,400 5,700
Absolute survival rate (2013 – 2014)3 17 (12 – 21) 15 (12 – 20) 11 (7 – 14) 10 (7 – 16)
Relative survival rate (2013 – 2014)3 21 (14 – 25) 18 (14 – 23) 17 (9 – 22) 16 (12 – 26)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.7.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C23 – C24, Germany 1999 – 2014/2015
Figure 3.7.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C23 – C24, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.7.2
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Table 3.7.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C23 – C24, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 18,700) 0.5 % (1 in 200) < 0.1 % (1 in 62,300) 0.3 % (1 in 310)
45 years < 0.1 % (1 in 4,100) 0.5 % (1 in 200) < 0.1 % (1 in 10,700) 0.3 % (1 in 310)
55 years 0.1 % (1 in 1,400) 0.5 % (1 in 200) < 0.1 % (1 in 2,900) 0.3 % (1 in 310)
65 years 0.2 % (1 in 580) 0.5 % (1 in 210) 0.1 % (1 in 920) 0.3 % (1 in 310)
75 years 0.3 % (1 in 380) 0.4 % (1 in 260) 0.2 % (1 in 600) 0.3 % (1 in 370)
Lifetime risk 0.5 % (1 in 200) 0.3 % (1 in 320)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 17,600) 0.6 % (1 in 170) < 0.1 % (1 in 56,500) 0.4 % (1 in 240)
45 years < 0.1 % (1 in 4,800) 0.6 % (1 in 170) < 0.1 % (1 in 9,100) 0.4 % (1 in 240)
55 years 0.1 % (1 in 1,500) 0.6 % (1 in 170) < 0.1 % (1 in 2,600) 0.4 % (1 in 240)
65 years 0.2 % (1 in 640) 0.6 % (1 in 180) 0.1 % (1 in 1,100) 0.4 % (1 in 250)
75 years 0.3 % (1 in 380) 0.5 % (1 in 220) 0.2 % (1 in 520) 0.4 % (1 in 280)
Lifetime risk 0.6 % (1 in 170) 0.4 % (1 in 240)
Figure 3.7.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C23 – C24, Germany 2013 – 2014
Figure 3.7.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C23 – C24, Germany 2013 – 2014
Figure 3.7.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C23 – C24, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
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12% 36% 39% 13%
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Figure 3.7.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C23 – C24, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.7.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C23 – C24, 2013 – 2014 or latest available year (details and sources, see appendix)
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48 Cancer in Germany Pancreas
Epidemiology
In 2014, around 17,100 people developed pancreatic 
cancer. Due to its unfavourable prognosis, almost as 
many people died of the disease. Since the 1990s, the 
age-standardised incidence and mortality rates have 
increased slightly, particularly among women. This 
development is especially evident among people aged 
65 or older. The absolute numbers of new cases and 
deaths have steadily increased over the years in both 
genders; a factor that is also linked to demographics.
Malignant neoplasms of the pancreas frequently 
cause no or non-specific symptoms in their early stag-
es, meaning that they often go undetected until a later 
stage. This results in a correspondingly unfavourable 
5-year relative survival rate of just 9 % for men and 
10 % for women, although rare malignant pancreatic 
islet cell tumours are associated with a signifi cantly 
better prognosis. Pancreatic carcinomas also lead to 
the lowest survival rates among all forms of cancer. 
They are also the fourth most common cause of death 
by cancer among women (8.2 %) and men (6.8 %), 
with a median age at diagnosis of 72 for men and 75 
for women.
Risk factors
Passive and active smoking have been confi rmed as 
risk factors associated with pancreatic cancer. Severe 
overweight (adiposity) and diabetes (type 2) as well as 
a very high level of alcohol consumption have nega-
tive impacts on health in this respect.
Patients with chronic infl ammation of the pan-
creas (pancreatitis) also have an increased risk of de-
veloping pancreatic cancer. An above-average inci-
dence of this disease is also found among fi rst-degree 
relatives of pancreatic cancer patients. It is unclear 
whether this is due to a shared hereditary disposition 
or lifestyle.
Frequent consumption of processed meats and 
smoked or grilled foods may also increase the risk of 
pancreatic cancer.
The role played by environmental factors and oc-
cupational exposure to harmful substances is still 
unclear. However, contact with pesticides, herbicides 
and fungicides may increase the risk of pancreatic 
carcinoma. Chlorinated hydrocarbons, chromium 
and chromium compounds, electromagnetic fi elds 
and fuel vapour are also suspected of increasing the 
risk of pancreatic carcinoma.
Table 3.8.1
Overview of key epidemiological parameters for Germany, ICD-10 C25
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 8,750 8,690 8,550 8,580 9,500 9,500
Crude incidence rate1 22.2 21.1 21.6 20.8 23.5 22.9
Standardised incidence rate1,2 14.5 10.7 13.9 10.4 14.4 11.1
Median age at diagnosis 72 75 72 75
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 8,273 8,328 8,231 8,384 8,497 8,659
Crude mortality rate1 21.0 20.2 20.7 20.3 21.2 20.9
Standardised mortality rate1,2 13.4 9.7 13.0 9.5 13.2 9.8
Median age at death 73 77 73 77 73 77
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 8,900 8,800 10,900 11,000
Absolute survival rate (2013 – 2014)3 8 (7 – 10) 9 (7 – 12) 5 (4 – 8) 6 (5 – 8)
Relative survival rate (2013 – 2014)3 9 (8 – 12) 10 (7 – 14) 8 (6 – 11) 8 (6 – 11)
3 in percentages (lowest and highest value of the included German federal states)
3.8 Pancreas
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Figure 3.8.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C25, Germany 1999 – 2014/2015
Figure 3.8.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C25, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.8.2









































50 Cancer in Germany Pancreas
Table 3.8.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C25, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 4,300) 1.8 % (1 in 57) < 0.1 % (1 in 5,600) 1.7 % (1 in 59)
45 years 0.1 % (1 in 960) 1.8 % (1 in 57) 0.1 % (1 in 1,200) 1.7 % (1 in 58)
55 years 0.3 % (1 in 310) 1.7 % (1 in 58) 0.3 % (1 in 360) 1.7 % (1 in 59)
65 years 0.6 % (1 in 160) 1.6 % (1 in 64) 0.6 % (1 in 170) 1.6 % (1 in 64)
75 years 0.8 % (1 in 130) 1.2 % (1 in 86) 0.8 % (1 in 120) 1.2 % (1 in 80)
Lifetime risk 1.7 % (1 in 57) 1.7 % (1 in 59)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 4,900) 1.7 % (1 in 59) < 0.1 % (1 in 9,100) 1.7 % (1 in 60)
45 years 0.1 % (1 in 1,400) 1.7 % (1 in 59) 0.1 % (1 in 1,800) 1.7 % (1 in 60)
55 years 0.2 % (1 in 460) 1.7 % (1 in 60) 0.2 % (1 in 580) 1.6 % (1 in 61)
65 years 0.5 % (1 in 220) 1.5 % (1 in 66) 0.4 % (1 in 230) 1.5 % (1 in 65)
75 years 0.7 % (1 in 140) 1.2 % (1 in 83) 0.7 % (1 in 140) 1.3 % (1 in 79)
Lifetime risk 1.7 % (1 in 59) 1.6 % (1 in 61)
Figure 3.8.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C25, Germany 2013 – 2014
Figure 3.8.4b
Relative survival rates up to 10 years after fi rst diagnosis, 
by sex, ICD-10 C25, Germany 2013 – 2014
Figure 3.8.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C25, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
5% 14% 57% 23%
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Figure 3.8.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C25, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.8.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C25, 2013 – 2014 or latest available year (details and sources, see appendix)
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52 Cancer in Germany Larynx
Epidemiology
Laryngeal cancer originates almost exclusively from 
squamous cells. Men are aff ected by laryngeal cancer 
considerably more often than women due to higher 
levels of consumption of tobacco products and alco-
hol. Over the course of a person’s life, one in 180 men, 
but just one in 1,000 women in Germany develops 
cancer of the larynx. The median age at diagnosis is 
65 years for women and 66 years for men; this is 
earlier than the average age for all types of cancer. 
Age-specifi c disease rates for cancer of the larynx are 
highest in women aged between 55 and 75 years, and 
men aged between 65 and 75 years; incidence and 
mortality rates among men have been declining since 
the early 1980s. However, despite significant in-
creases during the late 1980s and the 1990s, since the 
turn of the millennium, rates among women have 
remained largely unchanged. Demographic changes 
have led women to experience an increase in the ab-
solute number of deaths and morbidity rates from 
laryngeal cancer, and this is particularly the case 
among older women. In contrast, the absolute num-
ber of cases among men has reduced slightly. There 
is no signifi cant diff erence between 5-year relative 
survival rates in men and women, with 63 % for men, 
and 64 % for women. A higher proportion (44 %) of 
early tumour stages (T1) is diagnosed among men 
than women (37 %).
Risk factors
Smoking is the most important risk factor associated 
with the development of laryngeal cancer. Alcohol 
consumption also increases the likelihood of the con-
dition, with the combination of both being particular-
ly harmful. The influences of lifestyle and diet are still 
unclear, because, in the majority of cases, tobacco and 
alcohol consumption superimposeother risk factors. 
However, there are indications that increased con-
sumption of red meat, and a vitamin-deficient diet 
may also be linked to an increased risk of laryngeal 
cancer. There is a known link between tumours of the 
larynx and occupational exposure to asbestos, nickel, 
chromates, arsenics and polycyclic aromatic hydrocar-
bons. The role of infections with human papilloma 
viruses (HPV) has yet to be completely clarified. There 
are indications that infections with Helicobacter pylo-
ri may also be of significance.
First-degree relatives of patients with a laryngeal 




Overview of key epidemiological parameters for Germany, ICD-10 C32
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 3,050 540 2,980 520 2,900 600
Crude incidence rate1 7.7 1.3 7.5 1.3 7.1 1.5
Standardised incidence rate1,2 5.4 0.9 5.3 0.9 4.8 1.0
Median age at diagnosis 66 64 66 65
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 1,254 230 1,301 224 1,291 205
Crude mortality rate1 3.2 0.6 3.3 0.5 3.2 0.5
Standardised mortality rate1,2 2.2 0.3 2.2 0.3 2.1 0.3
Median age at death 69 68 71 70 70 69
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 10,900 1,800 18,500 2,900
Absolute survival rate (2013 – 2014)3 55 (49 – 59) 59 37 (29 – 42) 40
Relative survival rate (2013 – 2014)3 63 (56 – 66) 64 49 (39 – 54) 48
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.9.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C32, Germany 1999 – 2014/2015
Figure 3.9.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C32, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.9.2









































54 Cancer in Germany Larynx
Table 3.9.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C32, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 11,000) 0.6 % (1 in 170) < 0.1 % (1 in 50,000) 0.2 % (1 in 400)
45 years 0.1 % (1 in 1,700) 0.6 % (1 in 170) < 0.1 % (1 in 6,300) 0.3 % (1 in 400)
55 years 0.2 % (1 in 600) 0.5 % (1 in 190) 0.1 % (1 in 1,600) 0.2 % (1 in 410)
65 years 0.2 % (1 in 450) 0.4 % (1 in 240) 0.1 % (1 in 1,000) 0.2 % (1 in 490)
75 years 0.2 % (1 in 580) 0.2 % (1 in 420) 0.1 % (1 in 1,200) 0.1 % (1 in 760)
Lifetime risk 0.6 % (1 in 180) 0.2 % (1 in 410)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 40,500) 0.1 % (1 in 1,000) < 0.1 % (1 in 298,900) < 0.1 % (1 in 2,300)
45 years < 0.1 % (1 in 8,100) 0.1 % (1 in 1,000) < 0.1 % (1 in 31,600) < 0.1 % (1 in 2,300)
55 years < 0.1 % (1 in 3,300) 0.1 % (1 in 1,200) < 0.1 % (1 in 8,700) < 0.1 % (1 in 2,400)
65 years < 0.1 % (1 in 2,900) 0.1 % (1 in 1,700) < 0.1 % (1 in 7,100) < 0.1 % (1 in 3,100)
75 years < 0.1 % (1 in 5,700) < 0.1 % (1 in 3,700) < 0.1 % (1 in 8,400) < 0.1 % (1 in 4,900)
Lifetime risk 0.1 % (1 in 1,000) < 0.1 % (1 in 2,300)
Figure 3.9.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C32, Germany 2013 – 2014
Figure 3.9.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C32, Germany 2013 – 2014
Figure 3.9.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C32, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
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44% 19% 20% 16%
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Figure 3.9.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C32, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.9.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C32, 2013 – 2014 or latest available year (details and sources, see appendix)
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56 Cancer in Germany Lung
Epidemiology
In 2014, about 19,300 women and 34,500 men were 
diagnosed with malignant tumours of the lungs; 
15,524 women and 29,560 men died of the disease.
Age-standardised incidence and mortality rates 
show opposing trends among men and women. Rates 
have risen continuously since the end of the 1990s 
among women, but they have decreased over the 
same period among men. These diverging trends can 
be attributed to changes in smoking habits that oc-
curred in the past and which will probably continue 
to have an impact in the future. Lung cancer has one 
of the least favourable prognoses as it is associated 
with relatively low 5-year survival rates: 20 % for wom-
en and 15 % for men. In terms of histology, there are 
three main types of lung cancer: adenocarcinomas 
account for about half of all cases; squamous-cell car-
cinomas account for about one quarter and around 
one fi fth are small-cell lung carcinomas. Small-cell 
carcinomas have the worst prognosis due to their ten-
dency to metastasise early. In an international com-
parison of selected countries, the highest rates of lung 
cancer morbidity were found among women in Den-
mark and men in Belgium.
Risk factors and early detection
Tobacco smoke is the main risk factor associated with 
lung cancer. Among men, up to nine in ten, and at 
least six out of ten cases of lung cancer in women are 
due to active smoking. Passive smoking also increases 
a person’s risk of developing lung cancer.
Other risk factors play a comparatively minor 
role. Between 9 and 15 of 100 cases of lung cancer are 
attributable to exposure to various carcinogenic sub-
stances, including asbestos, polycyclic aromatic hy-
drocarbons and quartz and nickel dust. People who 
live in areas with a high natural radon emission have 
a higher risk of lung cancer, especially those who live 
in a building’s lower storeys. This also applies to 
 occupational exposure to radon or other sources of 
ionising radiation. Diesel exhaust fumes are the 
most important risk factor in terms of air pollutants. 
Other forms of environmental pollution (particulate 
matter) and hereditary factors are also presumed to 
increase the risk of lung cancer.
No established screening procedure for the early 
detection of lung cancer has been put in place for the 
population as a whole. The role that examinations, 
such as regular computed tomography scans, could 




Overview of key epidemiological parameters for Germany, ICD-10 C33 – C34
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 35,310 19,200 34,560 19,280 33,700 22,000
Crude incidence rate1 89.5 46.6 87.1 46.7 83.7 52.9
Standardised incidence rate1,2 59.6 29.1 57.3 29.0 53.1 31.8
Median age at diagnosis 70 69 70 69
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 29,708 15,140 29,560 15,524 29,378 15,881
Crude mortality rate1 75.3 36.8 74.5 37.6 73.1 38.3
Standardised mortality rate1,2 48.8 21.7 47.6 21.7 46.6 22.1
Median age at death 72 71 72 71 72 71
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 49,400 32,100 67,800 43,600
Absolute survival rate (2013 – 2014)3 13 (12 – 15) 18 (17 – 21) 8 (7 – 10) 12 (11 – 14)
Relative survival rate (2013 – 2014)3 15 (14 – 18) 20 (18 – 23) 11 (9 – 14) 16 (14 – 19)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.10.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C33 – C34, Germany 1999 – 2014/2015
Figure 3.10.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C33 – C34, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.10.2
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Table 3.10.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C33 – C34, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,500) 6.9 % (1 in 14) < 0.1 % (1 in 2,500) 6.0 % (1 in 17)
45 years 0.4 % (1 in 230) 7.0 % (1 in 14) 0.3 % (1 in 330) 6.0 % (1 in 17)
55 years 1.6 % (1 in 64) 6.8 % (1 in 15) 1.2 % (1 in 87) 6.0 % (1 in 17)
65 years 2.7 % (1 in 37) 5.8 % (1 in 17) 2.2 % (1 in 46) 5.3 % (1 in 19)
75 years 2.9 % (1 in 35) 4.0 % (1 in 25) 2.8 % (1 in 36) 4.0 % (1 in 25)
Lifetime risk 6.8 % (1 in 15) 5.9 % (1 in 17)
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,700) 3.6 % (1 in 28) < 0.1 % (1 in 3,600) 2.9 % (1 in 35)
45 years 0.3 % (1 in 300) 3.5 % (1 in 28) 0.2 % (1 in 470) 2.9 % (1 in 35)
55 years 0.9 % (1 in 110) 3.3 % (1 in 30) 0.6 % (1 in 160) 2.7 % (1 in 37)
65 years 1.2 % (1 in 84) 2.5 % (1 in 40) 0.9 % (1 in 110) 2.2 % (1 in 45)
75 years 1.1 % (1 in 95) 1.5 % (1 in 66) 0.9 % (1 in 110) 1.5 % (1 in 69)
Lifetime risk 3.6 % (1 in 28) 2.9 % (1 in 35)
Figure 3.10.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C33 – C34, Germany 2013 – 2014
Figure 3.10.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C33 – C34, Germany 2013 – 2014
Figure 3.10.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C33 – C34, Germany 2013 – 2014
no information
DCO
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17% 30% 23% 30%
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Figure 3.10.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C33 – C34, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.10.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C33 – C34, 2013 – 2014 or latest available year (details and sources, see appendix)
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60 Cancer in Germany Malignant melanoma of the skin
Epidemiology
In 2014, around 21,200 people in Germany – roughly 
about the same number of men and women – devel-
oped malignant melanoma of the skin. The median 
age at diagnosis for women was 60, which is compar-
atively low; for men it was seven years higher. The 
age-standardised incidence rates among women and 
men have markedly increased since 2008. This in-
crease is probably due to the fact that skin cancer 
screening began in Germany in July 2008. However, 
the incidence for both genders has increased fi ve-fold 
since the 1970s. Nevertheless, death rates have only 
increased slightly among men during the same peri-
od. The predominant type of malignant melanoma is 
superfi cial spreading melanoma, which has a favour-
able prognosis and is predominantly responsible for 
the increase in incidence rates. Other forms, in par-
ticular nodular and amelanotic melanoma, have 
 considerably less favourable prognoses. The 5-year 
relative survival rate in Germany for people with 
 malignant melanoma of the skin is 94 % (women) 
and 91 % (men). Two-thirds of all melanomas are de-
tected at an early stage (T1). As of 2014, no decline in 
the number of tumours identifi ed at an advanced 
stage has been identifi ed.
Risk factors and early detection
The most important endogenous risk factor associ-
ated with the development of malignant melanoma is 
the number of pigmented moles a person has. Malig-
nant melanomas are more likely to occur in people 
with a light skin type than in people with a darker skin 
type. If fi rst-degree relatives have developed malig-
nant melanomas, a family may have a genetic predis-
position to this form of cancer. However, the level of 
risk associated with developing a malignant melano-
ma in this situation depends on the genetic mutation 
in question. Moreover, patients who have already de-
veloped a melanoma, have an increased risk of devel-
oping skin cancer in the future.
The most important exogenous risk factor linked 
to malignant melanoma is ultraviolet (UV) radiation. 
This applies both to natural radiation from sunlight 
and to artifi cial UV radiation (such as in solariums). 
Exposure to the sun during childhood and adoles-
cence as well as »intermittent exposure to the sun« 
(typical during summer holidays) increases the risk of 
malignant melanoma. The current screening pro-
gramme enables men and women aged 35 or above to 
have their skin examined by a doctor with relevant 
training (such as dermatologists and general practi-
tioners) every two years.
3.11 Malignant melanoma of the skin
Table 3.11.1
Overview of key epidemiological parameters for Germany, ICD-10 C43
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 11,300 10,810 10,910 10,310 11,400 10,500
Crude incidence rate1 28.6 26.3 27.5 25.0 28.2 25.2
Standardised incidence rate1,2 20.6 19.8 19.5 18.6 19.4 18.6
Median age at diagnosis 67 59 67 60
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 1,787 1,255 1,804 1,270 1,767 1,287
Crude mortality rate1 4.5 3.1 4.5 3.1 4.4 3.1
Standardised mortality rate1,2 3.0 1.7 2.9 1.7 2.8 1.7
Median age at death 72 75 73 75 74 76
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 47,600 49,000 78,200 84,500
Absolute survival rate (2013 – 2014)3 78 (73 – 81) 86 (81 – 88) 65 (59 – 69) 77 (71 – 80)
Relative survival rate (2013 – 2014)3 91 (87 – 93) 94 (89 – 97) 89 (83 – 94) 94 (89 – 99)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.11.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C43, Germany 1999 – 2014/2015
Figure 3.11.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C43, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.11.2









































62 Cancer in Germany Malignant melanoma of the skin
Table 3.11.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C43, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 680) 2.1 % (1 in 48) < 0.1 % (1 in 9,300) 0.4 % (1 in 270)
45 years 0.3 % (1 in 390) 2.0 % (1 in 51) < 0.1 % (1 in 3,700) 0.4 % (1 in 280)
55 years 0.4 % (1 in 260) 1.8 % (1 in 57) 0.1 % (1 in 1,900) 0.3 % (1 in 290)
65 years 0.7 % (1 in 150) 1.5 % (1 in 65) 0.1 % (1 in 900) 0.3 % (1 in 300)
75 years 0.8 % (1 in 130) 1.1 % (1 in 92) 0.2 % (1 in 600) 0.3 % (1 in 360)
Lifetime risk 2.1 % (1 in 47) 0.4 % (1 in 270)
Women aged in the next ten years ever in the next ten years ever
35 years 0.3 % (1 in 400) 1.8 % (1 in 56) < 0.1 % (1 in 8,900) 0.2 % (1 in 410)
45 years 0.3 % (1 in 320) 1.5 % (1 in 65) < 0.1 % (1 in 4,900) 0.2 % (1 in 430)
55 years 0.3 % (1 in 300) 1.3 % (1 in 79) < 0.1 % (1 in 3,500) 0.2 % (1 in 460)
65 years 0.4 % (1 in 230) 1.0 % (1 in 100) 0.1 % (1 in 1,900) 0.2 % (1 in 500)
75 years 0.4 % (1 in 240) 0.6 % (1 in 160) 0.1 % (1 in 1,200) 0.2 % (1 in 590)
Lifetime risk 2.0 % (1 in 50) 0.2 % (1 in 410)
Figure 3.11.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C43, Germany 2013 – 2014
Figure 3.11.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C43, Germany  2013 – 2014
Figure 3.11.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C43, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
64% 15% 11% 10%



















63ICD-10 C43 Cancer in Germany
Figure 3.11.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C43, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.11.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C43, 2013 – 2014 or latest available year (details and sources, see appendix)
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64 Cancer in Germany Mesothelioma
Epidemiology
Malignant mesothelioma refers to a rare soft-tissue 
tumour that mainly occurs among elderly men. The 
pleura is aff ected in about 90 % of cases. In 2014, 
about 1,290 men and 310 women developed this dis-
ease in Germany.
The long latency period between exposure and 
illness means that despite the fact that more than 20 
years have passed since asbestos processing was 
banned in Germany, a clear decline in age-stand-
ardised disease or death rates has yet to be seen. 
 However, morbidity and mortality rates among men 
under the age of 65 years have declined markedly 
during this period, while they continued to rise 
among higher age groups until a few years ago.
Comparatively high morbidity rates continue to 
occur in northwest Germany in locations where the 
ship building industry was located and partly in those 
linked to the steel industry (such as in Bremen and 
neighbouring regions, Hamburg, Kiel and the Ruhr 
region). Populations in regions where asbestos 
 products were produced are also occasionally aff ected. 
Mesotheliomas have a very unfavourable prognosis, 
with 5-year relative survival rates of just 8 % in men 
and 17 % in women. As such, the number of deaths 
from this type of cancer is only slightly less than the 
number of new cases.
Risk factors
Even though Germany banned the processing of as-
bestos in 1993 (and an EU-wide ban soon followed), 
the inhalation of asbestos fibres still remains the 
main cause of the majority of newly diagnosed cases 
of mesothelioma. This is due to an average latency 
period between exposure and cancer diagnosis of over 
30 years in average. The affected occupational groups 
include metalworkers, welders, electricians, plumb-
ers, roofers, bricklayers, construction workers, auto-
motive engineers and tilers. Every year, Germany’s 
employer liability insurance associations recognise 
approximately 1,000 newly diagnosed cases. Even in 
cases where an occupation-related exposition to 
 asbestos cannot be determined, X-rays and tissue 
samples will often provide evidence for an asbestos 
contamination.
Loosely bound asbestos with high fibre content is 
particularly dangerous. By contrast, provided it re-
mains intact, asbestos-cement, which is found even 
today both in and on buildings, is deemed largely safe.
Further risk factors play only a subordinate role. 
Among them are exposure to other fi bres such as 
 Erionit or radiotherapy (of breast and abdomen).
3.12 Mesothelioma
Table 3.12.1
Overview of key epidemiological parameters for Germany, ICD-10 C45
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 1,370 350 1,290 310 1,380 340
Crude incidence rate1 3.5 0.9 3.3 0.7 3.4 0.8
Standardised incidence rate1,2 2.1 0.5 1.9 0.4 1.9 0.4
Median age at diagnosis 73 73 74 75
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 1,157 297 1,151 277 1,128 305
Crude mortality rate1 2.9 0.7 2.9 0.7 2.8 0.7
Standardised mortality rate1,2 1.7 0.4 1.7 0.3 1.6 0.3
Median age at death 75 75 75 76 76 76
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 1,700 600 2,000 800
Absolute survival rate (2013 – 2014)3 6 15 3 7
Relative survival rate (2013 – 2014)3 8 17 5 9
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.12.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C45, Germany 1999 – 2014/2015
Figure 3.12.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C45, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.12.2









































66 Cancer in Germany Mesothelioma
Table 3.12.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C45, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 50,000) 0.3 % (1 in 360) < 0.1 % (1 in 105,000) 0.2 % (1 in 410)
45 years < 0.1 % (1 in 11,000) 0.3 % (1 in 360) < 0.1 % (1 in 20,000) 0.2 % (1 in 410)
55 years < 0.1 % (1 in 2,900) 0.3 % (1 in 350) < 0.1 % (1 in 4,500) 0.2 % (1 in 400)
65 years 0.1 % (1 in 910) 0.3 % (1 in 360) 0.1 % (1 in 1,100) 0.3 % (1 in 400)
75 years 0.2 % (1 in 650) 0.2 % (1 in 480) 0.1 % (1 in 700) 0.2 % (1 in 490)
Lifetime risk 0.3 % (1 in 360) 0.2 % (1 in 420)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 360,000) 0.1 % (1 in 1,500) < 0.1 % (1 in 1,600,000) 0.1 % (1 in 1,700)
45 years < 0.1 % (1 in 43,000) 0.1 % (1 in 1,500) < 0.1 % (1 in 65,000) 0.1 % (1 in 1,700)
55 years < 0.1 % (1 in 9,200) 0.1 % (1 in 1,500) < 0.1 % (1 in 16,000) 0.1 % (1 in 1,700)
65 years < 0.1 % (1 in 4,300) 0.1 % (1 in 1,700) < 0.1 % (1 in 5,000) 0.1 % (1 in 1,800)
75 years < 0.1 % (1 in 3,600) < 0.1 % (1 in 2,600) < 0.1 % (1 in 4,000) < 0.1 % (1 in 2,500)
Lifetime risk 0.1 % (1 in 1,500) 0.1 % (1 in 1,700)
Figure 3.12.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C45, Germany 2013 – 2014
Figure 3.12.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C45, Germany 2013 – 2014
Figure 3.12.3
Distribution of T-stages at fi rst diagnosis by sex
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Figure 3.12.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C45, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.12.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C45, 2013 – 2014 or latest available year (details and sources, see appendix)











































































1 data incl. C38.4 (Malignant neoplasm of Pleura)
2 no data for incidence
3 mortality only 2013
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68 Cancer in Germany Soft tissue without mesothelioma
Epidemiology
This disease group includes the rare Kaposi sarcoma, 
occurring mainly on the skin and malignant tumours 
of the peripheral nerves, connective and other soft 
tissue such as the peritoneum and retroperitoneal soft 
tissue behind it. 84 % of all cases are sarcomas, which 
unlike carcinomas do not develop from epithelial or 
glandular tissue, but from connective tissue struc-
tures, which also include fatty tissue and muscles. 
Conversely, around 50 % of all sarcomas occur in 
 organs such as the gastro-intestinal tract, the sexual 
organs and the breast.
Out of the around 4,000 new malignant soft tis-
sue tumour cases, 35 % occur in the extremities. The 
two most prevalent types of soft tissue sarcoma in 
adulthood are the leiomyosarcoma originating in 
smooth muscle and liposarcoma (fatty tissue tumour). 
Rhabdomyosarcoma (RMS) occur almost exclusively 
in children and adolescents.
Since 1999, the age-standardised incidence and 
mortality rates for malignant soft tissue tumours in 
Germany have remained almost constant.
Risk factors
In most cases, soft tissue sarcomas have no clearly 
identifi able cause. Patients with rare hereditary can-
cer syndromes, however, face a higher risk of develop-
ing sarcomas. Presumably, a single (or multiple) ge-
netic mutation also may infl uences a person’s risk of 
developing a sarcoma.
In rare cases, following radiation therapy, a sar-
coma may occur in the irradiated area of the body. The 
human herpes virus type 8 (HHV8) causes the Kapo-
si sarcoma. In severely immuno-deficient patients, 
the Epstein-Barr virus (EBV) potentially also plays a 
role in the development of soft tissue sarcoma.
Environmental toxins and chemicals are poten-
tially also factors in sarcoma development. Evidence 
strongly indicates a link between vinyl chloride expo-
sure and angiosarcoma of the liver. Chronic inflam-
matory processes possibly also increase the risk of soft 
tissue sarcoma. Chronic lymphedema as a conse-
quence of a mastectomy (breast removal) can in rare 
cases result in the emergence of an angiosarcoma 
(Stewart Treves Syndrome). Whether diet or other 
lifestyle factors, such as tobacco and alcohol con-
sumption also have an infl uence remains unclear.
3.13 Soft tissue without mesothelioma
Table 3.13.1
Overview of key epidemiologic parameters for Germany, ICD-10 C46 – C49
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 2,140 1,880 2,040 1,870 2,300 2,000
Crude incidence rate1 5.4 4.6 5.2 4.5 5.8 4.8
Standardised incidence rate1,2 4.1 3.2 3.9 3.2 4.2 3.3
Median age at diagnosis 65 69 67 66
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 744 831 724 901 843 927
Crude mortality rate1 1.9 2.0 1.8 2.2 2.1 2.2
Standardised mortality rate1,2 1.3 1.2 1.2 1.2 1.4 1.3
Median age at death 72 73 72 73 71 74
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 6,700 5,600 10,800 9,200
Absolute survival rate (2013 – 2014)3 55 (48 – 59) 44 (35 – 47) 43 34 (27 – 39)
Relative survival rate (2013 – 2014)3 64 (55 – 69) 49 (38 – 53) 58 44 (35 – 50)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.13.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C46 – C49, Germany 1999 – 2014/2015
Figure 3.13.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C46 – C49, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.13.2









































70 Cancer in Germany Soft tissue without mesothelioma
Table 3.13.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C46 – C49, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 3,600) 0.4 % (1 in 260) < 0.1 % (1 in 22,400) 0.1 % (1 in 690)
45 years < 0.1 % (1 in 2,500) 0.4 % (1 in 280) < 0.1 % (1 in 9,200) 0.1 % (1 in 700)
55 years 0.1 % (1 in 1,500) 0.3 % (1 in 300) < 0.1 % (1 in 5,200) 0.1 % (1 in 730)
65 years 0.1 % (1 in 980) 0.3 % (1 in 350) < 0.1 % (1 in 2,400) 0.1 % (1 in 770)
75 years 0.2 % (1 in 650) 0.2 % (1 in 420) 0.1 % (1 in 1,400) 0.1 % (1 in 890)
Lifetime risk 0.4 % (1 in 230) 0.2 % (1 in 650)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 4,700) 0.3 % (1 in 310) < 0.1 % (1 in 15,100) 0.2 % (1 in 640)
45 years < 0.1 % (1 in 2,900) 0.3 % (1 in 330) < 0.1 % (1 in 8,000) 0.2 % (1 in 660)
55 years 0.1 % (1 in 1,900) 0.3 % (1 in 360) < 0.1 % (1 in 5,000) 0.1 % (1 in 710)
65 years 0.1 % (1 in 1,000) 0.2 % (1 in 430) < 0.1 % (1 in 2,400) 0.1 % (1 in 780)
75 years 0.1 % (1 in 950) 0.2 % (1 in 640) 0.1 % (1 in 1,700) 0.1 % (1 in 1,000)
Lifetime risk 0.4 % (1 in 280) 0.2 % (1 in 620)
Figure 3.13.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C46 – C49, Germany 2013 – 2014
Figure 3.13.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C46 – C49, Germany 2013 – 2014
Figure 3.13.3a
Proportion of histologic group of malignant soft tissue tumours, 
ICD-10 C46 – C49, Germany 2013 – 2014
Figure 3.13.3b
Distribution of sarcoma localizations, 
Germany 2013 – 2014
Sarcoma* 84%
Cystic, mucinous and






* classified according to NCIN criteria
  (2013, see »further literature«)
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Figure 3.13.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C46 – C49, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.13.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C46 – C49, 2013 – 2014 or latest available year (details and sources, see appendix)











































































1 data for C49 and C46.1 only 4 mortality only 2013
2 data incl. C38  5 no data for incidence
3 data for C47 and C49 only  
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72 Cancer in Germany Breast
Epidemiology
With around 69,000 new cases every year, breast can-
cer is by far the most common form of cancer among 
women. Roughly an additional 6,000 women are be-
ing diagnosed with a cancer in situ each year. Around 
1 % of new cases aff ect men.
Based on current incidence figures, about one in 
eight women will develop breast cancer over the 
course of her life. Almost three in every ten women 
are younger than 55 years at diagnosis. Incidence and 
mortality rates in former East Germany remain lower 
than in former West Germany. For women under 
55 years old, however, these diff erences have largely 
diminished by now.
Incidence rates of more recent years show the 
typical curve of a sharp increase after mammography 
screening was introduced between 2005 and 2009 
and a subsequent slow decline.
Progress in therapy has signifi cantly increased 
patients’ chances of survival and led to a drop in mor-
tality rates. In a few years, it should be possible to 
evaluate whether and to what degree screening can 
help further reduce the number of cases. A clear ten-
dency, however, is that in the corresponding age 
group fewer women suff er advanced forms of cancer 
than before the introduction of screenings.
Risk factors and early detection
An early menarche and a late menopause, childless-
ness and higher age at first birth are all associated 
with an increased risk of developing breast cancer. 
Conversely, several and/or early births and longer pe-
riods of breast-feeding reduce the risk of breast can-
cer. Hormone replacement therapy during and after 
menopause increases the risk of breast cancer. Ovula-
tion inhibitors containing hormones (»the pill«), on 
the other hand, have only a minor influence on in-
cidence rates.
Further risk factors include overweight and a lack 
of exercise after menopause, as well as alcohol con-
sumption. Moreover, smoking could also slightly in-
crease the risk.
In addition, the risk for women with very dense 
breast tissue or with certain benign breast neoplasms 
(lobular neoplasias and atypical ductal hyperplasias) 
is increased. Family clusters of breast or ovarian can-
cer, or undergoing radio therapy of the breast during 
childhood or at adolescent age constitute further risk 
factors. The statutory early detection programme 
offers women above 30 years of age an annual palpa-
tion examination of the breasts by a physician. Be-
tween 2005 and 2009, Germany introduced a quality 
assured Mammography Screening Programme where 
women between 50 and 69 years of age are now in-
vited to have their breasts X-rayed every two years.
3.14 Breast
Table 3.14.1
Overview of key epidemiological parameters for Germany, ICD-10 C50
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 670 70,820 650 69,220 700 71,900
Crude incidence rate1 1.7 172.0 1.6 167.7 1.8 173.0
Standardised incidence rate1,2 1.1 118.3 1.1 114.6 1.1 116.5
Median age at diagnosis 72 64 71 64
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 156 17,853 134 17,670 159 18,136
Crude mortality rate1 0.4 43.4 0.3 42.8 0.4 43.7
Standardised mortality rate1,2 0.2 23.6 0.2 23.0 0.3 23.0
Median age at death 74 74 73 74 75 75
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 2,400 311,400 3,800 559,900
Absolute survival rate (2013 – 2014)3 60 79 (79 – 81) 45 66 (64 – 68)
Relative survival rate (2013 – 2014)3 73 88 (87 – 88) 69 82 (81 – 83)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.14.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C50, Germany 1999 – 2014/2015
Figure 3.14.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C50, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.14.2









































74 Cancer in Germany Breast
Table 3.14.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C50, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 30,000) 0.1 % (1 in 740) < 0.1 % (1 in 267,000) < 0.1 % (1 in 2,900)
45 years < 0.1 % (1 in 12,100) 0.1 % (1 in 740) < 0.1 % (1 in 96,000) < 0.1 % (1 in 2,900)
55 years < 0.1 % (1 in 5,100) 0.1 % (1 in 760) < 0.1 % (1 in 32,000) < 0.1 % (1 in 2,900)
65 years < 0.1 % (1 in 2,100) 0.1 % (1 in 810) < 0.1 % (1 in 8,600) < 0.1 % (1 in 2,800)
75 years 0.1 % (1 in 1,500) 0.1 % (1 in 1,100) < 0.1 % (1 in 6,400) < 0.1 % (1 in 3,400)
Lifetime risk 0.1 % (1 in 740) < 0.1 % (1 in 2,900)
Women aged in the next ten years ever in the next ten years ever
35 years 0.9 % (1 in 110) 12.8 % (1 in 8) 0.1 % (1 in 1,000) 3.5 % (1 in 29)
45 years 2.1 % (1 in 47) 12.1 % (1 in 8) 0.3 % (1 in 380) 3.4 % (1 in 29)
55 years 3.0 % (1 in 34) 10.3 % (1 in 10) 0.5 % (1 in 200) 3.2 % (1 in 31)
65 years 3.6 % (1 in 28) 8.0 % (1 in 13) 0.8 % (1 in 120) 2.9 % (1 in 35)
75 years 3.3 % (1 in 30) 5.1 % (1 in 20) 1.2 % (1 in 81) 2.3 % (1 in 43)
Lifetime risk 12.9 % (1 in 8) 3.5 % (1 in 29)
Figure 3.14.4a
Absolute survival rates up to 10 years after fi rst diagnosis, 
women, ICD-10 C50, Germany 2013 – 2014
Figure 3.14.4b
Relative survival rates up to 10 years after fi rst diagnosis, 
women, ICD-10 C50, Germany 2013 – 2014
Figure 3.14.3
Distribution of T-stages at fi rst diagnosis for all women and women between 50 and 69 years 
(top: all cases; bottom: only valid reports) ICD-10 C50, Germany 2013 – 2014
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
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Figure 3.14.5
Registered age-standardised incidence and mortality rates in German federal states, women,  
ICD-10 C50, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.14.6
International comparison of age-standardised incidence and mortality rates, women, 
ICD-10 C50, 2013 – 2014 or latest available year (details and sources, see appendix)
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76 Cancer in Germany Vulva
Epidemiology
Over the last decade, Germany has registered a 
significant increase in the number of malignant vul-
var cancers. In 2014, around 3,130 women were diag-
nosed with this cancer. In the early 2000s, there were 
fewer than half as many cases. In contrast to the mor-
tality rates for most other gynaecological tumours, 
mortality rates too have increased slightly in recent 
years. In 2015, 940 women died from a vulvar cancer.
Women in the age-group under 70 years expe-
rienced the greatest increase in incidence rates, yet 
these fi gures have stabilised since 2010. Women over 
70 years still bear the majority of the disease burden 
and the median age at diagnosis is 72 years. Patients 
diagnosed with a malignant vulvar cancer have a 
5-year relative survival rate of 68 %. The vast majority 
of invasive carcinomas are diagnosed at an early tu-
mour stage (T1), although the lymph nodes are already 
affected in one of every four women diagnosed.
Incidence and mortality rates in Germany are 
highest in the Saarland. While data was not available 
for all neighbouring countries, incidence rates in Ger-
many appear to be generally higher, whereas mortal-
ity rates are similar.
Risk factors, early detection and prevention
Vulvar cancers are mostly (95 %) squamous cell carci-
nomas and occur as either non-keratinising or kerati-
nising carcinomas. The latter account for 65-80 % of 
all vulva squamous cell carcinomas.
Non-keratinising vulvar cancers and their 
pre-cancerous stages often correlate with a chronic 
infection with human papilloma virus (HPV) and 
 occur predominantly in younger women.
Keratinising vulvar cancers and their pre-cancer-
ous stages are not associated with HPV and occur 
mainly in elderly women. Degenerative and chronic 
inflammatory skin diseases such as Lichen sclerosus 
belong to the most important risk factors. Smoking 
and long-term immunosuppression (for example in 
organ transplant or HIV-patients), also increase the 
risk of developing vulvar cancer. HIV facilitates an 
HPV infection and thus increases the risk of develop-
ing vulvar cancer. The presence of other genital can-
cers or their precursors, for example cervical cancer 
or Paget’s disease of the vulva, are further risk factors.
Targeted early detection for vulvar cancer and its 
precancerous conditions is not available. Gynaecolog-
ical cancer early detection examinations should how-
ever cover the entire vulva. HPV vaccination is a pos-
sible means of prevention.
3.15 Vulva
Table 3.15.1
Overview of key epidemiological parameters for Germany, ICD-10 C51
Incidence 2013 2014 Prediction for 2018
Women Women Women
Incident cases 3,240 3,130 3,500
Crude incidence rate1 7.9 7.6 8.3
Standardised incidence rate1,2 4.6 4.4 4.9
Median age at diagnosis 72 72
Mortality 2013 2014 2015
Women Women Women
Deaths 833 849 940
Crude mortality rate1 2.0 2.1 2.3
Standardised mortality rate1,2 0.9 0.9 1.0
Median age at death 79 80 80
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Women Women
Prevalence 11,300 17,700
Absolute survival rate (2013 – 2014)3 57 (52 – 68) 43 (39 – 49)
Relative survival rate (2013 – 2014)3 68 (60 – 80) 62 (53 – 68)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.15.1b
Absolute numbers of incident cases and deaths, 
ICD-10 C51, Germany 1999 – 2014/2015
Figure 3.15.1a
Age-standardised incidence and mortality rates,
ICD-10 C51, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.15.2









































78 Cancer in Germany Vulva
Table 3.15.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C51, database 2014
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 3,600) 0.6 % (1 in 160) < 0.1 % (1 in 81,800) 0.2 % (1 in 590)
45 years 0.1 % (1 in 1,800) 0.6 % (1 in 170) < 0.1 % (1 in 23,800) 0.2 % (1 in 590)
55 years 0.1 % (1 in 1,100) 0.5 % (1 in 180) < 0.1 % (1 in 6,900) 0.2 % (1 in 590)
65 years 0.2 % (1 in 650) 0.5 % (1 in 210) < 0.1 % (1 in 3,100) 0.2 % (1 in 610)
75 years 0.2 % (1 in 470) 0.4 % (1 in 280) 0.1 % (1 in 1,400) 0.1 % (1 in 670)
Lifetime risk 0.6 % (1 in 160) 0.2 % (1 in 590)
Figure 3.15.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
ICD-10 C51, Germany 2013 – 2014
Figure 3.15.4b
Relative survival rates up to 10 years after fi rst diagnosis,
ICD-10 C51, Germany 2013 – 2014
Figure 3.15.3
Distribution of T-stages at fi rst diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C51, Germany 2013 – 2014
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Figure 3.15.5
Registered age-standardised incidence and mortality rates in German federal states, 
ICD-10 C51, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.15.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C51, 2013 – 2014 or latest available year (details and sources, see appendix)
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80 Cancer in Germany Cervix
Epidemiology
In 2014, around 4,540 women were diagnosed with 
cervical cancer in Germany. Around three quarters of 
these tumours are squamous cell carcinomas. Adeno-
carcinomas (approx. 20 %) occur more proximal, at 
the transition from uterus to cervix.
Following the strong decrease over the three past 
decades, the incidence rates for invasive cervical can-
cer have remained largely stable over the past decade. 
The highest incidence rates are currently found 
among women aged 35 to 60. The median age at 
 diagnosis for invasive carcinoma is 53 years. The far 
more frequent in situ carcinoma is usually diagnosed 
in early detection examinations of women generally 
around 20 years younger.
Currently, about 1,540 women in Germany die of 
cervical cancer every year. 30 years ago, this fi gure was 
more than twice as high. The fi ve-year relative surviv-
al rate after diagnosis of an invasive cervical tumour 
is 69 %. More than half of all invasive carcinomas are 
diagnosed at an early tumour stage (T1).
By international comparison, incidence and mor-
tality rates in countries with long-standing and 
well-organised early protection programmes are clear-
ly lower than in countries with no such programmes.
Risk factors, early detection and prevention
The main cause of cervical cancer is a sexually trans-
mitted infection of the human papillomavirus (HPV). 
Many women contract HPV at some point in their 
life. Usually the infection disappears without further 
effect, but in some cases it persists and a cervical car-
cinoma can develop, especially when it concerns the 
high-risk virus subtypes HPV 16 or 18. Further risk 
factors include smoking, infections of the genital area 
with other sexually transmitted diseases such as her-
pes simplex or chlamydia, becoming sexually active at 
a young age, several births and a severely impaired 
immune system. Taking oral contraceptives (»the 
pill«) over a long period is also associated with a 
slightly higher risk of developing cervical cancer. Pos-
sibly, a genetic predisposition plays a role in the devel-
opment of cervical cancers.
In Germany women aged 20 years and older are 
entitled to an annual cervical smear test (PAP smear) 
as screening, and, following 2018, women aged over 35 
years will be entitled to an HPV test every three years 
combined with a PAP smear. The German Standing 
Committee on Vaccination Recommendations (STIKO) 
recommends vaccinating girls aged 9 to 14 against 
HPV. Statutory health insurers cover the costs of vacci-
nation for girls who have missed a vaccination up to the 
age of 17. Nonetheless, this cannot replace screening 
examinations, as vaccination only provides protection 
against the most frequent high-risk HPV types.
3.16 Cervix
Table 3.16.1
Overview of key epidemiological parameters for Germany, ICD-10 C53
Incidence 2013 2014 Prediction for 2018
Women Women Women
Incident cases 4,700 4,540 4,300
Crude incidence rate1 11.4 11.0 10.3
Standardised incidence rate1,2 9.4 9.2 8.6
Median age at diagnosis 52 53
Mortality 2013 2014 2015
Women Women Women
Deaths 1,550 1,506 1,541
Crude mortality rate1 3.8 3.7 3.7
Standardised mortality rate1,2 2.5 2.4 2.4
Median age at death 65 65 66
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Women Women
Prevalence 17,500 32,500
Absolute survival rate (2013 – 2014)3 65 (64 – 73) 58 (55 – 64)
Relative survival rate (2013 – 2014)3 69 (67 – 78) 65 (60 – 72)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.16.1b
Absolute numbers of incident cases and deaths, 
ICD-10 C53, Germany 1999 – 2014/2015
Figure 3.16.1a
Age-standardised incidence and mortality rates, 
ICD-10 C53, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.16.2
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Table 3.16.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C53, database 2014
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
15 years < 0.1 % (1 in 11,900) 0.9 % (1 in 120) < 0.1 % (1 in 253,600) 0.3 % (1 in 350)
25 years 0.1 % (1 in 1,000) 0.8 % (1 in 120) < 0.1 % (1 in 17,800) 0.3 % (1 in 350)
35 years 0.2 % (1 in 600) 0.8 % (1 in 130) < 0.1 % (1 in 4,900) 0.3 % (1 in 350)
45 years 0.2 % (1 in 600) 0.6 % (1 in 170) < 0.1 % (1 in 2,300) 0.3 % (1 in 380)
55 years 0.2 % (1 in 650) 0.4 % (1 in 230) 0.1 % (1 in 1,700) 0.2 % (1 in 440)
65 years 0.1 % (1 in 790) 0.3 % (1 in 340) 0.1 % (1 in 1,700) 0.2 % (1 in 570)
75 years 0.1 % (1 in 830) 0.2 % (1 in 530) 0.1 % (1 in 1,300) 0.1 % (1 in 760)
Lifetime risk 0.8 % (1 in 120) 0.3 % (1 in 350)
Figure 3.16.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
ICD-10 C53, Germany 2013 – 2014
Figure 3.16.4b
Relative survival rates up to 10 years after fi rst diagnosis,
ICD-10 C53, Germany 2013 – 2014
Figure 3.16.3
Distribution of T-stages at fi rst diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C53, Germany 2013 – 2014
no information
DCO
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Figure 3.16.5
Registered age-standardised incidence and mortality rates in German federal states, 
ICD-10 C53, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.16.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C53, 2013 – 2014 or latest available year (details and sources, see appendix)
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84 Cancer in Germany Uterus
Epidemiology
With approximately 10,700 newly diagnosed cases 
every year, accounting for 4.7 % of all malignant neo-
plasms, malignant uterine (uterine or endometrial) 
cancer is the fourth most common form of cancer 
among women and the most common cancer of the 
female genital organs. Due to the good prognosis, the 
number of deaths from this cancer (2,600) per year 
is comparatively low. One in 50 women will develop 
cancer of the uterus over the course of her life and one 
in 200 will die. Cancer of the uterus incidence rates 
have fallen slightly recently, while age-standardised 
mortality rates remain almost constant. The median 
age at diagnosis is 69 years. Histologically, cancers of 
the uterus are mostly endometrial adenocarcinomas 
(i.e. originating from the lining of the uterus). In ap-
proximately 80 % of cases, diagnosis occurs at an ear-
ly stage (T1). Uterine carcinomas have one of the most 
favourable prognoses. Patients in Germany have a 
5-year relative survival rate of approximately 80 %. At 
the end of 2014, there were around 79,000 women 
alive in Germany, who had developed a uterine carci-
noma during the past ten years. Regional differences 
within Germany concerning incidence and mortality 
rates are relatively small. By international compari-
son, Eastern Europe, Scandinavia and the US report 
higher incidence rates.
Risk factors
About 80 % of endometrial carcinomas are hor-
mone-dependent. Long-term oestrogen levels there-
fore constitute a risk factor. Early first menstrual period 
(menarche), late onset of menopause (climacterium), 
childlessness and diseases of the ovaries all increase 
the risk. Oestrogen monotherapy during menopause 
also increases the risk, but when combined with pro-
gesterone, this eff ect is reduced. Oral contraceptives 
(»the pill«), in particular oestrogen-progesterone 
combinations, reduce the risk. For hormone-depen-
dent tumours, lifestyle risk factors also play a role, 
particularly overweight and lack of exercise. Women 
with type 2 diabetes mellitus are more frequently 
affected. Women with breast cancer who have been 
treated with tamoxifen also face a higher risk. Gene 
mutations related to hereditary nonpolyposis colo-
rectal carcinoma (HNPPC) also increase the uterine 
cancer risk.
For the rarer oestrogen-independent types, ad-
vanced age is considered a risk-factor. Exposure of the 
uterus to radiation can also increase the risk. The role 




Overview of key epidemiological parameters for Germany, ICD-10 C54 – C55
Incidence 2013 2014 Prediction for 2018
Women Women Women
Incident cases 10,740 10,680 10,600
Crude incidence rate1 26.1 25.9 25.5
Standardised incidence rate1,2 16.1 15.9 15.3
Median age at diagnosis 69 69
Mortality 2013 2014 2015
Women Women Women
Deaths 2,579 2,472 2,602
Crude mortality rate1 6.3 6.0 6.3
Standardised mortality rate1,2 3.1 2.9 3.0
Median age at death 76 76 77
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Women Women
Prevalence 44,000 79,300
Absolute survival rate (2013 – 2014)3 70 (68 – 72) 58 (55 – 62)
Relative survival rate (2013 – 2014)3 79 (77 – 81) 75 (74 – 79)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.17.1b
Absolute numbers of incident cases and deaths, 
ICD-10 C54 – C55, Germany 1999 – 2014/2015
Figure 3.17.1a
Age-standardised incidence and mortality rates, 
ICD-10 C54 – C55, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.17.2









































86 Cancer in Germany Uterus
Table 3.17.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C54 – C55, database 2014
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 2,100) 2.0 % (1 in 50) < 0.1 % (1 in 19,200) 0.5 % (1 in 200)
45 years 0.2 % (1 in 530) 2.0 % (1 in 51) < 0.1 % (1 in 5,600) 0.5 % (1 in 200)
55 years 0.5 % (1 in 210) 1.8 % (1 in 55) 0.1 % (1 in 1,500) 0.5 % (1 in 200)
65 years 0.6 % (1 in 160) 1.4 % (1 in 70) 0.1 % (1 in 790) 0.5 % (1 in 220)
75 years 0.6 % (1 in 160) 0.9 % (1 in 110) 0.2 % (1 in 450) 0.4 % (1 in 260)
Lifetime risk 2.0 % (1 in 50) 0.5 % (1 in 200)
Figure 3.17.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
ICD-10 C54 – C55, Germany 2013 – 2014
Figure 3.17.4b
Relative survival rates up to 10 years after fi rst diagnosis,
ICD-10 C54 – C55, Germany 2013 – 2014
Figure 3.17.3
Distribution of T-stages at fi rst diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C54 – C55, Germany 2013 – 2014
no information
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Figure 3.17.5
Registered age-standardised incidence and mortality rates in German federal states, 
ICD-10 C54 – C55, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.17.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C54 – C55, 2013 – 2014 or latest available year (details and sources, see appendix)
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88 Cancer in Germany Ovaries
Epidemiology
Ovarian cancer accounts for 3.2 % of all malignant 
neoplasms among women and 5.3 % of all female can-
cer-related deaths. The incidence rates increase con-
tinually up to the age of 85, while the median age at 
diagnosis is 70. Histologically, malignant tumours of 
the ovaries are predominantly moderately and poorly 
diff erentiated serous adenocarcinomas. Rare forms of 
ovarian cancer, such as germ cell tumours may al-
ready occur in girls and younger women. One in ap-
proximately 71 women will develop ovarian cancer 
over the course of her life. Since the year 2000, inci-
dence and mortality rates in Germany have continued 
to fall significantly, as have the absolute numbers of 
new cases. The diff erences in incidence and mortality 
rates between German federal states are small. Since 
diagnosis often only occurs at a late tumour stage 
(60 % at stage T3), patients with ovarian cancer have 
relatively unfavourable survival prospects. The 5-year 
relative survival rate in Germany is currently close to 
41 %. In 2014, around 33,000 women lived in Ger-
many, who had been diagnosed with ovarian cancer 
during the past ten years.
Risk factors
The risk of developing ovarian cancer primarily in-
creases with age. Overweight also plays a role. More-
over, there are important associations with hormonal 
factors: childlessness and infertility increase the risk 
of developing ovarian cancer, while several births and 
longer periods of breast-feeding reduce the risk. The 
impact on risk of early first menstrual period (men-
arche) or late menopause (climacterium) is not entire-
ly clear. In women with polycystic ovaries, evidence 
indicates that hormonal factors potentially also trans-
late into a higher risk of ovarian cancer. Hormone 
replacement therapy (and in particular oestrogen 
monotherapy) for women after menopause is a fur-
ther risk factor. In contrast, hormonal ovulation in-
hibitors (»the pill«) have a protective eff ect. Sterilisa-
tion by means of tubal ligation also reduces the risk 
for this cancer.
For women with first-degree relatives diagnosed 
with breast or ovarian cancer and for women who 
themselves have been diagnosed with breast, uterine 
or colorectal cancer, the risk is also higher. Under-
lying genetic mutations, above all of BRCA1 and 
BRCA2, considerably increase the risk, but only play 
a part in one out of ten cases.
3.18 Ovaries
Table 3.18.1
Overview of key epidemiological parameters for Germany, ICD-10 C56
Incidence 2013 2014 Prediction for 2018
Women Women Women
Incident cases 7,560 7,250 6,900
Crude incidence rate1 18.4 17.6 16.5
Standardised incidence rate1,2 11.6 11.0 10.1
Median age at diagnosis 69 70
Mortality 2013 2014 2015
Women Women Women
Deaths 5,466 5,354 5,431
Crude mortality rate1 13.3 13.0 13.1
Standardised mortality rate1,2 7.1 6.9 6.9
Median age at death 74 74 75
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Women Women
Prevalence 20,900 33,200
Absolute survival rate (2013 – 2014)3 37 (34 – 41) 27 (23 – 30)
Relative survival rate (2013 – 2014)3 41 (37 – 44) 32 (29 – 36)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.18.1b
Absolute numbers of incident cases and deaths, 
ICD-10 C56, Germany 1999 – 2014/2015
Figure 3.18.1a
Age-standardised incidence and mortality rates, 
ICD-10 C56, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.18.2
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Table 3.18.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C56, database 2014
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,600) 1.4 % (1 in 73) < 0.1 % (1 in 5,800) 1.1 % (1 in 95)
45 years 0.2 % (1 in 600) 1.3 % (1 in 75) 0.1 % (1 in 1,500) 1.0 % (1 in 96)
55 years 0.3 % (1 in 370) 1.2 % (1 in 84) 0.1 % (1 in 670) 1.0 % (1 in 100)
65 years 0.4 % (1 in 260) 1.0 % (1 in 100) 0.3 % (1 in 330) 0.9 % (1 in 110)
75 years 0.4 % (1 in 230) 0.7 % (1 in 150) 0.4 % (1 in 240) 0.7 % (1 in 150)
Lifetime risk 1.4 % (1 in 71) 1.0 % (1 in 95)
Figure 3.18.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
ICD-10 C56, Germany 2013 – 2014
Figure 3.18.4b
Relative survival rates up to 10 years after fi rst diagnosis,
ICD-10 C56, Germany 2013 – 2014
Figure 3.18.3
Distribution of T-stages at fi rst diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C56, Germany 2013 – 2014
no information
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Figure 3.18.5
Registered age-standardised incidence and mortality rates in German federal states, 
ICD-10 C56, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.18.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C56, 2013 – 2014 or latest available year (details and sources, see appendix)
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92 Cancer in Germany Prostate
Epidemiology
In 2014, around 57,400 new cases of prostate cancer 
were registered. After increasing for almost two 
 decades, age-standardised incidence rates have re-
mained largely constant since 2003 and have actually 
signifi cantly decreased since 2011. Many other west-
ern industrialised nations have observed a similar 
trend, which may be attributable to the increased but 
now declining use of the prostate-specific antigen test 
(PSA test) in the late 1980s in screening examina-
tions. By contrast, age-standardised mortality rates 
dropped continuously until 2007 and then levelled 
out. Compared to other central European countries, 
incidence rates in Germany are relatively low.
Prostate cancer patients are seldom younger 
than 50 years. For a 35-year old man, the risk of being 
diagnosed with prostate cancer within the next ten 
years is less than 0.1 %, while for a 75-year old man it 
is approximately 5 %.
The 5-year relative survival rate for prostate can-
cer is 91 %. Three out of four tumours are diagnosed 
at an early stage (T1 or T2).
Risk factors and early detection
Little is known about the causes of prostate carcinoma 
and the factors influencing the course of the disease. 
Age is an important risk factor. Moreover, the disease 
occurs more often among men of black African origin 
than among European or white North American men 
and is relatively rare among Asian men. The evidence 
conclusively shows that clusters of cases among close 
relatives are a risk factor. The male sex hormone (tes-
tosterone) also plays a part. Furthermore, chronic 
prostate infections and sexually transmitted diseases 
appear to increase the risk of prostate cancer.
There are few reliable findings regarding life-
style, diet or the environment. Normal weight and 
suffi  cient physical exercise, however, potentially de-
crease the risk of developing prostate cancer.
For men aged 45 years or older, Germany’s stat-
utory screening programme currently recommends a 
yearly interview focusing on complaints and other 
health-related changes, an examination of the external 
sexual organs, as well as a palpation examination of 
the prostate and the lymph nodes. Statutory screening 
does not include a PSA blood test, as, to date, there is 
no suffi  cient evidence of its additional benefit to jus-
tify population-wide PSA tests.
3.19 Prostate
Table 3.19.1
Overview of key epidemiological parameters for Germany, ICD-10 C61
Incidence 2013 2014 Prediction for 2018
Men Men Men
Incident cases 60,170 57,370 60,700
Crude incidence rate1 152.5 144.5 150.7
Standardised incidence rate1,2 99.0 92.7 92.7
Median age at diagnosis 71 72
Mortality 2013 2014 2015
Men Men Men
Deaths 13,408 13,704 13,900
Crude mortality rate1 34.0 34.5 34.6
Standardised mortality rate1,2 20.0 19.7 19.4
Median age at death 79 79 79
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Men
Prevalence 271,800 494,800
Absolute survival rate (2013 – 2014)3 76 (74 – 78) 59 (57 – 62)
Relative survival rate (2013 – 2014)3 91 (89 – 93) 90 (88 – 92)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.19.1b
Absolute numbers of incident cases and deaths, 
ICD-10 C61, Germany 1999 – 2014/2015
Figure 3.19.1a
Age-standardised incidence and mortality rates, 
ICD-10 C61, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.19.2
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Table 3.19.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C61, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 4,300) 12.1 % (1 in 8) < 0.1 % (1 in 120,000) 3.3 % (1 in 30)
45 years 0.4 % (1 in 230) 12.2 % (1 in 8) < 0.1 % (1 in 4,800) 3.4 % (1 in 30)
55 years 2.3 % (1 in 43) 12.3 % (1 in 8) 0.2 % (1 in 570) 3.5 % (1 in 29)
65 years 5.4 % (1 in 18) 11.2 % (1 in 9) 0.7 % (1 in 150) 3.7 % (1 in 27)
75 years 5.4 % (1 in 19) 7.8 % (1 in 13) 1.9 % (1 in 52) 3.8 % (1 in 27)
Lifetime risk 11.9 % (1 in 8) 3.3 % (1 in 31)
Figure 3.19.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
ICD-10 C61, Germany 2013 – 2014
Figure 3.19.4b
Relative survival rates up to 10 years after fi rst diagnosis,
ICD-10 C61, Germany 2013 – 2014
Figure 3.19.3
Distribution of T-stages at fi rst diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C61, Germany 2013 – 2014
no information
DCO
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Figure 3.19.5
Registered age-standardised incidence and mortality rates in German federal states, 
ICD-10 C61, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.19.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C61, 2013 – 2014 or latest available year (details and sources, see appendix)
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96 Cancer in Germany Testicle
Epidemiology
In 2014, around 4,070 men in Germany were diag-
nosed with testicular cancer. This is 1.6 % of all cases 
of cancer in men, making it relatively rare.
In contrast to almost all other types of cancer, 
most cases are diagnosed at the comparatively young 
age of 25 to 45 years. In this age group, testicular can-
cer is the most common malignant tumour in men. 
Correspondingly, the median age at diagnosis is 38 
years.
In Germany and other European countries, 
age-standardised incidence rates now remain almost 
constant following decades that saw a steady increase 
in the number of cases. Over 90 % of testicular tu-
mours are diagnosed in the early stages T1 or T2. His-
tologically, testicular cancers are predominantly germ 
cell tumours, of which approximately two thirds are 
seminomas. Malignant teratoma or mixed seminoma 
and teratoma tumours make up one in six cases.
Since the introduction of cis-platinum in chemo-
therapy for testicular cancer over 30 years ago, this 
disease has become one of the malignant neoplasms 
with the most favourable prognoses (currently with a 
5-year survival rate of 96 %) and a low mortality rate 
(145 deaths in 2015).
Risk factors and early detection
Even after proper treatment, cryptorchidism (un-
descended testis) remains a risk factor for testicular 
cancer. The risk in men, who have already developed 
cancer or a preliminary stage of cancer in one testicle, 
of developing a tumour in the other testicle, is also 
increased. Rare genetic conditions that aff ect sexual 
development such as the Klinefelter syndrome also 
increase the testicular cancer risk.
Genetic predisposition possibly plays a role in a 
small number of cases. The sons and brothers of tes-
ticular cancer patients have a significantly higher risk 
of developing the disease themselves.
A birth weight below 2,500 g or above 4,500 g as 
well as being tall in stature are also being discussed as 
possible risk factors. The reasons behind the observed 
increase in incidence rates over the past few decades 
are not fully understood. Current fi ndings suggest 
that lifestyle and environmental factors have no eff ect 
on the development of testicular cancer.
However, evidence clearly indicates that an early 
diagnosis correlates with a better prognosis. Follow-
ing puberty, adolescents and men are therefore 
 advised to carry out regular self-examination by pal-
pation of the testes. The statutory early detection 
 programme offers men above 45 an annual examina-
tion of the sexual organs.
3.20 Testicle
Table 3.20.1
Overview of key epidemiological parameters for Germany, ICD-10 C62
Incidence 2013 2014 Prediction for 2018
Men Men Men
Incident cases 4,200 4,070 4,400
Crude incidence rate1 10.7 10.3 10.9
Standardised incidence rate1,2 10.7 10.3 11.0
Median age at diagnosis 38 38
Mortality 2013 2014 2015
Men Men Men
Deaths 158 153 145
Crude mortality rate1 0.4 0.4 0.4
Standardised mortality rate1,2 0.3 0.3 0.3
Median age at death 49 51 48
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Men
Prevalence 19,700 39,600
Absolute survival rate (2013 – 2014)3 95 (91 – 96) 92 (90 – 94)
Relative survival rate (2013 – 2014)3 96 (93 – 98) 96 (93 – 97)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.20.1b
Absolute numbers of incident cases and deaths,
ICD-10 C62, Germany 1999 – 2014/2015
Figure 3.20.1a
Age-standardised incidence and mortality rates, 
ICD-10 C62, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.20.2
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Table 3.20.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C62, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
15 years 0.1 % (1 in 1,000) 0.8 % (1 in 130) < 0.1 % (1 in 57,100) < 0.1 % (1 in 3,400)
25 years 0.2 % (1 in 410) 0.7 % (1 in 150) < 0.1 % (1 in 21,700) < 0.1 % (1 in 3,600)
35 years 0.2 % (1 in 470) 0.4 % (1 in 230) < 0.1 % (1 in 23,500) < 0.1 % (1 in 4,300)
45 years 0.1 % (1 in 740) 0.2 % (1 in 450) < 0.1 % (1 in 19,000) < 0.1 % (1 in 5,200)
55 years 0.1 % (1 in 1,900) 0.1 % (1 in 1,100) < 0.1 % (1 in 21,200) < 0.1 % (1 in 6,900)
65 years < 0.1 % (1 in 4,600) < 0.1 % (1 in 2,400) < 0.1 % (1 in 37,500) < 0.1 % (1 in 9,300)
75 years < 0.1 % (1 in 5,800) < 0.1 % (1 in 3,900) < 0.1 % (1 in 16,400) < 0.1 % (1 in 9,700)
Lifetime risk 0.8 % (1 in 130) < 0.1 % (1 in 3,400)
Figure 3.20.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
ICD-10 C62, Germany 2013 – 2014
Figure 3.20.4b
Relative survival rates up to 10 years after fi rst diagnosis,
ICD-10 C62, Germany 2013 – 2014
Figure 3.20.3
Distribution of T-stages at fi rst diagnosis (top: all cases; bottom: only valid reports)
ICD-10 C62, Germany 2013 – 2014
no information
DCO
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Figure 3.20.5
Registered age-standardised incidence and mortality rates in German federal states, 
ICD-10 C62, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.20.6
International comparison of age-standardised incidence and mortality rates,
ICD-10 C62, 2013 – 2014 or latest available year (details and sources, see appendix)
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100 Cancer in Germany Kidney
Epidemiology
Malignant neoplasms of the kidney develop from var-
ious tissues. In adults the most frequent type (96 % 
of cases) are renal cell carcinomas (hypernephromas). 
In children, who however only rarely develop the con-
dition, nephroblastomas (Wilms’ tumours) are more 
frequent. Since the end of the 1990s, the absolute 
number of new cases in men has been rising contin-
uously, while in women the corresponding fi gure has 
been dropping since 2009. Age-standardised inci-
dence rates have remained fairly constant for men 
and women over the whole period, although the inci-
dence rate for men is twice as high as for women. 
Age-standardised mortality rates for both sexes pres-
ent a slight downward trend. The median age at diag-
nosis is 67 years for men and 72 years for women. 
The prognosis for kidney carcinoma is comparatively 
favourable, the 5-year relative survival rate for kidney 
tumours is 77 % for both sexes. Around three-quarters 
of kidney tumours are diagnosed at a relatively early 
stage (T1 and T2). In regional and/or international 
comparison, incidence and mortality rates are com-
paratively high in the eastern federal states, as well as 
in the Czech Republic.
Risk factors
Smoking and passive smoking, as well as hyperten-
sion and obesity are considered the most important 
risk factors. Furthermore, a lack of physical activity 
seems to increase a person’s kidney cancer risk. 
Chronic renal insufficiency, regardless of its cause, 
generally promotes carcinogenesis in the kidney. 
Nephrotoxic medications or repeated inflammations 
of the urinary tract can for example be a cause. More-
over, following kidney transplantation, the immu-
no-suppressed patient has an increased risk of devel-
oping a renal cell carcinoma.
Familial predisposition is probably only a factor 
in few cases. Approximately 4 % of renal cell carcino-
mas occur in patients with complex hereditary diseas-
es such as Hippel-Lindau syndrome. Renal cell carci-
nomas caused by genetic factors are often multifocal 
and occur more often at a younger age than kidney 
cancers in patients without a genetic disposition.
3.21 Kidney
Table 3.21.1
Overview of key epidemiological parameters for Germany, ICD-10 C64
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 9,430 5,590 9,480 5,480 9,900 5,200
Crude incidence rate1 23.9 13.6 23.9 13.3 24.5 12.6
Standardised incidence rate1,2 16.6 8.0 16.5 7.8 16.3 7.3
Median age at diagnosis 68 72 67 72
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 3,358 2,100 3,243 2,035 3,306 2,106
Crude mortality rate1 8.5 5.1 8.2 4.9 8.2 5.1
Standardised mortality rate1,2 5.4 2.3 5.1 2.2 5.0 2.2
Median age at death 74 78 74 78 75 79
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 36,200 21,900 61,600 38,000
Absolute survival rate (2013 – 2014)3 66 (63 – 69) 68 (67 – 71) 51 (45 – 55) 53 (52 – 57)
Relative survival rate (2013 – 2014)3 77 (73 – 79) 77 (75 – 80) 70 (63 – 74) 71 (69 – 73)
3 in percentages (lowest and highest value of the included German federal states)
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Abbildung 3.21.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C64, Germany 1999 – 2014/2015
Figure 3.21.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C64, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.21.2









































102 Cancer in Germany Kidney
Table 3.21.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C64, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,700) 1.8 % (1 in 56) < 0.1 % (1 in 16,400) 0.7 % (1 in 140)
45 years 0.2 % (1 in 560) 1.8 % (1 in 57) < 0.1 % (1 in 3,200) 0.7 % (1 in 140)
55 years 0.4 % (1 in 250) 1.6 % (1 in 61) 0.1 % (1 in 1,000) 0.7 % (1 in 140)
65 years 0.7 % (1 in 150) 1.4 % (1 in 73) 0.2 % (1 in 450) 0.7 % (1 in 150)
75 years 0.7 % (1 in 150) 0.9 % (1 in 110) 0.4 % (1 in 280) 0.6 % (1 in 180)
Lifetime risk 1.8 % (1 in 56) 0.7 % (1 in 140)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 3,800) 1.0 % (1 in 96) <0.1 % (1 in 51,700) 0.4 % (1 in 240)
45 years 0.1 % (1 in 1,300) 1.0 % (1 in 98) <0.1 % (1 in 8,700) 0.4 % (1 in 240)
55 years 0.2 % (1 in 540) 1.0 % (1 in 100) <0.1 % (1 in 2,700) 0.4 % (1 in 240)
65 years 0.3 % (1 in 310) 0.8 % (1 in 120) 0.1 % (1 in 1,100) 0.4 % (1 in 250)
75 years 0.4 % (1 in 250) 0.6 % (1 in 170) 0.2 % (1 in 500) 0.4 % (1 in 280)
Lifetime risk 1.1 % (1 in 95) 0.4 % (1 in 240)
Figure 3.21.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C64, Germany 2013 – 2014
Figure 3.21.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C64, Germany 2013 – 2014
Figure 3.21.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C64, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
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Figure 3.21.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C64, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.21.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C64, 2013 – 2014 or latest available year (details and sources, see appendix)
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104 Cancer in Germany Bladder
Epidemiology
Around 15,800 people, one quarter of them women, 
were newly diagnosed with an invasive bladder carci-
noma in Germany in 2014. In addition, about 13,700 
were diagnosed with non-invasive papillary carcino-
ma or in situ tumours of the bladder. Especially the 
latter have a high tendency of progression and recur-
rence. Therefore, they are of particular clinical rele-
vance, even though they are not classifi ed as malig-
nant tumours according to ICD-10. The majority of 
bladder cancers are carcinomas of the urothelium, 
which frequently develop simultaneously in multiple 
sites in the bladder and urinary tract. For men, the 
age-standardised incidence and mortality rates indi-
cate a clear downward trend since the 1990s, which is 
probably due to lower levels of tobacco consumption, 
and, possibly, to a decreased exposure to occupational 
carcinogens. For women, both rates remained rela-
tively stable over the years although they are signifi -
cantly lower compared to men. The higher survival 
rates of men compared to women correlate with a 
more favourable distribution regarding the stage of 
the tumour at diagnosis (48 % vs. 35 % T1 tumours).
Risk factors
Smoking, both active and passive, is considered the 
most important risk factor. Exposure to certain chem-
icals such as aromatic amines also increases the risk 
of developing bladder cancer. In Europe, the known 
hazardous substances have largely been eliminated 
from industrial processes and workplaces. However, 
the latency period between exposure and the develop-
ment of cancer is long, which means that bladder car-
cinomas caused by occupational exposure to now 
forbidden chemicals, will continue to be registered. 
Cytostatic drugs used in chemotherapy and radiation 
therapy of this part of the body can also increase the 
bladder cancer risk. Other medicines such as piogli-
tazone (used to treat diabetics) also appear to cause 
bladder cancer.
Furthermore, air pollution, as well as arsenic and 
chlorine in drinking water increase the risk for devel-
oping a carcinoma of the bladder. Chronic inflamma-
tory damage to the mucosa of the bladder also increas-
es the risk. Family clusters have been observed. 
Furthermore, studies indicate that by aff ecting a pa-
tient’s sensitivity to carcinogens, genetic factors play 
a role in the development of bladder cancer.
3.22 Bladder
Table 3.22.1
Overview of key epidemiological parameters for Germany, ICD-10 C67
Incidence 2013 2014 Prediction for 2018













Crude incidence rate1 30.4 (57.5)4 10.4 (17.8)4 29.4 (56.5)4 10.1 (17.2)4 30.2 (57.4)4 10.6 (18.2)4
Standardised incidence rate1,2 19.2 (36.8)4 5.1 (9.3)4 18.2 (35.5)4 4.9 (8.9)4 17.7 (34.1)4 4.9 (9.5)4
Median age at diagnosis 74 (73)4 77 (74)4 74 (74)4 76 (75)4
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 3,894 1,863 3,897 1,795 3,963 1,872
Crude mortality rate1 9.9 4.5 9.8 4.4 9.9 4.5
Standardised mortality rate1,2 6.0 1.8 5.8 1.8 5.7 1.8
Median age at death 78 82 79 82 79 82
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years









Absolute survival rate (2013 – 2014)3 45 (42 – 51) 38 (35 – 45) 30 (28 – 34) 28 (26 – 34)
Relative survival rate (2013 – 2014)3 57 (54 – 64) 47 (41 – 55) 50 (47 – 56) 44 (37 – 53)
3 in percentages (lowest and highest value of the included German federal states)
4 in parentheses: including in situ tumours and neoplasms of uncertain or unknown behavior (D09.0, D41.1)
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Figure 3.22.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C67, Germany 1999 – 2014/2015
Figure 3.22.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C67, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.22.2
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Table 3.22.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C67, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 5,200) 2.6 % (1 in 39) < 0.1 % (1 in 43,600) 1.0 % (1 in 110)
45 years 0.1 % (1 in 940) 2.6 % (1 in 39) < 0.1 % (1 in 5,300) 1.0 % (1 in 100)
55 years 0.4 % (1 in 280) 2.6 % (1 in 39) 0.1 % (1 in 1,600) 1.0 % (1 in 100)
65 years 0.8 % (1 in 130) 2.5 % (1 in 40) 0.2 % (1 in 510) 1.0 % (1 in 99)
75 years 1.3 % (1 in 76) 2.1 % (1 in 47) 0.5 % (1 in 190) 1.0 % (1 in 97)
Lifetime risk 2.5 % (1 in 39) 0.9 % (1 in 110)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 10,200) 0.9 % (1 in 120) < 0.1 % (1 in 57,400) 0.4 % (1 in 250)
45 years < 0.1 % (1 in 2,700) 0.9 % (1 in 120) < 0.1 % (1 in 10,800) 0.4 % (1 in 250)
55 years 0.1 % (1 in 1,000) 0.8 % (1 in 120) < 0.1 % (1 in 4,300) 0.4 % (1 in 250)
65 years 0.2 % (1 in 490) 0.8 % (1 in 130) 0.1 % (1 in 1,700) 0.4 % (1 in 260)
75 years 0.4 % (1 in 280) 0.7 % (1 in 150) 0.2 % (1 in 600) 0.4 % (1 in 270)
Lifetime risk 0.9 % (1 in 120) 0.4 % (1 in 260)
Figure 3.22.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C67, Germany 2013 – 2014
Figure 3.22.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C67, Germany 2013 – 2014
Figure 3.22.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C67, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
48% 33% 13% 6%
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Figure 3.22.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C67, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.22.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C67, 2013 – 2014 or latest available year (details and sources, see appendix)
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3 no comparable data for incidence
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108 Cancer in Germany Central nervous system
Epidemiology
The vast majority (95 %) of cancers of the central ner-
vous system (CNS) occur in the brain. The remaining 
5 % concerns cancers of the meninges, cranial nerves 
and the spinal nerves of the cauda equina. Malignant 
neoplasms of the central nervous system do not devel-
op out of the nerve cells themselves but originate 
from glial cells, the nerve sheaths and meninges. His-
tologically, glioms are the most frequent form found 
in adults, with approximately three quarters of these 
being glioblastomas (grade IV astrocytomas). Babies 
and infants are mostly aff ected by embryonal tu-
mours. In 2014, around 3,160 women and 3,900 men 
in Germany developed CNS cancers. Men show high-
er incidence and mortality rates across all age groups 
than women and have a median age at diagnosis of 62 
years, 4 years earlier than women. CNS tumours can 
occur at any age. In Germany, since the turn of the 
millennium, mortality rates have remained constant. 
However, demographic shifts have led the absolute 
number of malignant neoplasms to rise. The 5-year 
relative survival rates for malignant CNS cancer pa-
tients have improved slightly and are currently at 
20 % (men) and 23 % (women), whereby the rates for 
glioblastomas of the brain are signifi cantly lower (be-
low 10 %).
Risk factors
The reasons why people develop brain tumours re-
main largely unclear. The only exceptions are the rare 
hereditary tumour syndromes, which are associated 
with a significantly higher brain tumour risk. Patients 
who have undergone therapeutic radiation of the head 
have a slightly increased risk of developing a brain 
tumour after a long latency period. This applies in 
particular, when such therapy occurs at childhood or 
adolescent age. CT scans at childhood age potentially 
also marginally increase the risk of developing a brain 
tumour.
No conclusive evidence exists for a link between 
mobile phone usage and brain tumours. However, it 
is impossible to absolutely rule out an increased risk. 
This is particularly true for people who use their mo-
biles and smart phones frequently and over many 
hours each day. There is no evidence that viruses, tox-
ic substances or lifestyle factors such as smoking or 
drinking alcohol increase the risk for brain tumours.
First-degree relatives of patients with brain tu-
mours have a slightly higher risk of developing a 
brain tumour themselves. Genetic factors are there-
fore presumably also a factor.
3.23 Central nervous system
Table 3.23.1
Overview of key epidemiological parameters for Germany, ICD-10 C70 – C72
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 4,030 3,360 3,880 3,160 4,200 3,500
Crude incidence rate1 10.2 8.2 9.8 7.7 10.5 8.5
Standardised incidence rate1,2 8.0 5.8 7.6 5.4 8.1 5.8
Median age at diagnosis 63 65 62 66
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 3,252 2,563 3,340 2,765 3,317 2,535
Crude mortality rate1 8.2 6.2 8.4 6.7 8.3 6.1
Standardised mortality rate1,2 6.0 4.0 6.1 4.1 5.9 3.8
Median age at death 66 70 66 71 66 70
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 7,200 5,700 10,900 8,700
Absolute survival rate (2013 – 2014)3 19 (16 – 26) 21 (17 – 29) 14 (11 – 23) 16 (10 – 24)
Relative survival rate (2013 – 2014)3 20 (17 – 27) 23 (18 – 30) 16 (12 – 26) 18 (11 – 26)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.23.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C70 – C72, Germany 1999 – 2014/2015
Figure 3.23.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C70 – C72, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.23.2









































110 Cancer in Germany Central nervous system
Table 3.23.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C70 – C72, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 2,100) 0.7 % (1 in 150) < 0.1 % (1 in 3,100) 0.6 % (1 in 170)
45 years 0.1 % (1 in 1,100) 0.6 % (1 in 160) 0.1 % (1 in 1,400) 0.6 % (1 in 180)
55 years 0.2 % (1 in 660) 0.6 % (1 in 180) 0.1 % (1 in 810) 0.5 % (1 in 200)
65 years 0.2 % (1 in 470) 0.5 % (1 in 220) 0.2 % (1 in 510) 0.4 % (1 in 230)
75 years 0.2 % (1 in 440) 0.3 % (1 in 330) 0.2 % (1 in 460) 0.3 % (1 in 340)
Lifetime risk 0.8 % (1 in 130) 0.6 % (1 in 160)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 2,600) 0.6 % (1 in 180) < 0.1 % (1 in 5,100) 0.5 % (1 in 220)
45 years 0.1 % (1 in 1,500) 0.5 % (1 in 190) < 0.1 % (1 in 2,200) 0.4 % (1 in 230)
55 years 0.1 % (1 in 910) 0.5 % (1 in 210) 0.1 % (1 in 1,100) 0.4 % (1 in 250)
65 years 0.2 % (1 in 590) 0.4 % (1 in 260) 0.1 % (1 in 740) 0.3 % (1 in 300)
75 years 0.2 % (1 in 550) 0.2 % (1 in 410) 0.2 % (1 in 640) 0.2 % (1 in 440)
Lifetime risk 0.6 % (1 in 160) 0.5 % (1 in 210)
Figure 3.23.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C70 – C72, Germany 2013 – 2014
Figure 3.23.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C70 – C72, Germany 2013 – 2014
Figure 3.23.3
Distribution of histologic types in malignant brain tumours according to WHO-classifi cation (2016), 
Germany 2013 – 2014, by sex (DCO cases excluded)
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Figure 3.23.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C70 – C72, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.23.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C70 – C72, 2013 – 2014 or latest available year (details and sources, see appendix)
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Risk factors
Ionizing radiation has been established as a risk fac-
tor for thyroid cancer. In particular, in children, the 
thyroid gland is radiation-sensitive. The risk for thy-
roid cancer increases, if the thyroid gland is in the 
radiation fi eld during radiotherapy. Consumption of 
radioactive iodine for example in the wake of the 
Chernobyl disaster, also translated into a higher risk 
of developing thyroid cancer in the aff ected former 
Soviet Republics.
There is no conclusive evidence concerning the 
role of further dietary, or lifestyle factors, or environ-
mental risks. Furthermore, it remains unclear as to 
why the incidence among women is higher than 
among men. Many patients have a history of iodine 
deficiency or benign thyroid diseases such as struma 
(goitre) and adenoma, which increase the risk for thy-
roid carcinomas. About a fi fth of patients with rare 
medullary thyroid carcinoma have autosomal domi-
nant hereditary genetic mutations. Medullary thyroid 
carcinomas also occur in combination with other 
endocrine tumours - as part of a so-called type 2 mul-
tiple endocrine neoplasia (MEN 2). A genetic compo-
nent is also suspected for papillary thyroid carcino-
mas.
Epidemiology
In 2014, approximately 4,280 women and 1,840 men 
were diagnosed with thyroid cancer. The median age 
at diagnosis was 51 years for women and 55 for men.
Between 1999 and 2014, whilst the age-stand-
ardised incidence rates for both sexes increased sig-
nifi cantly, mortality rates in Germany for both men 
and women decreased slightly. However, this applied 
exclusively to papillary carcinomas with a generally 
favourable prognosis and predominantly younger 
adults. Mostly, this is attributed to the increased use 
of diagnostic imaging techniques and improved ex-
amination methods, which are also used to diagnose 
additional diseases. In Germany, Bavaria and North 
Rhine-Westphalia record the highest incidence rates 
for both sexes and, internationally, rates are highest 
in the USA and Austria in the selected group of coun-
tries.
The majority of thyroid gland cancers are diag-
nosed at an early stage (T1, 63 % women and 52 % 
men) and have a favourable prognosis with 5-year 
relative survival rate of 94 % among women and 87 % 
among men (exception: 5-year survival with anaplas-
tic carcinoma approximately 10 %).
3.24 Thyroid gland
Table 3.24.1
Overview of key epidemiological parameters for Germany, ICD-10 C73
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 1,960 4,230 1,840 4,280 2,200 4,500
Crude incidence rate1 5.0 10.3 4.6 10.4 5.5 10.8
Standardised incidence rate1,2 4.1 8.9 3.8 9.2 4.6 9.8
Median age at diagnosis 55 52 55 51
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 297 479 342 390 300 416
Crude mortality rate1 0.8 1.2 0.9 0.9 0.8 1.0
Standardised mortality rate1,2 0.5 0.5 0.6 0.4 0.5 0.4
Median age at death 74 78 73 79 73 79
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 8,000 20,200 14,100 37,600
Absolute survival rate (2013 – 2014)3 81 (71 – 92) 90 (82 – 94) 71 (61 – 80) 84 (74 – 90)
Relative survival rate (2013 – 2014)3 87 (77 – 98) 94 (87 – 97) 84 (75 – 93) 92 (84 – 98)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.24.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C73, Germany 1999 – 2014/2015
Figure 3.24.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C73, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.24.2









































114 Cancer in Germany Thyroid gland
Table 3.24.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C73, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
25 years < 0.1 % (1 in 3,200) 0.3 % (1 in 290) < 0.1 % (1 in 582,200) 0.1 % (1 in 1,600)
35 years 0.1 % (1 in 1,900) 0.3 % (1 in 320) < 0.1 % (1 in 140,200) 0.1 % (1 in 1,600)
45 years 0.1 % (1 in 1,500) 0.3 % (1 in 380) < 0.1 % (1 in 38,300) 0.1 % (1 in 1,600)
55 years 0.1 % (1 in 1,300) 0.2 % (1 in 490) < 0.1 % (1 in 11,600) 0.1 % (1 in 1,600)
65 years 0.1 % (1 in 1,300) 0.1 % (1 in 700) < 0.1 % (1 in 5,000) 0.1 % (1 in 1,700)
75 years 0.1 % (1 in 1,600) 0.1 % (1 in 1,200) < 0.1 % (1 in 2,900) 0.1 % (1 in 2,000)
Lifetime risk 0.4 % (1 in 280) 0.1 % (1 in 1,600)
Women aged in the next ten years ever in the next ten years ever
25 years 0.1 % (1 in 1,000) 0.7 % (1 in 140) < 0.1 % (1 in 490,000) 0.1 % (1 in 1,000)
35 years 0.1 % (1 in 710) 0.6 % (1 in 160) < 0.1 % (1 in 200,000) 0.1 % (1 in 1,000)
45 years 0.1 % (1 in 700) 0.5 % (1 in 200) < 0.1 % (1 in 33,000) 0.1 % (1 in 1,000)
55 years 0.1 % (1 in 690) 0.4 % (1 in 280) < 0.1 % (1 in 13,000) 0.1 % (1 in 1,000)
65 years 0.1 % (1 in 850) 0.2 % (1 in 440) < 0.1 % (1 in 4,300) 0.1 % (1 in 1,100)
75 years 0.1 % (1 in 1,100) 0.1 % (1 in 800) < 0.1 % (1 in 2,200) 0.1 % (1 in 1,300)
Lifetime risk 0.8 % (1 in 130) 0.1 % (1 in 1,000)
Figure 3.24.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C73, Germany 2013 – 2014
Figure 3.24.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C73, Germany 2013 – 2014
Figure 3.24.3
Distribution of T-stages at fi rst diagnosis by sex (top: all cases; bottom: only valid reports)
ICD-10 C73, Germany 2013 – 2014
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
52% 15% 26% 7%



















115ICD-10 C73 Cancer in Germany
Figure 3.24.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C73, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.24.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C73, 2013 – 2014 or latest available year (details and sources, see appendix)
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Risk factors
Hodgkin’s lymphoma risk factors are not completely 
understood. Congenital or acquired immunodefi -
ciency disorders, such as an HIV infection, apparent-
ly increase the risk of developing Hodgkin lympho-
ma.
EBV infections and glandular fever (infectious 
mononucleosis) may potentially be involved in the 
development of Hodgkin’s lymphoma. However, this 
presumably only applies to a small number of cases 
of Hodgkin lymphoma. The role of lifestyle-related 
risk factors and environmental hazards in Hodgkin’s 
lymphoma development remains unclear. Possibly, a 
long-term cigarette smoking habit is related to a high-
er Hodgkin lymphoma risk.
The risk of children and siblings of Hodgkin 
lymphoma patients of developing the disease is 
slightly increased. The factors involved are not fully 
understood and research is ongoing.
For the majority of cases, there is no clearly iden-
tifi able cause and numerous factors presumably are 
at play before a Hodgkin lymphoma develops.
Epidemiology
Hodgkin’s lymphoma is distinguished from non- 
Hodgkin lymphomas by the presence of Reed- 
 Sternberg giant cells in the bone marrow visible 
through a microscope.
Hodgkin’s lymphoma is a rare disease. In 2014, 
in Germany, around 1,340 men and 1,030 women 
were diagnosed with Hodgkin’s lymphoma. While 
the disease can occur at any age, about one in ten 
patients was under 20 at diagnosis. The risk of devel-
oping Hodgkin’s lymphoma at any stage in life is 
0.2 % for women and 0.3 % for men.
Since around 2006, Hodgkin lymphoma inci-
dence rates, as well as the absolute number of new 
cases, have been rising slowly, while a decreasing 
number of people die of the disease. In 2014, just 
over 300 patients died from Hodgkin’s lymphoma, 
which was almost 200 less than ten years ago. Corre-
spondingly, the disease has a favourable prognosis, 
with about 85 % of women and 84 % of men still alive 
5 years after diagnosis. Due to the chronic, relapsing 
nature of the disease, the side effects of therapy (in-




Overview of key epidemiological parameters for Germany, ICD-10 C81
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 1,360 1,030 1,340 1,030 1,500 1,100
Crude incidence rate1 3.5 2.5 3.4 2.5 3.6 2.7
Standardised incidence rate1,2 3.2 2.4 3.1 2.4 3.2 2.6
Median age at diagnosis 44 42 49 45
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 185 171 183 150 180 132
Crude mortality rate1 0.5 0.4 0.5 0.4 0.5 0.3
Standardised mortality rate1,2 0.3 0.2 0.3 0.2 0.3 0.2
Median age at death 74 77 72 75 70 76
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 5,500 4,300 9,900 7,700
Absolute survival rate (2013 – 2014)3 80 (75 – 84) 82 (76 – 86) 71 (67 – 74) 76 (67 – 82)
Relative survival rate (2013 – 2014)3 84 (79 – 87) 85 (81 – 90) 78 (76 – 82) 81 (74 – 87)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.25.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C81, Germany 1999 – 2014/2015
Figure 3.25.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C81, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.25.2
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Table 3.25.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C81, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
15 years < 0.1 % (1 in 2,600) 0.2 % (1 in 410) < 0.1 % (1 in 150,000) < 0.1 % (1 in 2,500)
25 years < 0.1 % (1 in 2,500) 0.2 % (1 in 480) < 0.1 % (1 in 76,000) < 0.1 % (1 in 2,500)
35 years < 0.1 % (1 in 2,500) 0.2 % (1 in 590) < 0.1 % (1 in 63,000) < 0.1 % (1 in 2,600)
45 years < 0.1 % (1 in 3,200) 0.1 % (1 in 770) < 0.1 % (1 in 52,000) < 0.1 % (1 in 2,600)
55 years < 0.1 % (1 in 3,100) 0.1 % (1 in 970) < 0.1 % (1 in 29,000) < 0.1 % (1 in 2,700)
Lifetime risk 0.3 % (1 in 380) < 0.1 % (1 in 2,500)
Women aged in the next ten years ever in the next ten years ever
15 years < 0.1 % (1 in 2,200) 0.2 % (1 in 510) < 0.1 % (1 in 250,000) < 0.1 % (1 in 2,900)
25 years < 0.1 % (1 in 2,500) 0.2 % (1 in 660) < 0.1 % (1 in 230,000) < 0.1 % (1 in 3,000)
35 years < 0.1 % (1 in 4,600) 0.1 % (1 in 890) < 0.1 % (1 in 73,000) < 0.1 % (1 in 3,000)
45 years < 0.1 % (1 in 6,300) 0.1 % (1 in 1,100) < 0.1 % (1 in 70,000) < 0.1 % (1 in 3,100)
55 years < 0.1 % (1 in 5,700) 0.1 % (1 in 1,300) < 0.1 % (1 in 25,000) < 0.1 % (1 in 3,200)
Lifetime risk 0.2 % (1 in 470) < 0.1 % (1 in 3,000)
Figure 3.25.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C81, Germany 2013 – 2014
Figure 3.25.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C81, Germany 2013 – 2014
Figure 3.25.3
Distribution of T-stages at fi rst diagnosis by sex
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Figure 3.25.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C81, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.25.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C81, 2013 – 2014 or latest available year (details and sources, see appendix)
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120 Cancer in Germany Non-Hodgkin lymphomas
Risk factors
There are no identifi able general risk factors for 
non-Hodgkin lymphoma. Immunodeficiency (con-
genital or acquired), radiation, chemotherapy and 
some rare autoimmune diseases increase a person’s 
risk of developing certain lymphomas. Some viruses 
and other pathogens are considered a risk factor in 
specifi c lymphomas. For example, an infection with 
the Epstein-Barr virus (EBV, glandular fever) is asso-
ciated with the Burkitt’s lymphoma, which is en-
demic to Africa. Chronic infection of the stomach 
with Helicobacter pylori is a factor in lymphoma of 
the gastric mucosa (MALT lymphoma).
Benzenes and related substances can promote 
the development of certain non-Hodgkin lympho-
mas. Other environmental pollutants, as well as life-
style factors are also being discussed as causes of 
lymphomas. Patients from families that have a high-
er rate of lymphomas, have a slightly higher risk of 
developing a lymphoma. The exact links remain un-
clear.
In many patients, the defi nite cause of a lympho-
ma is not identifi able. Presumably, multiple factors 
are involved in the development of a non-Hodgkin 
lymphoma.
Epidemiology
Non-Hodgkin lymphomas grow from the cells of the 
lymphatic system, and thereby most commonly from 
B-lymphocytes. Indolent (slow growth) and aggres-
sive (fast growth) types are distinguished. In 2014, 
around 17,000 new cases of non-Hodgkin lymphoma 
were registered. While it may occur at childhood age, 
the disease usually develops at older age. For men, 
the median age at diagnosis is 70 and 73 for women.
The significant increases in age-standardised 
incidence rates should be seen within the context of 
falling leukaemia rates, since clinically, doctors now 
tend to classify chronic lymphatic leukaemia as in-
dolent non-Hodgkin lymphoma. Around half of all 
cases are non-follicular lymphomas.
Age-standardised mortality rates have seen a 
downward trend in both men and women since the 
turn of the millennium and, while lower for women 
compared to men, now remain at a nearly constant 
level. They approximately correspond to internation-
al fi gures.
With a 5-year relative survival rate of 67 % for 
men and 71 % for women, the prognosis for non- 
Hodgkin lymphomas is generally favourable. Treat-
ment of some forms, even some of the highly aggres-
sive ones, can now result in a permanent cure.
3.26 Non-Hodgkin lymphomas
Table 3.26.1
Overview of key epidemiological parameters for Germany, ICD-10 C82 – C88
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 9,140 8,010 9,160 7,880 9,700 8,600
Crude incidence rate1 23.2 19.5 23.1 19.1 23.9 20.6
Standardised incidence rate1,2 16.1 11.7 15.9 11.2 16.0 11.8
Median age at diagnosis 70 72 70 73
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 3,507 2,992 3,560 2,949 3,619 2,975
Crude mortality rate1 8.9 7.3 9.0 7.1 9.0 7.2
Standardised mortality rate1,2 5.5 3.3 5.5 3.1 5.4 3.1
Median age at death 75 78 75 79 76 79
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 31,400 28,100 51,100 46,800
Absolute survival rate (2013 – 2014)3 57 (56 – 60) 62 (59 – 64) 41 (40 – 45) 48 (45 – 53)
Relative survival rate (2013 – 2014)3 67 (65 – 70) 71 (65 – 73) 57 (55 – 60) 63 (56 – 70)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.26.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C82 – C88, Germany 1999 – 2014/2015
Figure 3.26.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C82 – C88, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.26.2
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Table 3.26.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C82 – C88, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,300) 1.7 % (1 in 57) < 0.1 % (1 in 9,900) 0.8 % (1 in 130)
45 years 0.1 % (1 in 670) 1.7 % (1 in 59) < 0.1 % (1 in 3,800) 0.8 % (1 in 130)
55 years 0.3 % (1 in 330) 1.6 % (1 in 63) 0.1 % (1 in 1,300) 0.8 % (1 in 130)
65 years 0.6 % (1 in 170) 1.4 % (1 in 69) 0.2 % (1 in 450) 0.8 % (1 in 130)
75 years 0.8 % (1 in 130) 1.1 % (1 in 91) 0.4 % (1 in 240) 0.7 % (1 in 150)
Lifetime risk 1.8 % (1 in 55) 0.8 % (1 in 130)
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,800) 1.5 % (1 in 68) < 0.1 % (1 in 17,600) 0.6 % (1 in 170)
45 years 0.1 % (1 in 860) 1.4 % (1 in 70) < 0.1 % (1 in 6,700) 0.6 % (1 in 170)
55 years 0.3 % (1 in 400) 1.3 % (1 in 74) < 0.1 % (1 in 2,300) 0.6 % (1 in 170)
65 years 0.4 % (1 in 230) 1.2 % (1 in 86) 0.1 % (1 in 730) 0.6 % (1 in 170)
75 years 0.5 % (1 in 190) 0.8 % (1 in 120) 0.3 % (1 in 340) 0.5 % (1 in 200)
Lifetime risk 1.5 % (1 in 66) 0.6 % (1 in 170)
Figure 3.26.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C82 – C88, Germany 2013 – 2014
Figure 3.26.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C82 – C88, Germany 2013 – 2014
Figure 3.26.3
Distribution of T-stages at fi rst diagnosis by sex
T-stages are not defi ned for non-Hodgkin lymphomas.
Table 3.26.3
Proportion of the various non-Hodgkin lymphomas for all new diagnoses C82 – C88, 
by sex, Germany 2013 – 2014
C821 C832 C843 C854 C865 C886
Men 16 % 50 % 8 % 18 % 2 % 6 %
Women 21 % 45 % 6 % 19 % 2 % 8 %
1 Follicular lymphoma
2 Non-follicular lymphoma
3 Mature T/NK-cell lymphomas
4 Other and unspecifi ed types 
of non-Hodgkin lymphoma
5 Other specifi ed types of T/NK-cell lymphoma
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Figure 3.26.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C82 – C88, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.26.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C82 – C88, 2013 – 2014 or latest available year (details and sources, see appendix)
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1 data for mortality for C81–C86   4 no comparable data for incidence
2 data for incidence for C82–C85/C86 and C96 5 no data for incidence
3 data for incidence for C82–C85 and C96  6 mortality only 2013   
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Risk factors
The causes of plasmacytomas (multiple myeloma) 
remain largely unclear. A monoclonal gammopathy 
of undetermined significance (MGUS) is considered 
a precursor stage of multiple myeloma. Further rec-
ognised risk factors for multiple myeloma include 
advanced age, male gender and a family predisposi-
tion.
While familial clustering has been observed, 
there is no conclusive evidence of the role played by 
hereditary factors. Nonetheless, variations in inci-
dence rates within different population groups could 
still be related to genetic factors.
Chronic infections such as HIV or hepatitis C 
are associated with an increased risk of multiple 
 myeloma. According to data from recent studies, 
 obesity is linked to an increased risk, too.
Whether lifestyle factors and exposure to envi-
ronmental toxins or radiation have a signifi cant im-
pact on a person’s myeloma risk has been assessed 
with confl icting results.
Epidemiology
Multiple myeloma (or plasmacytoma) is a malignant 
growth of anti-body-producing plasma cells. Usually, 
the disease will start in the bone marrow, form mul-
tiple myeloma and produce complications such as 
bone fractures, bone pain and changes in the blood 
count. In only 1 % of cases approximately, the condi-
tion is diagnosed in organs not associated with bone 
marrow (extramedullary plasmacytoma).
In 2014, approximately 3,550 men and 2,960 
women were newly diagnosed with the illness in Ger-
many. The risk of developing the disease increases 
significantly at an older age and patients aged under 
45 years are extremely rare (only about 2 % of all 
 cases). Standardised for age, the incidence rates for 
women and men are now almost constant, whereas 
the trend in mortality rates has seen a slight decline 
for both genders.
Considering a 5-year relative survival rate of ap-
proximately 47 % for women and 49 % for men, the 
prognosis is rather unfavourable. Even following 
high-dose therapy and autologous stem cell trans-
plantation, no permanent cure can be expected. How-
ever, in some cases the condition may be asymp-
tomatic for a relatively long period, and temporary 
remissions during therapy are possible.
3.27 Multiple myeloma
Table 3.27.1
Overview of key epidemiological parameters for Germany, ICD-10 C90
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 3,670 2,940 3,550 2,960 3,900 3,100
Crude incidence rate1 9.3 7.1 9.0 7.2 9.7 7.5
Standardised incidence rate1,2 6.0 3.9 5.7 3.8 6.0 3.9
Median age at diagnosis 72 74 72 74
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 2,146 1,835 2,071 1,910 2,149 1,950
Crude mortality rate1 5.4 4.5 5.2 4.6 5.4 4.7
Standardised mortality rate1,2 3.3 2.1 3.1 2.1 3.1 2.1
Median age at death 75 77 76 77 76 77
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 11,100 9,200 15,500 13,300
Absolute survival rate (2013 – 2014)3 41 (34 – 45) 41 (36 – 51) 21 (17 – 29) 24 (20 – 31)
Relative survival rate (2013 – 2014)3 49 (40 – 54) 47 (41 – 58) 30 (24 – 39) 32 (27 – 40)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.27.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C90, Germany 1999 – 2014/2015
Figure 3.27.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C90, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.27.2
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Table 3.27.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C90, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 7,300) 0.7 % (1 in 140) < 0.1 % (1 in 72,000) 0.5 % (1 in 220)
45 years < 0.1 % (1 in 2,200) 0.7 % (1 in 140) < 0.1 % (1 in 6,600) 0.5 % (1 in 210)
55 years 0.1 % (1 in 820) 0.7 % (1 in 140) < 0.1 % (1 in 2,000) 0.5 % (1 in 210)
65 years 0.3 % (1 in 400) 0.7 % (1 in 150) 0.1 % (1 in 670) 0.5 % (1 in 210)
75 years 0.4 % (1 in 280) 0.5 % (1 in 200) 0.3 % (1 in 380) 0.4 % (1 in 250)
Lifetime risk 0.7 % (1 in 140) 0.5 % (1 in 220)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 10,000) 0.6 % (1 in 180) < 0.1 % (1 in 71,000) 0.4 % (1 in 270)
45 years < 0.1 % (1 in 3,100) 0.6 % (1 in 180) < 0.1 % (1 in 11,000) 0.4 % (1 in 270)
55 years 0.1 % (1 in 1,200) 0.5 % (1 in 190) < 0.1 % (1 in 3,000) 0.4 % (1 in 270)
65 years 0.2 % (1 in 580) 0.5 % (1 in 210) 0.1 % (1 in 1,000) 0.4 % (1 in 290)
75 years 0.2 % (1 in 420) 0.3 % (1 in 290) 0.2 % (1 in 560) 0.3 % (1 in 350)
Lifetime risk 0.6 % (1 in 180) 0.4 % (1 in 280)
Figure 3.27.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C90, Germany 2013 – 2014
Figure 3.27.4b
Relative survival rates up to 10 years after fi rst diagnosis, 
by sex, ICD-10 C90, Germany 2013 – 2014
Figure 3.27.3
Distribution of T-stages at fi rst diagnosis by sex
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Figure 3.27.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C90, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.27.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C90, 2013 – 2014 or latest available year (details and sources, see appendix)
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Risk factors
For the group of all leukaemias no universal risk fac-
tor has been identifi ed. However, some factors do 
increase the risk of certain types of leukaemia. Risk 
factors for acute leukaemia include ionising radiation 
and cytostatic drugs. Occupational exposure to ben-
zenes or 1,3-butadiene can be the rationale for accep-
tance of a leukaemia as an occupational disease. A 
number of rare genetic mutations, such as trisomy 
21, can increase the risk of leukaemia. With the excep-
tion of the T-lymphotropic virus (HTLV), which is 
extremely rare in Europe, no further viruses have so 
far been identifi ed as increasing the risk of leukae-
mia. Several additional risk factors are currently be-
ing examined as causes of leukaemia. This includes 
environmental and lifestyle factors such as smoking 
or overweight. So far, however, there is no conclusive 
evidence for such a link.
For most leukaemia patients, it is not possible to 
clearly identify the cause. Several factors likely need 
to interact in order for leukaemia to develop.
Epidemiology
In 2014, some 13,700 people in Germany were diag-
nosed with leukaemia, 4 % of whom were under 15 
years of age. The risk of leukaemia for children and 
young adults decreases with age. Beyond the age of 
30, however, the risk increases continuously, and in-
cidence rates are higher for men than for women. 
One in 64 men and one in 85 women will develop 
leukaemia during their lifetime. While age-stand-
ardised incidence rates remained relatively stable 
between 1999 and 2014, age-standardised mortality 
rates have decreased. Around 40 % of newly diag-
nosed leukaemias were chronic lymphocytic leukae-
mias (CLL) and around 21 % acute myeloid leukaemia 
(AML). The prognosis depends on the type of leukae-
mia and the age of a patient at diagnosis. Childhood 
forms of leukaemia have by far the most favourable 
prognoses, whereas its acute forms in adults contin-
ue to have a poor prognosis. Overall, about a third of 
adult patients are still alive ten years after diagnosis. 
However, a permanent cure for chronic leukaemia, 




Overview of key epidemiological parameters for Germany, ICD-10 C91 – C95
Incidence 2013 2014 Prediction for 2018
Men Women Men Women Men Women
Incident cases 7,660 5,960 7,640 6,060 8,200 6,400
Crude incidence rate1 19.4 14.5 19.3 14.7 20.4 15.5
Standardised incidence rate1,2 13.8 8.9 13.6 8.9 13.9 9.1
Median age at diagnosis 71 73 71 73
Mortality 2013 2014 2015
Men Women Men Women Men Women
Deaths 4,395 3,560 4,168 3,575 4,290 3,579
Crude mortality rate1 11.1 8.7 10.5 8.7 10.7 8.6
Standardised mortality rate1,2 7.0 4.1 6.4 4.0 6.5 3.9
Median age at death 75 78 76 78 76 79
1 per 100,000 persons  2 age-standardised (old European Standard)    
Prevalence and survival rates after 5 years after 10 years
Men Women Men Women
Prevalence 21,400 16,000 34,500 26,500
Absolute survival rate (2013 – 2014)3 50 (44 – 58) 51 (47 – 57) 34 (27 – 42) 37 (34 – 45)
Relative survival rate (2013 – 2014)3 59 (51 – 68) 58 (53 – 65) 47 (36 – 58) 48 (43 – 59)
3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.28.1b
Absolute numbers of incident cases and deaths, 
by sex, ICD-10 C91 – C95, Germany 1999 – 2014/2015
Figure 3.28.1a
Age-standardised incidence and mortality rates, 
by sex, ICD-10 C91 – C95, Germany 1999 – 2014/2015
per 100,000 (old European Standard)
Figure 3.28.2
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Table 3.28.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C91 – C95, database 2014
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 2,100) 1.5 % (1 in 68) < 0.1 % (1 in 6,800) 1.0 % (1 in 110)
45 years 0.1 % (1 in 980) 1.4 % (1 in 70) < 0.1 % (1 in 3,300) 1.0 % (1 in 110)
55 years 0.2 % (1 in 440) 1.4 % (1 in 72) 0.1 % (1 in 1,100) 1.0 % (1 in 100)
65 years 0.4 % (1 in 220) 1.3 % (1 in 78) 0.3 % (1 in 390) 1.0 % (1 in 100)
75 years 0.7 % (1 in 150) 1.1 % (1 in 95) 0.5 % (1 in 190) 0.9 % (1 in 110)
Lifetime risk 1.6 % (1 in 64) 1.0 % (1 in 100)
Women aged in the next ten years ever in the next ten years ever
35 years < 0.1 % (1 in 2,500) 1.1 % (1 in 93) < 0.1 % (1 in 10,400) 0.7 % (1 in 140)
45 years 0.1 % (1 in 1,400) 1.0 % (1 in 95) < 0.1 % (1 in 4,800) 0.7 % (1 in 140)
55 years 0.2 % (1 in 650) 1.0 % (1 in 100) 0.1 % (1 in 1,800) 0.7 % (1 in 140)
65 years 0.3 % (1 in 360) 0.9 % (1 in 110) 0.1 % (1 in 690) 0.7 % (1 in 150)
75 years 0.4 % (1 in 240) 0.7 % (1 in 140) 0.3 % (1 in 310) 0.6 % (1 in 170)
Lifetime risk 1.2 % (1 in 85) 0.7 % (1 in 140)
Figure 3.28.4a
Absolute survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C91 – C95, Germany 2013 – 2014
Figure 3.28.4b
Relative survival rates up to 10 years after fi rst diagnosis,
by sex, ICD-10 C91 – C95, Germany 2013 – 2014
Figure 3.28.3 
Distribution of T-stages at fi rst diagnosis by sex
T-stages are not defi ned for leukaemias.
Table 3.28.3
Proportion of the various leukaemia forms for all new diagnoses C91 – C95, by sex, Germany 2013 – 2014
ALL1 CLL2 AML3 CML4 others5
Men 7 % 42 % 19 % 7 % 24 %
Women 7 % 38 % 22 % 8 % 25 %
1 Acute lymphatic leukaemia (C91.0)
2 Chronic lymphatic leukaemia (C91.1)
3 Acute myeloid leukaemia (C92.0)
4 Chronic myeloid leukaemia (C92.1)
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Figure 3.28.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C91 – C95, 2013 – 2014
per 100,000 (old European Standard)
Figure 3.28.6
International comparison of age-standardised incidence and mortality rates, by sex, 
ICD-10 C91 – C95, 2013 – 2014 or latest available year (details and sources, see appendix)
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(C80) or other and ill-defined sites (C26, C76). All 
others are presented in Table 3.29.1. For detailed 
 fi gures for estimated nationwide incidence and mor-
tality rates, for instance by age group and year of 
 diagnosis see: www.krebsdaten.de/database.
Rare malignant tumours
Around 5 % of all malignant neoplasms (excluding 
non-melanoma skin cancer) affect sites not covered 
in the preceding chapters. Of these, approximately 
half again are malignant tumours of unspecified site 
3.29 Rare cancer sites and non-melanoma skin cancer
Table 3.29.1
Frequency, median age at diagnosis and survival rates for rare malignant tumours in Germany (2014)
Cancer site ICD-10 Incident cases Deaths age at diagnosis1 rel. 5-Y-SR2
 Men Women Men Women Men Women total
Small intestine C17 1,240 1,030 309 274 68 71 59
Nasal cavity, nasal sinuses and middle ear C30 – C31 550 350 128 63 64 65 54
Mediastinum and other intrathoracic organs C37 – C39 290 210 195 119 65 69 42
Bone and articular cartilage C40 – C41 430 340 252 175 55 56 63
Vagina and other female genital organs C52, C57, C58 1,190 456 71 52
Penis and other male genital organs C60, C63 950 197 70 71
Urinary tract excl. kidney and bladder C65, C66, C68 1,730 1,040 2,584 1,193 74 75 42
Eye C69 460 390 139 118 67 65 79
Adrenal gland and other endocrine glands C74, C75 230 240 407 327 57 63 54
Other and unspecifi ed malignant neoplasms 
of lymphoid, haematopoietic and related 
tissue C96 100 80 27 16 50 59 78
1 Median   2 relative 5-year survival rate in percentage, men and women, period 2013 – 2014
Table 3.29.2
Frequency, median age at diagnosis and survival rates for types of non-melanoma skin cancer in Germany (2014)
Cancer site ICD-O-3 Incident cases Deaths age at diagnosis1 rel. 5-Y-SR2
 Men Women Men Women Men Women total
Basaliomas 8090 – 8110 85,400 83,700 73 71 104
Squamous cell carcinomas 8050 – 8084 29,300 20,100 77 79 96
Unspecifi c histology 8000 – 8035 600 600 75 75 83
Other types 1,200 900 76 75 81
Total 116,500 105,300 435 351 74 73 102
1 Median   2 relative 5-year survival rate in percentage, men and women, period 2013 – 2014
Non-melanoma skin cancer
Most non-melanoma skin cancers are either basal cell 
carcinomas or squamous-cell carcinomas, both of 
which occur predominantly at advanced age (Table 
3.29.2). In both types, the most important risk factor 
is the long-term eff ect of the ultraviolet part of sun-
light, which is why they regularly occur on the face or 
the head and neck.
Basal cell carcinomas only metastasise in very 
exceptional circumstances, and they are therefore 
usually not life threatening. However, their growth 
can have a destructive eff ect on surrounding tissue 
and, given an unfavourable site, therefore consider-
ably reduce a patient’s quality of life. The relative sur-
vival rate of over 100 % for basal cell carcinomas is 
most likely explained by the detection of tumours in 
older, otherwise healthy people.
Squamous-cell carcinomas are slightly more like-
ly to metastasise, prognoses are nonetheless general-
ly good. An acquired immune-deficiency and/or im-
muno-suppression, for example following transplant 
surgery, can encourage the development of this tu-
mour.
Rare forms of skin cancer include Merkel-cell tu-
mours, fibrosarcoma and carcinoma of the sebaceous 
and sweat glands. Cause of death statistics do not dif-
ferentiate between the diff erent forms of non-melano-
ma skin cancer.
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Since taking up its work in 1980, the German Child-
hood Cancer Registry (GCCR) has been based at the 
Institute of Medical Biostatistics, Epidemiology and 
Informatics at the University Medical Centre of the 
Johannes Gutenberg University Mainz. From the out-
set, the GCCR was conceived to enable close cooper-
ation with the Society for Paediatric Oncology and 
Haematology (GPOH) and its associated hospitals. 
This feature of the registry distinguishes it from adult 
oncology and has allowed it to become a nationwide 
epidemiologic childhood cancer registry with a high 
level of data quality and over 95 % coverage (since 
about 1987) has been built up covering the whole of 
Germany. The GCCR thus meets the international 
standards for an epidemiological cancer registry. A 
further feature of the GCCR is its active, open-ended, 
long-term follow-up observation of patients into 
adulthood. The registry therefore also provides a basis 
for researching late effects and secondary tumours, as 
well as studies with long-term survivors in general.
The registry includes children who have been di-
agnosed with a malignant disease or a histologically 
benign brain tumour before their 15th birthday and 
are part of the German resident population at diagno-
sis. The GCCR also registers cancer cases in eastern 
Germany since 1991. Since 1 January 2009, the GCCR 
has been registering all children and adolescents up 
to the age of 18 years (i. e. those, who receive their 
diagnosis before their 18th birthday) on the basis of 
the Guideline of the Joint Federal Committee on 
Quality-Assurance Measures for the In-Patient Care 
of Children and Adolescents with Haemato-Oncolog-
ical Diseases. This will make it possible to better con-
sider the needs of the collaborating hospitals which 
have been combining paediatric and adolescent med-
icine for several years now and thus also treat cancer 
patients aged 15 years and over.
Currently, the data pool contains the data of 
around 57,000 patients.
Childhood cancer incidence
Germany registers around 1,750 cases of cancer in 
children aged under the age of 15 every year. With 
around 11 million children under 15, this translates 
into an incidence rate of about 6.8 per 100,000 chil-
dren for this age group. For a child, the likelihood of 
developing a malignant cancer within the first 15 years 
of his/her life is 0.2 %. Roughly, one in 410 children 
is diagnosed with a malignant cancer before their 15th 
birthday. Since 2009, when registration of all chil-
dren and adolescents up to the age of 18 began, an 
additional 360 cases aged between 15 and 17 years have 
been registered on average each year. 1,253 patients 
were diagnosed with a further cancer (subsequent 
cancer) within the first 30 years after their initial diag-
nosis, a rate of 6.6 % of patients (cumulative inci-
dence).
Survival probability
Less than 1 % of all cancer patients are children aged 
under 15. Nonetheless, malignant neoplasms are the 
second most common cause of death for children. 
Luckily, survival prospects have improved over the 
past 30 years, in particular due to signifi cantly more 
diff erentiated diagnoses and multimodal therapies. 
Whereas in the early 1980s, the fi ve-year relative sur-
vival rate of children with cancer was 67 %; this figure 
has now risen to 85 %. Regarding the total number of 
patients included in the registry and diagnosed with 
cancer and subsequently followed up between 2004 
and 2013, the fi ve-year rate was 85 %, the ten-year rate 
83 % and the fi fteen-year rate 82 %.
Gradually, the encouraging rise in the number of 
long-term survivors has shifted the focus on the long-
4 Cancer in children
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term observation of former paediatric cancer patients. 
The GCCR database is in this regard an ideal basis for 
studying long-term survivors. As the above figures 
reveal, already today, statements on long-term surviv-
al (for example after 15 years or more), as well as esti-
mates regarding the risk of developing a second neo-
plasia after suff ering cancer in childhood, are now 
possible. Further potential research fi elds include the 
incidence of other long-term impacts, such as the pos-
sible consequences of therapy on fertility, or studies 
that examine the health risks of descendants or car-
diovascular implications of therapy at later stages of 
life. About 35,000 of the more than 46,000 patients 
currently known to be alive have been registered for 
at least five years. The majority of these former pa-
tients are now aged 18 or over.
Range of diagnoses
Compared to adults, children present a very diff erent 
range of cancers. Most children develop embryonal 
tumours (neuroblastomas, retinoblastomas, nephro-
blastomas, medulloblastomas, embryonic rhabdo-
myosarcomas or germ-cell tumours). Carcinomas, by 
contrast, are very rare in children (accounting for only 
about 3 % of all malignant cancers). Diagnostically, 
the most important groups of cancer in children are 
leukaemias (32.9 %), CNS tumours (24.6 %) and lym-
phomas (10.7 %). Cancer incidence rates for children 
aged under five are about twice as high as in the 5 to 
14 age group. The median age at onset for children 
aged under fi fteen is five years, ten months. Boys are 
diagnosed with cancer 1.2 times more frequently than 
girls.
Figure 4.2
Incident cases by age and sex, all childhood malignancies
Number of cases per 100,000 by age group, determined for the period 2004 – 2015
Figure 4.3
Incident cases by age and sex, childhood acute lymphatic leukaemia (ALL)
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Figure 4.4
Trends of incidence of selected diagnostic groups and for all childhood malignancies
Number of cases per 100,000 (age standardised), including eastern Germany since 1991
Figure 4.5
Trends of incidence of childhood leukaemias, myeloproliferative and myelodysplastic disorders
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Leukaemias
Among under 15 year olds, leukaemia accounts for 
about one third of all cancer cases. The most common 
single diagnosis overall (25.8 %) is lymphatic leukae-
mia (LL). It occurs more than twice as frequently 
among children under the age of five as in all other 
age groups. 4.3 % of all childhood malignancies are 
acute myeloid leukaemias (AML). AML is most com-
mon among children under the age of two. The sur-
vival prospects for AML are signifi cantly lower than 
for LL. About 11 % of all subsequent neoplasms are 
AML.
The causes of childhood leukaemia still remain 
largely unclear today. For a long time, environmental 
factors were suspected as playing a role in the devel-
opment of leukaemia at childhood age. In the mean-
time, it has however become quite clear that the num-
ber of cases related to environmental factors (such as 
low-dose ionising radiation, non-ionising radiation 
and pesticides) is quite small, even though a loose 
association of these factors with childhood leukaemia 
cannot be ruled out. A number of facts have given 
greater weight to hypotheses that assign a key role to 
infections and the immune system in childhood leu-
kaemia. Increasingly, genetic causes continue to be 
researched and discussed for all childhood neoplasia.
Lymphomas
The most common lymphomas are non-Hodgkin 
lymphomas (NHL), including Burkittʼs lymphoma 
(6.3 %) and Hodgkin’s lymphomas (4.5 %). The 
chances of survival for patients with Hodgkin’s lym-
phoma are among the best in paediatric oncology. 
Unfortunately, with more than 13 % the frequency of 
subsequent cancer (within 30 years after diagnosis) 
following a Hodgkin’s lymphoma is particularly high. 
Children with congenital or acquired immuno-
deficiency and those who have had immunosuppres-
sive therapy are at increased risk of developing NHL.
CNS tumours
The most commonly diagnosed CNS tumours are as-
trocytomas (11.5 %), intracranial and intraspinal em-
bryonal tumours (4.4 %) and ependymomas (1.9 %). 
23 % of subsequent neoplasms are CNS tumours. 
Potentially, the increase in the incidence rates of CNS 
tumours observed in a number of western countries 
over the past few decades are related to better registra-
tion and also with general changes in environmental 
factors and related exposures. For example, a number 
of epidemiological studies is investigating the in-
fluence of ionising radiation, electromagnetic fields, 
pesticides, the mother’s diet, as well as of genetic as-
pects.
Other common malignant diseases
Other common malignant cancers in childhood in-
clude neuroblastomas (nerve-cell tumours), nephro-
blastomas (kidney tumours), germ-cell tumours, 
bone tumours and rhabdomyosarcomas (tumours of 
the skeletal muscle). The prognosis for children with 
nephroblastoma or germ-cell tumour is much more 
favourable than for the other tumours. Skin tumours 
and thyroid cancer and breast cancer among young 
women are other frequent subsequent cancers.
Table 4.1
Incidence and survival rates for the most common diagnoses, determined for the period 2004 – 2013
Cancer cites Incidence1 Survival rate in %2
after 5 years after 10 years after 15 years
Hodgkin’s lymphomas 0.6 99 98 97
Retinoblastomas 0.4 97 97 97
Germ-cell tumours 0.5 94 93 93
Nephroblastomas 1 94 93 93
Lymphoid leukaemias 4.4 92 91 90
Non-Hodgkin lymphomas 0.7 89 88 86
Astrocytomas 1.8 82 79 78
Neuroblastomas and ganglioneuroblastomas 1.4 80 78 77
Rhabdomyosarcomas 0.7 74 73 73
Acute myeloid leukaemias 0.5 74 72 71
Osteosarcomas 0.3 76 71 70
Intracranial and intraspinale embryonal tumours 0.7 67 60 57
All malignancies 16.8 85 83 82
1 Related to 100,000 children under the age of 15, age standardised (standard: Segi world population), children diagnosed 2006 – 2015
2 Brenner H, Spix C. Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates. 
Br J Cancer 89, 1260 – 1265, 2003
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to cancer registration and cancer epidemiology 
(e. g. active participation in working groups of 
the German National Cancer Plan, in the Asso-
ciation of Population-based Cancer Registries in 
Germany (GEKID), International Association of 
Cancer Registries (IACR) membership)
The work of the German Centre for Cancer Registry 
Data is supported by a scientific advisory board with 
an offi  ce at the RKI. This advisory board can also 
grant permission for the dataset at the German Cen-
tre for Cancer Registry Data to be made available to 
third parties if a justified and, in particular, scientific 
interest can be substantiated. Further information on 
the application process as well as the German Centre 
for Cancer Registry Data is available on the Internet 
at www.krebsdaten.de/english.
Staff  of the German Centre for Cancer Registry Data:
Dr Klaus Kraywinkel (section head)











After the Federal Cancer Registry Data Act (Bundes-
krebsregisterdatengesetz – BKRG) came into force in 
August 2009, the German Centre for Cancer Registry 
Data was set up at the beginning of 2010 as an inde-
pendent division within the Robert Koch Institute’s 
Department of Epidemiology and Health Reporting 
to perform the tasks laid down in the Act:
▶ to check the completeness of case finding and of 
the variables included in the anonymised data 
submitted by the epidemiological (popula-
tion-based) state cancer registries
▶ to create, maintain and update a dataset from the 
data transmitted by the state cancer registries 
and checked by the ZfKD
▶ to further enhance methods and standards for 
data collection and data transfer, and to analyse 
the data together with the state cancer registries
▶ to regularly estimate and analyse cancer inci-
dence, mortality, survival rates, stage distribu-
tion at diagnosis, and other indicators, particu-
larly prevalence, the risk of developing and dying 
of the disease, and how these indicators change 
over time
▶ to examine regional differences in selected can-
cer sites
▶ to provide a dataset for evaluating health-policy 
measures for cancer prevention, cancer screen-
ing, cancer treatment and healthcare
▶ to conduct analyses and studies on cancer and to 
publish the results in national and international 
journals
▶ to conduct a nationwide record linkage for the 
detection of duplicate notifications and to in-
form the cancer registries accordingly
▶ to publish a report on cancer incidence and 
trends in Germany in consultation with the state 
cancer registries every two years (»Cancer in 
Germany«)
▶ to write a comprehensive report on cancer in 
Germany every five years; the first edition was 
published in November 2016
▶ to complement classic print-products with inter-
active analysis tools based on annually updated 
data and an expanded presence on the Internet
▶ to use additional data sources to describe all as-
pects of cancer in Germany
▶ to engage in international cooperations
▶ to collaborate in scientific bodies as well as Euro-
pean and international organizations dedicated 
5 Appendix
5.1  The German Centre for Cancer Registry Data at the Robert Koch Institute 
(Zentrum für Krebsregisterdaten, ZfKD)
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▶ to initiate joint research activities
▶ to promote the scientifi c use of the popula-
tion-based cancer registries
▶ to use the data to advance quality assurance in
oncological care
Essential results of the GEKID activities in the past 
years:
▶ Enhancement of the interactive GEKID-Atlas
regarding actual cancer incidence, mortality and 
survival in the federal states; the GEKID-Atlas
made significant contributions to the scientific
usage of cancer registry data and is available via
the GEKID-Homepage
▶ Enhancement of the uniform minimum data
format for the report to a registry as well as an
interchange format for the forwarding of data
according to the place of residence and for the
data exchange with the German Centre for Can-
cer Registry Data at the RKI
▶ Evaluation and publication of results of survival
analyses in Germany together with German
Cancer Research Centre, supported by German
Cancer Aid
Information on GEKID can be obtained on the 
Inter-net at www.gekid.de/home or from the re-
spective regional member registries (see address 
section, appendix 5.4).
Contacts for the Association of Population-based 
Cancer Registries in Germany (Gesellschaft der epi-
demiologischen Krebsregister in Deutschland e.V., 
GEKID) (see address section, appendix 5.4):
Prof Dr Alexander Katalinic
(Chair of GEKID, Schleswig-Holstein Cancer Re-
gistry)
Dr Stefan Hentschel
 (1st Vice-chair, Hamburg Cancer Registry)
Roland Stabenow
 (2nd Vice-chair, Joint Cancer Registry)
The Association of Population-based Cancer Regis-
tries in Germany (GEKID) was formed in 2004 as a 
registered, non-profit-making association. GEKID’s 
members include not only all Germany’s popula-
tion-based cancer registries, but also a tumour centre 
and interested scientists working in the field of can-
cer epidemiology. In the field of cancer control, 
GEKID cooperates closely with the Federal Ministry 
of Health, particularly in the context of the National 
Cancer Plan, and the German Centre for Cancer Reg-
istry Data based at the Robert Koch Institute (RKI). 
GEKID also participates actively in a wide range of 
scientific committees especially in working groups 
preparing the uniform data set for clinical and epide-
miological cancer registration.
The association’s primary task is to standardise 
as far as possible the content and methodology of 
cancer registration, despite the diff erences in legisla-
tion between the federal states. The comparability of 
results from the cancer registries can only be assured 
by nationwide cooperation. To promote such cooper-
ation, GEKID published »The Manual of Popula-
tion-based Cancer Registration« a few years ago. To-
gether with the Association of German Tumour 
Centers (ADT), this manual is currently being up-
dated and expanded to include elements of clinical 
cancer registration.
Furthermore, GEKID is a joint point of contact 
for the population-based cancer registries on all is-
sues of common interest and represents the regis-
tries at the European level. GEKID is a member of the 
European Network of Cancer Registries (ENCR) and 
the International Association of Cancer Registries 
(IACR).
In its charter, GEKID has set itself the following tasks:
▶ to be the point of contact both for national and
international cooperation partners and for the
interested public
▶ to provide information on the status of cancer
registration in Germany to the (professional)
public and explain the aims of population-based 
cancer registration
▶ to engage in joint information activities and thus 
help the individual cancer registries achieve and 
maintain complete registration
▶ to define standards on content as a basis for the
comparability of population-based cancer regis-
tries
▶ to coordinate tasks involving all the registries
and foster contacts with clinical tumour docu-
mentation
5.2 Association of Population-based Cancer Registries in Germany
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of Science, Research and Art (MWK) and the Federal 
Ministry of Health. As a result, the service provides 
information independently, free from conflicts of in-
terest and free of charge. In its capacity as national 
reference centre for cancer information, the Cancer 
Information Service is committed to providing the 
highest possible standard of information. Through 
its accompanying research, the Service also provides 
feedback on how cancer patients and their relatives 
experience the health care situation in Germany.
Further information on the mission and meth-
ods of the Cancer Information Service can be found 
by following the link: www.krebsinformationsdienst. 
de/info/german-cancer-information-service-2017.pdf
Cancer Information Service (KID)
Telephone: + 49 (0)800 – 420 30 40, 
(Free within Germany) Daily from 08:00 to 20:00 
E-Mail: krebsinformationsdienst@dkfz.de, 
Answers usually within 2 working days
Internet: www.krebsinformationsdienst.de and 
www.facebook.com/krebsinformationsdienst
Cancer Information Service.med
Telephone: +49 (0)800 – 430 40 50, 
(Free within Germany) Daily from 08.00 to 20.00 
E-Mail: kid.med@dkfz.de,
Answers usually within 2 working days
Internet: www.krebsinformationsdienst.de/fachkreise
Contact partners at the Cancer Information Service 
KID (also see address section, appendix 5.4):
Dr. Susanne Weg-Remers
Head of the Cancer Information Service (KID) 
Dr. Andrea Penzkofer
Head of the Working Group »Knowledge Manage-
ment« at KID
The Cancer Information Service »KID« was founded 
in 1986 to provide personal telephone contacts for 
patients, their relatives and the interested public with 
questions regarding cancer. Today, doctors provide 
up-to-date, scientifi cally sound answers to around 
35,000 questions every year by phone, by e-mail and 
in consultations in both Heidelberg and Dresden. 
Even representatives from occupational groups in-
volved in the care of cancer patients turn to the Can-
cer Information Service. The information on off er is 
individually tailored to the needs of the various target 
groups:
▶ Patients as well as their relatives and friends are
interested primarily in detailed information re-
lating to diagnosis and treatment options, living 
with the disease and additional points of contact 
within the healthcare system. For interested cit-
izens, the main focus is on risk factors, cancer
prevention and early detection or on current can-
cer research. The comprehensive information of 
the Cancer Information Service strengthens the
health literacy of individuals and creates the
 basis for communicating at eye-level with phy-
sicians, so that those aff ected can engage in an
informed decision-making process.
▶ Professionals in occupations concerned with
cancer receive pertinent information on the tele-
phone and via email quickly, reliably, competent-
ly, and based on the best available scientific
evidence. The clear preparation of research re-
sults and the individual compilation of relevant
sources generate direct added value for patient
care.
Via its website www.krebsinformationsdienst.de the 
Cancer Information Service conveys the latest knowl-
edge about cancer, useful addresses, additional con-
tacts and tips on further links and information mate-
rial. 700,000 individual visitors per month used this 
facility in 2016. On the social networking site Face-
book, the service posts breaking news and invites 
discussion. For professionals, the website off ers rele-
vant information on medical research and provides 
links to further scientific sources. Newsletters for 
medical professionals, especially for psycho-oncolo-
gists, convey current information about cancer.
The Cancer Information Service is provided by 
the German Cancer research Centre (DKFZ) in Hei-
delberg, the largest bio-medical research establish-
ment in Germany. The service is financed by funds 
from the Federal Ministry of Education and Research 
(BMBF), the State of Baden-Württemberg’s Ministry 
5.3  KID – The Cancer Information Service provided by the German Cancer 
Research Centre
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5.4 Addresses
Krebsregister Baden-Württemberg (Baden-Württemberg Cancer Registry)
Epidemiologisches Krebsregister (Population-based Cancer Registry)
Deutsches Krebsforschungszentrum Heidelberg (German Cancer Research Centre)
Im Neuenheimer Feld 581
69120 Heidelberg Telephone: +49 (0)6221/42 42 20
 E-Mail: ekr-bw@dkfz.de
 Internet: www.krebsregister-bw.de
Krebsregister Baden-Württemberg (Baden-Württemberg Cancer Registry)
Vertrauensstelle (Baden-Württemberg Confidentiality Unit)
bei der Deutschen Rentenversicherung (German Pension Insurance) Baden-Württemberg
Gartenstraße 105
76135 Karlsruhe Telephone: +49 (0)721/82 57 90 00 Telefax: +49 (0)721/82 59 97 90 99
 E-Mail: vs@drv-bw.de
 Internet: www.krebsregister-bw.de
Klinische Landesregisterstelle des Krebsregisters Baden-Württemberg (Clinical State Registration Unit) bei 
der Baden-Württembergischen Krankenhausgesellschaft e.V. (Baden-Württemberg Hospital Association)
Birkenwaldstraße 145
70191 Stuttgart Telephone: +49 (0)711/2 57 77 70 Telefax: +49 (0)711/2 57 77 79
 E-Mail: info@klr-krbw.de
 Internet: www.krebsregister-bw.de
Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (Bavarian Health and Food Safety Authority)
Zentrum für Krebsfrüherkennung und Krebsregistrierung (Registration Unit)
Schweinauer Hauptstraße 80
90441 Nürnberg Telephone: +49 (0)9131/68 08 29 20 Telefax: +49 (0)9131/68 08 29 05
 E-Mail: zkfr@lgl.bayern.de
 Internet: www.krebsregister-bayern.de
Bevölkerungsbezogenes Krebsregister Bayern (Bavaria Population-based Cancer Registry) 
Vertrauensstelle (Confidentiality Unit), Klinikum Nürnberg-Nord
Professor-Ernst-Nathan-Straße 1
90419 Nürnberg Telephone: +49 (0)911/3 78 67 38 Telefax: +49 (0)911/3 78 76 19
 E-Mail: vertrauensstelle@klinikum-nuernberg.de 
 Internet: www.krebsregister-bayern.de
Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und 
der Freistaaten Sachsen und Thüringen (GKR)
(Joint Cancer Registry of Berlin, Brandenburg, Mecklenburg-West Pomerania, Saxony-Anhalt, Saxony)
Brodauer Straße 16–22
12621 Berlin Telephone: +49 (0)30/56 58 11 00 (R) Telefax: +49 (0)30/56 58 11 99 (R)
  +49 (0)30/56 58 12 00 (V)  +49 (0)30/56 58 12 99 (V)
 E-Mail: registerstelle@gkr.berlin.de vertrauensstelle@gkr.berlin.de
 Internet: www.krebsregister.berlin.de
Bremer Krebsregister Auswertungsstelle (Bremen Cancer Registry)
Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH
(Leibniz Institute for Prevention Research and Epidemiology)
Achterstraße 30
28359 Bremen Telephone: +49 (0)421/21 85 69 61 Telefax: +49 (0)421/21 85 68 21
 E-Mail: krebsregister@leibniz-bips.de
 Internet: www.krebsregister.bremen.de
(R) = Registerstelle (Registry Unit)   (V) = Vertrauensstelle (Confidentiality Unit)
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Vertrauensstelle des Bremer Krebsregisters (Confidentiality Unit)
Kassenärztliche Vereinigung Bremen
Achterstraße 30
28359 Bremen Telephone: +49 (0)421/21 85 69 99
 E-Mail: vbkr.kvhb@t-online.de
Hamburgisches Krebsregister (Hamburg Cancer Registry)
Behörde für Gesundheit und Verbraucherschutz (State Ministry of Health and Consumer Protection)
Billstraße 80
20539 Hamburg Telephone: +49 (0)40/4 28 37 22 11 Telefax: +49 (0)40/4 27 31 00 94
 E-Mail: hamburgischeskrebsregister@bgv.hamburg.de 
 Internet: www.hamburg.de/krebsregister
Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen
Landesauswertungsstelle des Hessischen Krebsregisters
Walter-Möller-Platz 1
60439 Frankfurt am Main Telephone: +49 (0)69/1 56 77 12 Telefax: +49 (0)69/1 56 77 16
 E-Mail: Ernst-Alfred.Burkhardt@hlpug.hessen.de 
 Internet: www.hlpug.de
Vertrauensstelle des Hessischen Krebsregisters (Confidentiality Unit of Hesse Cancer Registry) 
bei der Landesärztekammer Hessen
Im Vogelsgesang 3
60488 Frankfurt/Main Telephone: +49 (0)69/7 89 04 50 Telefax: +49 (0)69/78 90 45 29
 E-Mail: vertrauensstelle@laekh.de 
 Internet: www.laekh.de
Epidemiologisches Krebsregister Niedersachsen (Lower Saxony Population-based Cancer Registry)
OFFIS CARE GmbH
Industriestraße 9
26121 Oldenburg Telephone: +49 (0)441/36 10 56 12 Telefax: +49 (0)441/36 10 56 10
 E-Mail: registerstelle@krebsregister-niedersachsen.de
 Internet: www.krebsregister-niedersachsen.de
Niedersächsisches Landesgesundheitsamt (Lower Saxony Local Health Authority)
Vertrauensstelle Epidemiologisches Krebsregister Niedersachsen 
(Confidentiality Unit of Lower Saxony Population-based Cancer Registry)
Andreaestraße 7
30159 Hannover Telephone: +49 (0)511/4 50 53 80 Telefax: +49 (0)511/4 50 51 32
 E-Mail: vertrauensstelle.ekn@nlga.niedersachsen.de
 Internet: www.krebsregister-niedersachsen.de
Landeskrebsregister Nordrhein-Westfalen gGmbH 
(North Rhine-Westphalia Population-based Cancer Registry)
Gesundheitscampus 10
44801 Bochum Telephone: +49 (0)234/54509-000 Telefax: +49 (0)234/54509-499
  +49 (0)234/54509-111 (Zentrale Servicerufnummer=Hotline)
 E-Mail: info@krebsregister.nrw.de
 Internet: www.krebsregister.nrw.de
Krebsregister Rheinland-Pfalz gGmbH (Rhineland-Palatinate Cancer Registry)
Große Bleiche 46
55116 Mainz Zentrale: +49 (0)6131/9 71 75 0 Telefax: +49 (0)6131/9 71 75 90
 E-Mail: info@krebsregister-rlp.de
 Internet: www.krebsregister-rlp.de
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Krebsregister Saarland (Saarland Cancer Registry)
Ministerium für Soziales, Gesundheit, Frauen und Familie 
(Ministry of Social Affairs, Health, Women and Family) 
Präsident-Baltz-Straße 5
66119 Saarbrücken Telephone: +49 (0)681/5 01 58 05 (R) Telefax: +49 (0)681/5 01 59 98
  +49 (0)681/5 01 45 38 (V)
 E-Mail: koordinierungsstelle@krebsregister.saarland.de 
 Internet: www.krebsregister.saarland.de
Krebsregister Schleswig-Holstein (Schleswig-Holstein Cancer Registry)
Registerstelle (Registry Unit)
Institut für Krebsepidemiologie e. V. (Institute for Cancer Epidemiology)
Ratzeburger Allee 160, Haus 50
23562 Lübeck Telephone: +49 (0)451/50 05 21 01 Telefax: +49 (0)451/50 05 21 04
 E-Mail: info@krebsregister-sh.de
 Internet: www.krebsregister-sh.de
Vertrauensstelle des Krebsregisters (Confidentiality Unit of Schleswig-Holstein Cancer Registry)
bei der Ärztekammer Schleswig-Holstein (at Schleswig-Holstein Medical Council)
Bismarckallee 8–12
23795 Bad Segeberg Telephone: +49 (0)4551/80 38 52
 E-Mail: krebsregister-sh@aeksh.de
Deutsches Kinderkrebsregister (German Childhood Cancer Registry)
Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI)
(Institute of Medical Biostatistics, Epidemiology and Informatics)
Obere Zahlbacher Str. 69
55131 Mainz Telephone: +49 (0)6131/17 31 11 Telefax: +49 (0)6131/17 44 62
 E-Mail: info@kinderkrebsregister.de
 Internet: www.kinderkrebsregister.de
Krebsinformationsdienst (KID) (Cancer Information Service)
Deutsches Krebsforschungszentrum (German Cancer Research Centre)
Im Neuenheimer Feld 280
69120 Heidelberg Telephone: +49 (0)6221/42 28 90 (secretariat)
 E-Mail: krebsinformationsdienst@dkfz.de 
 Internet: www.krebsinformationsdienst.de
Further contacts
Zentrum für Krebsregisterdaten im Robert Koch-Institut
(German Centre for Cancer Registry Data at the Robert Koch Institute)
General-Pape-Straße 62–66
12101 Berlin Telephone: +49 (0)30/1 87 54 33 81 
 E-Mail: krebsdaten@rki.de
 Internet: www.krebsdaten.de/english
Bundesministerium für Gesundheit (Federal Ministry of Health) 
53107 Bonn
Referat 311 Telephone: +49 (0)228/9 94 41 15 10 Telefax: +49 (0)228/9 94 41 49 62
Referat 315 Telephone: +49 (0)228/9 94 41 31 08 Telefax: +49 (0)228/9 94 41 49 38
 E-Mail: poststelle@bmg.bund.de
 Internet: www.bmg.bund.de
(R) = Registerstelle (Registry Unit)   (V) = Vertrauensstelle (Confidentiality Unit)
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5.5 Sources for international comparison of cancer incidence and mortality rates 
 (for the years 2013–2014, if not otherwise stated. Access date: July to October 2017)
Netherlands: Netherlands Cancer Registry
 http://www.cijfersoverkanker.nl/?language=en
Sweden, Finland, Association of the Nordic Cancer Registries (ANCR)
Denmark: http://www-dep.iarc.fr/nordcan/English/frame.asp
Poland: Zakład Epidemiologii i Prewencji Nowotworów Centrum Onkologii-Instytut 
 http://onkologia.org.pl/raporty/#tabela_nowotwor
Czech Republic:  SVOD Web Portal
 http://www.svod.cz/?sec=aktuality&lang=en
 Data for all cancer (C00 – C97 w/o. C44) and for Leukaemias (C91 – 95): 
 Institute of Health Information and Statistics of the Czech Republic (UZIS)
 Cancer Incidence in the Czech Republic, 2014 
 http://www.uzis.cz/
Belgium: Incidence: Belgian Cancer Registry
 http://www.kankerregister.org/
 Mortality: Eurostat, Statistical offi  ce of European Union 
 http://ec.europa.eu/eurostat/web/health/causes-death/data/database
France:  Incidence data for 2013/2014 not available by editorial deadline
 Mortality: Eurostat, Statistical offi  ce of European Union 
 http://ec.europa.eu/eurostat/web/health/causes-death/data/database
USA: Incidence: National Cancer Institute Surveillance, Epidemiology, and End Results (SEER)
 Program 
 http://seer.cancer.gov/canques/incidence.html 
 Mortality: http://seer.cancer.gov/canques/mortality.html and 
 United States Department of Health and Human Services (US DHHS), Centers for Disease 
 Control and Prevention (CDC), National Center for Health Statistics (NCHS), 
 Underlying Cause of Death 1999–2015 on CDC WONDER Online Database, released 2016.
England: Offi  ce for National Statistics (GB)
 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions
 anddiseases
Switzerland: NICER – National Institute for Cancer Epidemiology and Registration 
 http://www.nicer.org/de/statistiken-atlas/
Austria: STATISTIK AUSTRIA, Austrian Cancer Registry. Access date: 15th November 2016
 Further information/data for mortality for individually diagnoses and countries: 
 WHO mortality database 
 http://apps.who.int/healthinfo/statistics/mortality/causeofdeath_query/
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